Moleculaire karakterisatie van pathofysiologische processen in IBD en hun therapeutisch potentieel by Vanhove, Wiebe
1 
 
KU Leuven 
Biomedical Sciences Group 
Faculty of Medicine 
Department of Chronic Diseases, Metabolism and Ageing 
Translational Research in GastroIntestinal Disorders (TARGID) – IBD group 
 
 
 
MOLECULAR CHARACTERIZATION OF 
PATHOPHYSIOLOGIC PATHWAYS IN IBD AND ITS 
THERAPEUTIC POTENTIAL 
SUBTITLE OF THE PHD 
 
WIEBE VANHOVE 
Dissertation presented in 
partial fulfilment of the 
requirements for the degree 
of Doctor in Biomedical 
Sciences 
Jury: 
Promoter:  Prof. Dr. Severine Vermeire 
Co-promoters:  Dr. Ingrid Arijs 
  Dr. Kris Nys 
Chair:   Prof. Dr. Kristin Verbeke 
Secretary:  Prof. Dr. Guy Boeckxstaens 
Jury members: Prof. Dr. Guy Boeckxstaens 
  Prof. Dr. Patrizia Agostinis 
  Prof. Dr. Debby Laukens 
  Prof. Dr. Arthur Kaser 
Leuven, November 16, 2017 
2 
 
  
3 
 
Contents 
LIST OF ABBREVIATIONS ............................................................................................................. 8 
CHAPTER 1  INTRODUCTION .................................................................................................... 13 
1. The paradigm of patient management in IBD ............................................................... 15 
2. Toward innovative management of IBD ....................................................................... 17 
2.1. Anti-IL-12/23 .......................................................................................................... 17 
2.2. Janus kinases inhibition ......................................................................................... 18 
2.3. Leukocyte trafficking .............................................................................................. 20 
3. Targeting early events in IBD pathogenesis to restore intestinal homeostasis ............ 21 
3.1. Anti-Smad7 (TGF-β/BMP signaling) and other antisense oligonucleotides .......... 21 
3.2. Cell-based therapies............................................................................................... 24 
4. Future prospects in IBD management .......................................................................... 26 
4.1. A mechanism-based approach ............................................................................... 26 
4.2. Toward personalized IBD management ................................................................. 31 
5. Conclusion ..................................................................................................................... 33 
6. References ..................................................................................................................... 35 
CHAPTER 2  RESEARCH OBJECTIVES ......................................................................................... 43 
PART I    IN VIVO TARGETING OF THE JAK-STAT PATHWAY IN IBD .......................................... 47 
CHAPTER 3  SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) WITH FILGOTINIB REVERSES 
PATHOGENIC PROCESSES IN PRECLINICAL MODELS FOR IBD .................................................. 49 
1. Introduction ................................................................................................................... 52 
2. Materials and Methods ................................................................................................. 54 
2.1. Reagents ................................................................................................................. 54 
2.2. Mice ........................................................................................................................ 54 
2.3. Induction of chronic colitis and Experimental setup ............................................. 54 
2.4. Monitoring of disease ............................................................................................ 54 
4 
 
2.5. Statistical analysis .................................................................................................. 56 
3. Results ........................................................................................................................... 57 
3.1. Pilot experiments ................................................................................................... 57 
3.2. Filgotinib reduces body weight loss and inflammatory scores.............................. 59 
4. Discussion ...................................................................................................................... 61 
5. References ..................................................................................................................... 64 
PART II   FUNCTIONAL TRANSLATION OF IDENTIFIED PATHWAYS IN IBD ................................ 67 
CHAPTER 4 BIOPSY-DERIVED INTESTINAL EPITHELIAL CELL CULTURES FOR PATHWAY BASED 
STRATIFICATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE ................................ 69 
1. Abstract ......................................................................................................................... 71 
2. Introduction ................................................................................................................... 72 
3. Materials and methods ................................................................................................. 74 
3.1. Patients and ethical statement .............................................................................. 74 
3.2. Isolation and culturing of IECs ............................................................................... 75 
3.3. Immunocytochemistry ........................................................................................... 76 
3.4. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis ................. 77 
3.5. ER stress induction ................................................................................................. 78 
3.6. Binding immunoglobulin protein (BiP)/Glucose-regulated protein 78 (GRP78) ELISA
 78 
3.7. Statistical analysis .................................................................................................. 78 
4. Results ........................................................................................................................... 79 
4.1. IECs and epithelial characterization ....................................................................... 79 
4.2. Genetic risk in ER stress and autophagy genes and the epithelial ER stress response
 82 
5. Discussion ...................................................................................................................... 86 
6. Supplementary material ................................................................................................ 90 
5 
 
7. References ..................................................................................................................... 92 
CHAPTER 5 STRONG UPREGULATION OF AIM2 AND IFI16 INFLAMMASOMES IN THE MUCOSA 
OF PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE ............................................... 95 
1. Abstract ......................................................................................................................... 97 
2. Introduction ................................................................................................................... 98 
3. Materials and methods ............................................................................................... 100 
3.1. Patients and biopsy specimens ............................................................................ 100 
3.2. Mucosal gene expression analysis ....................................................................... 100 
3.3. RNA isolation ........................................................................................................ 100 
3.4. Whole-genome gene expression analysis ............................................................ 101 
3.5. qRT-PCR analysis .................................................................................................. 101 
3.6. Immunohistochemistry ........................................................................................ 102 
3.7. Western blot analysis ........................................................................................... 102 
3.8. Ethical considerations .......................................................................................... 102 
4. Results ......................................................................................................................... 103 
4.1. Gene expression of different inflammasome subtypes in IBD colonic mucosa .. 103 
4.2. Validation of AIM2 and IFI16 expression at the protein level ............................. 107 
4.3. Immunohistochemistry ........................................................................................ 108 
5. Discussion .................................................................................................................... 111 
6. Supplementary material .............................................................................................. 115 
6.1. Protocol details .................................................................................................... 115 
6.2. Supplementary tables .......................................................................................... 117 
6.3. Supplementary figures ......................................................................................... 118 
7. References ................................................................................................................... 120 
CHAPTER 6  MUCOSAL EXPRESSION OF AUTOPHAGY AND ER STRESS GENES IN 
INFLAMMATORY BOWEL DISEASES ........................................................................................ 125 
6 
 
1. Introduction and aim ................................................................................................... 127 
2. Material and methods ................................................................................................. 128 
2.1. Selection of ER stress and autophagy associated genes ..................................... 128 
3. Results ......................................................................................................................... 129 
3.1. ER stress genes ..................................................................................................... 129 
3.2. Autophagy genes ................................................................................................. 134 
4. Discussion .................................................................................................................... 137 
5. Supplementary material .............................................................................................. 142 
5.1. Filtering of ER stress genes .................................................................................. 142 
5.2. Filtering of autophagy genes ............................................................................... 142 
5.3. Supplementary tables .......................................................................................... 143 
6. References ................................................................................................................... 144 
CHAPTER 7  CONCLUDING DISCUSSION ................................................................................. 149 
1. General discussion ....................................................................................................... 151 
2. Future perspectives ..................................................................................................... 159 
3. References ................................................................................................................... 162 
SUMMARIES ........................................................................................................................... 167 
1. English summary ......................................................................................................... 167 
2. Nederlandstalige samenvatting .................................................................................. 169 
3. Popular summary ........................................................................................................ 171 
4. Popular summary (Dutch) ........................................................................................... 173 
SCIENTIFIC ACKNOWLEDGEMENTS ........................................................................................ 175 
PERSONAL CONTRIBUTION .................................................................................................... 176 
CONFLICTS OF INTEREST STATEMENT .................................................................................... 177 
ACKNOWLEDGEMENTS - DANKWOORD ................................................................................ 178 
CURRICULUM VITAE ............................................................................................................... 190 
7 
 
SCIENTIFIC COMMUNICATIONS ............................................................................................. 192 
 
8 
 
LIST OF ABBREVIATIONS 
AIM2 Absent in melanoma 2 
AMPK AMP-activated protein kinase  
ASC Apoptosis-associated speck-like protein containing a CARD 
ASO Antisense oligonucleotide 
ATG14 Autophagy Related 14 
ATG16L1 Autophagy Related 16 Like 1 
ATG4D Autophagy Related 4D Cysteine Peptidase 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BF Brightfield 
BiP Binding immunoglobulin protein 
BSA Bovine serum albumin 
CALR Calreticulin 
CARD Caspase recruitment domain 
CARD15 Caspase recruitment domain-containing protein 15 
CASP1 Caspase-1 
CCS Complete chelating solution 
CD Crohn's disease 
CHMP2A  Charged Multivesicular Body Protein 2A 
CHMP4B  Charged Multivesicular Body Protein 4B  
CK-18 Cytokeratin-18 
CK-20 Cytokeratin-20 
DAI Disease activity index 
DAMP Danger associated molecular pattern 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide  
DNA Deoxyribonucleic acid  
DNAJB11 DnaJ Heat Shock Protein Family (Hsp40) Member B11 
DNAJB9 DnaJ Heat Shock Protein Family (Hsp40) Member B9  
dsDNA Double stranded DNA 
DSS Dextran Sodium Sulfate 
EDTA  Ethylenediaminetetraacetic acid 
EGF Epidermal Growth Factor 
ELISA Enzyme linked immunosorbent assay 
EMA European Medicines Agency 
eQTL Expression quantitative trait loci 
ER Endoplasmic reticulum 
ERAD ER-associated degradation  
9 
 
ERC European Research Council 
ESCRT Endosomal Sorting Complex Required for Transport 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FDR False discovery rate 
FELASA  Federation for Laboratory Animal Science Associations 
FHC Fetal human colon  
FKBP14 FK506 Binding Protein 14  
GABARAPL1 GABA Type A Receptor Associated Protein Like 1 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GRP78 78 kDa glucose-regulated protein 
GvHD Graft-versus-host disease 
HERPUD1 Homocysteine Inducible ER Protein With Ubiquitin Like Domain 1 
HIN Hematopoietic interferon-inducible nuclear protein 
HLA Human Leukocyte Antigen 
HMGB1 High mobility group box-1 
hpi Hours post isolation 
HRP Horseradish peroxidase 
HSP90B1 Heat Shock Protein 90 Beta Family Member 1  
HSPA5 Heat Shock Protein Family A (Hsp70) Member 5 
HYOU1 Hypoxia Up-Regulated 1  
IBD Inflammatory bowel disease 
IC50 Half maximal inhibitory concentration 
IEC Intestinal epithelial cell  
IFI16 Interferon inducible 16  
IFIX Interferon-inducible protein X  
IFN Interferon 
IFX Infliximab 
IgG Immunoglobulin G 
IHC Immunohistochemistry 
IL Interleukin 
i.p. intraperitoneal 
IQR Interquertile range 
IRGM Immunity Related GTPase M 
i.v. Intravenous 
JAK Janus kinase 
JAKINIB Janus kinase inhibitor 
KDELR3 KDEL (Lys-Asp-Glu-Leu) Endoplasmic Reticulum Protein Retention Receptor 3  
KI67 Antigen Ki-67/Marker Of Proliferation Ki-67 
LGR5 Leucine Rich Repeat Containing G Protein-Coupled Receptor 5 
10 
 
LIMMA linear models for microarray data  
LP Lamina propria 
LPS Lipopolysaccharide 
LRRK2  Leucine Rich Repeat Kinase 2  
MADCAM Mucosal Addressin Cell Adhesion Molecule 
MAP1LC3A Microtubule Associated Protein 1 Light Chain 3 Alpha 
MIAME Minimum information about a microarray experiment 
MNDA Myeloid Cell Nuclear Differentiation Antigen 
mNoggin Murine Noggin 
mRNA Messenger RNA 
mtDNA Mitochondrial DNA 
MTMR3 Myotubularin Related Protein 3 
mTOR Mechanistic/Mammalian target of rapamycin 
MTX Methotrexate  
MUC2 Mucin 2 
NFAT1 Nuclear factor of activated T-cells 
NLR NOD like receptor 
NLRC4 NLR family, CARD domain containing 4  
NLRP NLR family, pyrin domain containing 
NOD2 Nucleotide-binding oligomerization domain-containing protein 2 
ORMDL3 ORMDL Sphingolipid Biosynthesis Regulator 3 
P62 Sequestosome-1 
PAMP Patogen associated molecular pattern 
PBA Phenylbutyrate  
PBS  Phosphate buffered saline 
PCR Polymerase chain reaction 
PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 
PDGFR-α Platelet derived growth factor receptor-alpha 
PDIA5 Protein Disulfide Isomerase Family A Member 5 
PDIA6 Protein Disulfide Isomerase Family A Member 6 
PE Phosphatidylethanolamine  
PFA Paraformaldehyde  
PRKAB2 Protein Kinase AMP-Activated Non-Catalytic Subunit Beta 2 
PRR Pattern recognition receptor 
PtdIns Phosphatidylinositol  
PtdIns3P PtdIns 3-phosphate  
PYHIN Pyrin and HIN domain family 
qRT-PCR Quantitative realtime-polymerase chain reaction 
RA Risk allele 
RA Rheumatoid arthritis  
RIPA Radioimmunoprecipitation assay 
11 
 
ROCK Rho-Associated Protein Kinase  
ROS Reactive oxygen species 
Rspo1  R-Spondin 1 
s.c. Subcutaneous 
SCID Severe combined immunodeficiency  
SEC61A1 Sec61 Translocon Alpha 1 Subunit  
SMAD SMAD family member 3 
Smad7 Mothers against decapentaplegic homolog 7 
SNP Single nucleotide polymorphism 
SPF Specific-pathogen-free  
SRPR SRP Receptor Alpha Subunit 
SSR1 Signal Sequence Receptor Subunit 1 
STAT Signal transducer, and activator of transcription 
SYVN1 Synoviolin 1 
TCR T cell receptor 
TDT Terminal deoxynucleotidyl transferase 
Tg Thapsigargin 
TGF-β Transforming growth factor-beta 
TNF-α Tumor necrosis factor-alpha 
TPMT Thiopurine methyltransferase 
Treg Regulatory T cell 
TUDCA Tauroursodeoxycholic acid  
TYK2 Tyrosine Kinase 2 
UC Ulcerative colitis 
ULK1 Unc-51 Like Autophagy Activating Kinase 1 
UPR Unfolded protein response 
USA United States of America 
VCAM Vascular Cell Adhesion Molecule 
WB Western blot 
WFS1 Wolframin ER Transmembrane Glycoprotei 
Wnt3a Wnt Family Member 3A 
XBP1 X-Box Binding Protein 1 
ZO-1 Zonula Occludens 1 
 
13 
 
CHAPTER 1 
 
INTRODUCTION 
  
14 
 
  
15 
 
CHAPTER 1: INTRODUCTION 
This chapter has been adapted from Vanhove W, Nys K, Vermeire S. Therapeutic innovations 
in inflammatory bowel diseases. Clin Pharmacol Ther. 2016 Jan;99(1):49-58. 
1. The paradigm of patient management in IBD 
Inflammatory bowel disease (IBD) is characterized by a chronic transmural (in case of Crohn’s 
disease) or mucosal (in case of ulcerative colitis) inflammatory infiltrate as a result of a 
defective immune response to enteric microbiota. Crohn’s disease and ulcerative colitis are 
considered the two opposite phenotypes of the spectrum and both diseases have their highest 
incidence rates between 15 and 25 years of age. The most noteworthy advance in the 
treatment management of IBD of the past decades has certainly been the introduction of 
monoclonal antibodies directed to tumor necrosis factor-alpha (TNF-α). The role of TNF-α in 
IBD was indicated by several studies showing upregulation of this cytokine in stool, serum, 
and the intestinal mucosa of patients with IBD1-4. Pivotal randomized controlled trials have 
demonstrated efficacy in induction and maintenance of remission, in endoscopic healing, and 
in the reduction of surgical resections and hospitalization rates5-11. In August 1998 (and one 
year later, also in Europe), Remicade® (infliximab (IFX)), a chimeric monoclonal anti-TNF 
antibody, was approved by the US Food and Drug Administration (FDA) for short-term 
treatment of moderate-to-severe Crohn’s disease in patients who did not respond to 
conventional therapy or had a fistulizing phenotype and, as such, IFX became the first bio-
logical agent that was approved for IBD treatment. Over the years, humanized and human 
antibodies were introduced, which presented improvements in the way of administration 
from i.v. to s.c. and in reducing immunogenicity and allergic reactions. Currently, IFX, 
adalimumab, certolizumab pegol, and golimumab are all approved for treatment of IBD. A 
recent meta-analysis by Hazlewood et al. compared all anti-TNFs and concluded that 
adalimumab and the combination of IFX with azathioprine were the most effective therapies 
to induce and maintain remission in patients with Crohn’s disease12. A TNF-efficacy meta-
analysis has also been performed for ulcerative colitis; overall, the results point to a slightly 
increased benefit of IFX over adalimumab and golimumab for the induction and maintenance 
of clinical response, remission, and mucosal healing13. Although anti-TNF agents are 
efficacious in a significant proportion of patients, there are several concerns. In terms of 
efficacy, only 30–50% of patients will achieve clinical and mucosal remission, considered to be 
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the goal of therapy currently, therefore leaving large margins for improvement. The long-term 
corticosteroid-free remission rates are even lower and do not succeed 20–30%. Second, these 
agents have a quick onset of action but are hindered by significant loss of response, which is 
largely explained by antibody formation and increased clearance rates. Third, although the 
overall safety profile is considered safe, there are concerns with respect to particular rare 
malignancies (hepatosplenic T-cell lymphoma, melanomas). However, more common are the 
psoriasiform skin lesions that occur in 20% of patients and may be incapacitating because of 
their location in the face14.  
From a mechanistic conceptual point of view, anti-TNF agents reduce the inflammatory 
infiltrate but do not block the underlying pathogenic triggers. Hence, treatment cessation 
results in recurrence of inflammation within one year in more than 50% of patients. The 
PREVENT study investigated if anti-TNF, when started immediately postoperative in the case 
of a curative resection of Crohn’s disease, could prevent disease recurrence. Although the 
proportion of patients with endoscopic disease recurrence was significantly lower in the anti-
TNF treated arm than in the placebo-treated arm, the results showed that anti-TNF is not able 
to fully stop disease progression15. 
 
All these points illustrate the need to continue the search for novel therapeutic agents. This 
development could be situated on various levels. First of all, there are the many compounds -  
monoclonal antibodies and/or small molecules - that target inflammatory cells. A different 
approach consists of impacting on very early events of disease pathogenesis, and stimulates 
or suppresses the disease depending on the target. The recent anti-sense therapy against 
Smad7 could be considered in this approach; but so are the various cell-based therapies. 
However, a truly innovative management would be one that is based on the underlying 
mechanisms of disease. In contrast to the general acceptance of a multifactorial etiology of 
the disease, treatment of IBD so far is very “homogenous” and consists of (non)-specific anti-
inflammatory agents, including corticosteroids, immunosuppressive drugs (azathioprine and 
methotrexate), and/or anti-TNF monoclonal antibodies. It is surprising that the advances in 
translational knowledge about the factors triggering disease onset have not been translated 
to approach the disease from a molecular angle. Nevertheless, a number of key cellular 
pathways have emerged, including bacterial recognition, autophagy, endoplasmic reticulum 
17 
 
stress, and intestinal barrier function. If the therapeutic approach could be based on the 
underlying functional mechanisms driving the disease in a given patient, this would represent 
a breakthrough in the current paradigm of treating complex multifactorial inflammatory 
conditions and could revolutionize the paradigm of disease management. 
2. Toward innovative management of IBD 
 
The relatively high treatment failure rate of anti-TNF therapy and the emergence of new 
therapeutic classes highlight the need for patient selection, a more thoughtful use of anti-TNF 
agents, and targeting new pathways involved in IBD. In line with TNF blockade, an evident 
choice for IBD therapeutics is compounds that target other inflammatory mechanisms or cells. 
In that perspective, new cytokine antibodies or strategies inhibiting downstream cytokine 
signaling or adhesion molecules have shown potential and/or have been approved recently. 
2.1. Anti-IL-12/23 
Interleukin (IL)-12 and IL-23 are important proinflammatory cytokines belonging to the IL-12 
superfamily. They are composed of the same p40 subunit allowing simultaneous inhibition of 
these cytokines. Their association with IBD is well accepted as both cytokines are upregulated 
in intestinal mucosa of patients with IBD and genetic polymorphisms in the genes encoding 
the IL-23 receptor as well as the p40 subunit are associated with IBD16. These findings are 
supported by the fact that IL-12 and IL-23 mitigate the differentiation of naive T cells into Th1 
and Th17 cells, respectively, and thus contribute to the lymphocytic signature that is 
associated with IBD17. The phase 2 randomized, placebo-controlled trial in patients with 
Crohn’s disease demonstrated that ustekinumab, a human monoclonal anti-p40 anti-body, 
was most efficacious in anti-TNF exposed patients with Crohn’s disease18. As such, subsequent 
studies with this compound focused on this specific patient group and confirmed previous 
results19, 20. The efficacy of ustekinumab in anti-TNF naive patients was addressed in the large 
phase 3 UNITI programs: UNITI-1 was designed to study the short-term efficacy of 
ustekinumab in patients with Crohn’s disease with failure or intolerance to anti-TNF, whereas 
only anti-TNF naive CD patients were included in UNITI-2. These studies gave a final 
confirmation that ustekinumab is equally effective regardless of previous anti-TNF exposure. 
Apparent differences between UNITI-1 and -2 can be explained by differences in disease 
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duration and the fact that disease was less refractory in the UNITI-2 population21. This drug 
has in the meanwhile been approved by the FDA and EMA to treat moderate-to-severe CD. 
In contrast to ustekinumab, which allows simultaneous suppression of two cytokines, data 
from a phase II trial with MEDI2070 have recently been released. This human anti-IL-23 
antibody that does not target IL-12 and significantly affects clinical and biological readouts in 
patients with Crohn’s disease refractory to TNF antagonists22. Similar phase II results were 
obtained with another IL-23-selective antibody, risankizumab23. However, whether these 
compounds will outperform their competitors remains to be demonstrated. 
Besides TNF-a, IL-12, and IL-23, several other cytokines have been shown to be involved in IBD 
and may therefore act as potential drug targets. One of these is IL-17; unfortunately, the 
development of the human anti-IL-17A antibody secukinumab was stopped because of 
absence of a clear treatment benefit and worsening of Crohn’s disease in some patients24.  
2.2. Janus kinases inhibition 
 
Inflammatory cytokine function can also be blocked by inhibiting the intracellular cytokine-
mediated signals, typically via the Jak-Stat pathway. Janus kinases (Jaks) & signal transducers, 
and activators of transcription (Stats) are intracellular signaling molecules that mediate the 
signal of initial ligand-receptor binding to modulation of gene expression. The mammalian Jak 
family consists of four members that each transduce the signal of a specific set of cytokines 
and thereby are highly involved in inflammatory responses (Figure 1). For an overview on the 
Jak-Stat pathway, we refer the readers to Murray et al25. The relationship between Jak-Stat 
signaling (including their upstream ligand-receptor systems) and IBD has been extensively 
highlighted by animal studies, genetic association, and increased levels of cytokines that 
converge to Jak-Stat16, 26.  
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Figure 1: The JAK family plays a central role in signaling transduction for multiple growth factors as well as 
cytokines, including the ones that have been implicated in the pathogenesis of autoimmune diseases as based 
on genome wide association studies as well as mouse models of inflammation. 
As Jak-Stat signaling is involved in a number of (auto)inflammatory diseases, several oral small 
molecules have been developed. Some of them (tofacitinib and filgotinib) have shown efficacy 
in preclinical studies and are currently clinically tested for the treatment of IBD27, 28. Tofacitinib 
is an oral pan-Jak inhibitor that preferentially binds to Jak1 and 3 (and Jak2 at higher 
concentrations), hereby diminishing the downstream effects of several IBD-associated 
cytokines27. The two phase III induction trials (OCTAVE 1 and 2) in UC showed a significant 
benefit over placebo with an increased infection risk as major adverse event29. In patients with 
moderate-to-severe ulcerative colitis, the oral administration of 10 and 15 mg doses resulted 
in significant dose-related reduction of most clinical and endoscopic disease parameters as 
well as inflammatory biomarker levels at week eight30. Because of these promising results, 
tofacitinib has been filed to the EMA for the treatment of UC. On the other hand, the phase II 
tofacitinib trial in Crohn’s disease showed less convincing results, in part, because of high 
placebo response rates31.  
Filgotinib (GLPG0634) is a JAK1-selective (also JAK2 at higher dosage) small molecule inhibitor, 
potentially resulting in a better safety profile. Encouraging results of phase II trials for the 
treatment of Crohn’s disease but also rheumatoid arthritis have been published and a large 
phase III program is ongoing32, 33. Preclinical studies showed convincing efficacy in models of 
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dextran sulfate sodium28 and adoptive T-cell transfer murine colitis (presented in this thesis 
manuscript) with a significant improvement of symptom and histological scores. 
Jak inhibitors therefore seem to be promising IBD drug candidates. Nevertheless, their safety 
profile when used for maintenance will be crucial. Tofacitinib could lead to unwanted 
blockade of erythropoietin signaling through JAK2 inhibition, aggravating anemia, which is 
already an IBD-related comorbidity34. Furthermore, as IL-10 partially exerts its 
immunoregulatory effect through JAK1, both agents could theoretically aggravate intestinal 
inflammation in a subset of patients25, 26. Accurate patient selection and careful dose 
optimization when using small-molecule Jak inhibitors in IBD is therefore recommended. 
2.3. Leukocyte trafficking 
 
Another promising idea is to dampen the influx of immune cells toward the inflamed sites in 
the intestinal mucosa, rather than targeting inflammatory cells and mediators that are already 
present. There are several arguments favoring the development of anti-leukocyte migration 
strategies in IBD. First of all, IBD is characterized by a strong adhesion molecule-mediated 
mucosal infiltration of leukocytes. Next, VCAM-1, the ligand for integrin α4β1, is upregulated 
in the vascular endothelium of the inflamed gut35. Furthermore, MADCAM, the ligand for 
integrin α4β7, which is responsible for the trafficking of lymphocytes to the gut, is also 
upregulated in IBD mucosa36. Preclinical studies showed efficacy of blocking integrin α4β7 in 
the spontaneous cotton top tamarin colitis model37, 38. More recently, the genetic association 
between IBD and integrins (integrin alpha-L), chemokines, and chemokine receptors has been 
uncovered16.  
Anti-integrin strategies have been developed and two compounds, natalizumab and 
vedolizumab, are FDA approved for the treatment of IBD. Although clinical trials (ENCORE and 
ENACT) showed encouraging results for natalizumab (anti-α4) in patients with Crohn’s disease, 
in addition, leukocyte migration to the central nervous system was prevented, promoting 
progressive multifocal leukoencephalopathy, an often lethal disease caused by reactivation of 
John Cunningham virus in the brain39, 40. Natalizumab is only approved in the United States 
and not in Europe41, 42. A more favorable safety profile was obtained for vedolizumab, a 
humanized monoclonal antibody that selectively binds α4β7 integrin, therefor selectively 
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targeting gut homing leukocytes. The large phase 3 GEMINI programs demonstrated superior 
efficacy in induction and maintenance of remission and, as of 2014, vedolizumab was 
approved by the FDA and the European Medicines Agency for treatment of Crohn’s disease 
and ulcerative colitis. In contrast to the GEMINI I study in ulcerative colitis,43 the GEMINI II 
program in Crohn’s disease showed a slower onset of response, both for anti-TNF naive 
(GEMINI II)44 and nonresponsive patients (GEMINI III),45 indicating the need for a bridging 
therapy46. The recently published open-label GEMINI long-term safety trial data show that 
both UC and CD patients benefit from vedolizumab therapy in the long term47.  
Etrolizumab, a humanized monoclonal anti-β7 antibody, demonstrated significant clinical 
improvement and favorable safety in a phase 2 study in patients with moderate-to-severe 
ulcerative colitis and failure to respond to conventional treatments48. Based on these 
encouraging results, a large phase 3 program is ongoing in which some studies also include an 
active comparator arm against anti-TNF agents (e.g., NCT02136069 and NCT02163759). 
3. Targeting early events in IBD pathogenesis to restore intestinal homeostasis 
Despite the fact that blocking leukocyte trafficking and downregulating local inflammatory 
responses have shown clinical benefits in IBD, these treatments cannot fully interfere with the 
chronic cycle of inflammation without continuous drug therapy. New approaches are needed 
that target initial events in intestinal inflammatory pathogenesis in order to reset the mucosal 
immune system to a state of homeostasis. A provocative study published in the New England 
Journal of Medicine earlier this year indicated that this may be achieved by antisense-
mediated targeting of disturbed TGF-signaling. Likewise, cell-based therapies may also hold 
this promise. 
3.1. Anti-Smad7 (TGF-β/BMP signaling) and other antisense oligonucleotides 
TGF-β is a pleiotropic cytokine involved in embryonic development, but it is also responsible 
for cellular homeostasis by exerting anti-inflammatory effects. In short, binding of TGF-β to its 
type II receptor causes recruitment and activation of a type I receptor, which, in turn, 
phosphorylates the second messenger complex, SMAD2/3. SMAD2/3-P recruits and binds 
SMAD4, forming a complex which will translocate to the nucleus where it acts as a 
transcription factor eventually leading to downregulated nuclear factor-kappa B signaling 
after exposure to inflammatory cytokines, and thus tempering the inflammatory response49. 
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SMAD7 is a negative regulator of TGF-β signaling by binding to the type I receptor, hereby 
interfering with SMAD2/3 phosphorylation50. Both TGF-β and SMAD7 proteins are 
upregulated in IBD mucosa, accompanied by a reduction in SMAD3 phospho-rylation50, 51. 
These observations have been confirmed in animal models of TNBS and oxazolone-induced 
colitis. Furthermore, administration of oral anti-SMAD7 oligonucleotide, interfering with 
SMAD7 mRNA translation, reduced colitis in mice52. These findings led to the development of 
Mongersen®, an oral anti-SMAD7 oligonucleotide, for the treatment of IBD. The phase II trial 
by Monteleone et al., in which a two-week administration of Mongersen® led to a clinical 
response that was sustained for over three months, indicated a very long-term treatment 
effect53. The results of this study needed confirmation by studies that included endoscopy and 
thus recently the efficacy of Mongersen® was also confirmed at an endoscopic level in a small 
open label study by Feagan et al.54, 55. Nevertheless, there are is still a need for properly sized, 
placebo controlled studies that include endoscopy-based endpoints. Also, safety concerns 
have been raised as increased TGF-β signaling may induce fibronectin and collagen synthesis 
leading to fibrosis and stenosis of the bowel54. This was not observed during a phase I trial 
with six months of follow-up, as indicated by small intestine contrast ultrasonography and 
serum markers of fibrosis; although such side effects can only be excluded after long-term 
observation56. Nevertheless, the rate and longevity of clinical improvement in the Monteleone 
et al. study of 2015 strengthens the hypothesis that this drug can actually reset the mucosal 
immune system and has given many gastroenterologists high expectations53. 
Binding (and thereby degradation of) target mRNA with (orally administrable) antisense 
molecules allows significant and specific inhibition of the involved pathway (Figure 2). It is 
therefore not surprising that antisense molecules targeting other players in IBD pathogenesis 
have been developed and clinically tested. 
Alicaforsen is an intercellular adhesion molecule-1 antisense oligonucleotide designed for 
rectal (local) administration in patients with ulcerative colitis. Intercellular adhesion molecule-
1 is a transmembrane protein that is expressed on many cell types involved in intestinal 
inflammation such as epithelial, endothelial, and immune cells57. It is involved in leukocyte 
migration as well as cell-to-cell immune signaling. Suppressing intercellular adhesion 
molecule-1 should therefore act on intestinal inflammation at multiple levels. This might 
explain why clinical studies in patients with ulcerative colitis have shown both long-term and 
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short-term efficacy57, 58. The topical administration route of Alicaforsen has also led to a 
successful open-label trial in patients with pouchitis and a phase III program is ongoing 
(NCT02525523)59. However, it showed no efficacy when administered i.v. to patients with 
Crohn’s disease60.  
The class of antisense oligonucleotides (ASOs) is generally considered as safe, however, 
preclinical studies indicated slight histological and functional changes in the kidneys of 
monkeys that were treated with higher doses of ASO, these alterations co-occurred with the 
accumulation of ASO molecules in the kidney61. These findings might explain a case of acute 
kidney injury with renal ASO accumulation in a 56-year-old woman who was treated with an 
ASO directed against PCSK9 and will need to be further investigated62. 
 
Figure 2: The TGF-b1 receptor transduces its signal by phosphorylating SMAD2 and 3 after which it will form a 
complex with SMAD4 and translo-cate to the nucleus where they will act as a transcription factor. The phos-
phorylated SMAD complex will alter transcription, leading to inflammatory suppression, and promoting cellular 
homeostasis. SMAD7 is a negative regulator of TGF-b signaling by interacting with the receptor and thereby 
preventing SMAD2/3 phosphorylation after initial binding of the ligand. Mongersen interferes with this 
inhibitory process by selectively binding SMAD7 mRNA and hereby preventing translation and promoting RNAse 
H dependent degradation of the mRNA molecule. 
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3.2. Cell-based therapies 
Another highly promising concept in IBD management has been the introduction of cell-based 
therapies (i.e., the administration of ex vivo expanded/manipulated (stem) cells that have 
immunosuppressive effects and that are derived from the patient’s own tissue (autologous) 
or from HLA-matching donors (allogeneic))63. Allogeneic and autologous hematopoietic stem 
cell transplantation has been used successfully in oncology. When used in patients who had 
concomitant Crohn’s disease, this treatment induced remission, which was believed to result 
from profound immunosuppressive and tissue-repair inducing properties63, 64. Results of the 
Autologous Stem Cell Transplantation International Crohn’s Disease trial indicate that the 
promising treatment efficacy cannot only be explained by pretransplant conditioning. 
Nevertheless, the mortality risk associated with bone marrow transplantation makes this 
approach unfavorable as treatment for nonlethal diseases, such as IBD. 
Mesenchymal stromal cells refer to several bone-marrow derived proliferative cell types that 
can differentiate into a wide variety of nonhematopoietic cells in vitro. These cells inhibit 
cellular inflammatory responses and induce an immunotolerant phenotype in the gut65-67. 
Their wide distribution throughout the body and their preliminary efficacy in Crohn’s disease 
without immune suppression or bone marrow depletion makes mesenchymal stromal cells 
therapy an ideal alternative to bone marrow or stem cell transplantation. Phase I and II studies 
in moderate-to-severe Crohn’s disease showed promising results and high potential to reset 
the intestinal mucosa into immunologic homeostasis66-68.  
Alternative or more easily available cell sources are being tested for mesenchymal stromal 
cells therapy. In 2009, a phase II study showed that autologous adipose-derived stem cells 
could successfully heal complex perianal fistulas in both patients with Crohn’s disease and 
patients without Crohn’s disease69. Administration of allogeneic adipose-derived stem cells 
also showed efficacy in phase II70 and III71 trials and has led to the FDA approval of Cx601 for 
the treatment of complex perianal fistulas in Crohn’s disease. European Medicines Agency 
approval is expected in the first quarter of 2018. In 2012, Desreumaux et al.72 published the 
results of the first clinical trial showing safety and efficacy of i.v. administration of ex vivo 
expanded, autologous blood-derived regulatory T lymphocytes (Ovasave) to patients with 
refractory Crohn’s disease72 but the phase IIb study was temporary halted (NCT02327221). An 
overview of cell-based therapies that have already been clinically tested is given in Table 1. 
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Table 1: An overview of cell-based therapies that have already been clinically tested in IBD management 
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4. Future prospects in IBD management 
4.1.  A mechanism-based approach 
Given the multifactorial etiology of IBD and the heterogeneity in clinical phenotypes, a 
management system based on the key cellular pathways triggering or contributing to disease 
onset should be attempted. It is surprising that the advances in knowledge about the 
molecular factors have not been translated to approach the disease from a molecular angle. 
Such a molecular angle will allow us to functionally characterize the main pathways identified 
in IBD in a given patient and correlate this to meaningful outcomes. This seems a more 
intelligent approach but has never been explored. Moreover, this would represent a 
breakthrough for treating complex multifactorial inflammatory conditions in general. 
The current hypothesis in IBD is that the disease results from a faulty immune recognition, 
tolerance, and defense against the commensal microbiota and dietary antigens present in 
Westernized diets and in a genetically susceptible host73. The genetic progress has been 
instrumental thanks to collaborative efforts led by the international IBD Genetics Consortium. 
Of the more than 200 IBD susceptibility loci identified today by genome-wide association 
studies and subsequent meta-analyses, key cellular pathways have emerged, including 
bacterial recognition, autophagy, endoplasmic reticulum stress, and intestinal barrier 
function16, 74. Probably the largest theme resulting from genetic studies in IBD is that a 
deficient bacterial recognition and handling underlies disease pathogenesis. This was first 
demonstrated by the identification of NOD2/CARD15 mutations in 200175, 76. Subsequently, 
murine models of colitis and human studies linked mutations in this gene to defective Paneth 
cell function and defensin secretion77, 78.  
A second important pathway in disease pathogenesis relates to intestinal barrier function. The 
gut mucosa is constantly exposed to a huge burden of dietary antigens, diverse 
microorganisms, and external compounds. Its ability to act as a barrier against the passage of 
potentially harmful molecules is therefore critical for normal homeostasis. The single cell layer 
of the intestinal epithelium constitutes the primary determinant of intestinal barrier function, 
along with the mucus layer and immunity-related responses (innate immune cells and 
secreted proteins)79. A primary defect in barrier function in IBD is underscored by animal colitis 
models, in which increased intestinal permeability precedes disease expression by weeks to 
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months80. Moreover, in clinically asymptomatic patients with Crohn’s disease, an impaired 
permeability was found to precede clinical relapse and the onset of symptoms by up to one 
year. These barrier defects also exist in a subset of unaffected family members of patients 
with Crohn’s disease81. An interesting case described a 21-year-old girl with a strong family 
history of IBD who had an increased intestinal permeability at least eight years before the 
diagnosis of Crohn’s disease82. In addition, human genome-wide association studies identified 
several variants in epithelial cell integrity genes. Endoplasmic reticulum stress-induced 
signaling (the unfolded protein response, UPR) and autophagy are essential for maintaining 
normal cellular homeostasis and appropriate immune/inflammatory responses in the human 
body83-85. The UPR is a stress response mechanism essential for cell homeostasis which is 
activated by an accumulation of un- or misfolded proteins in the endoplasmatic reticulum (ER), 
a status called ER stress. Activation of the UPR will lead to translational attenuation, induction 
of chaperones and increased proteasomal degradation in order to reduce the protein load and 
increase the protein folding capacity of the ER. Defects in the UPR machinery or prolonged ER 
stress can lead to inflammation and even apoptosis (Figure 3). As such ER stress/UPR can be 
directly involved in the pathogenesis of IBD by interfering with protein secretion (mucus 
proteins, anti-microbial factors and cytokines), by causing defects in the epithelial barrier of 
the gut and by responding inadequately to commensals or pathogens84, 86, 87 
 
Figure 3: Accumulation of unfolded or misfolded proteins in the ER activates the unfolded protein response 
(UPR) which comprises four distinct cellular processes: (A) Transcriptional induction of ER chaperones increases 
protein folding activity and prevents protein aggregation. (B) Translational attenuation reduces the load of new 
protein synthesis and prevents further accumulation of unfolded proteins. (C) The ER-associated degradation 
(ERAD) pathway eliminates misfolded proteins by the ubiquitin-proteasome system. (D) Unresolved ER stress 
(eg. when the UPR is severely impaired) can eventually lead to apoptosis. Figure reproduced from Araki et al.88 
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Autophagy is an important well-conserved cellular clearance mechanism 89, 90. This process 
contributes to homeostasis by provision of essential nutrients in times of nutrient deprivation. 
Autophagy also has several immunologic functions by aiding in the clearance of intracellular 
microbes or organelles, antigen presentation, inflammasome inhibition and cytokine 
secretion (Figure 4). Hence, defects in this pathway can disturb the innate as well as the 
adaptive immune response to microorganisms and therefore contribute to the pathogenesis 
of IBD85, 89, 91-94.  
 
Figure 4: Autophagy interacts with essential steps in the immune response. This catabolic process aids in the 
direct detection and elimination of microbes and/or pathogens. Upon activation of PRRs autophagy might be 
induced as an effector mechanism, while intracellular SLRs directly target microbes and/or pathogens for 
autophagosome encapsulation. Malfunctioning or damaged mitochondria release ROS and mitochondrial 
dsDNA, which can activate inflammasomes resulting in the production of proinflammatory mediators. 
Autophagosomal removal of these malfunctioning organelles thereby regulates or inhibits inflammasome 
activation. Autophagy might also aid in the unconventional secretion of cytoplasmic components such as 
antimicrobial compounds and/or proinflammatory mediators. Finally, autophagosomes fuse with lysosomes to 
degrade their content (microbes, pathogens and endogenous cytoplasmic content). The generated peptides can 
subsequently be shuttled towards the cell membrane for MHC class II-based antigen presentation resulting in 
regulation of adaptive immune responses. Abbreviations: dsDNA, double-stranded DNA; PRR, pattern 
recognition receptor; ROS, reactive oxygen species; SLR, sequestosome 1/p62-like receptor. Figure reproduced 
from Nys et al.89 
Both the ER stress and the autophagy pathways can interact with inflammasomes. These are 
important immune regulators for intestinal homeostasis that allow recruitment and activation 
of the inflammatory caspase-1 upon stimulation of one of the inflammasome-sensors by a 
wide variety of intracellular danger and pathogen associated molecular patterns (DAMPs & 
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PAMP respectively). Caspase-1 activation will lead to the maturation and secretion of IL-1β 
and IL-18, which are important inflammatory mediators. Furthermore, activated caspase-1 
can also trigger pyroptosis, a specific form of cell death associated with inflammation. In 
contrast to apoptosis, pyroptosis will release cytoplasmic components into the extracellular 
space which can fuel inflammatory processes in adjacent cells. Inflammasome activation can 
have homeostatic functions in the intestinal epithelium by providing adequate amounts of IL-
18 which is needed for intestinal cell proliferation and barrier function. In contrast, 
inflammasome activation in the lamina propria (LP) has detrimental effects as both IL-18 and 
IL-1β will induce production of other pro-inflammatory cytokines and chemokines leading to 
intestinal inflammation95-100 (Figure 5).  
 
Figure 5: Components of the inflammasomes, their assembly and activation. Representative image showing the 
general mechanisms of activation of the inflammasomes largely based on NLRP3 inflammasome signaling. A 
large variety of endogenous and exogenous (microbial) molecules (DAMPs and PAMPs) can induce the 
inflammasome cascade. Two signals are needed to secrete the inflammasome related cytokines IL-1β and IL-18 
and other cytokines (such us IL-6 and TNFα), one comes from TLRs and the other one from the cytoplasmatic 
NLRs to, at the end, induce inflammation or pyroptosis. Figure reproduced from Aguilera et al.97 
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These pathways are perturbed in IBD by demonstration of genetic defects in XBP1 and 
ORMDL3 (ER stress), IRGM, ATG16L1, and LRRK2 (autophagy) and NLRP3 (inflammasome)16, 
101. Additionally, our group also added ULK-1 (ATG1) to the list of autophagy-related Crohn’s 
disease susceptibility genes102, 103. Interestingly, ER stress, autophagy and inflammasomes 
seem to be cross-linked. Several studies have shown that the UPR can activate autophagy 
mechanisms, implicating that defects in the autophagy machinery can lead to an increased ER 
stress and vice versa93, 103, 104. Moreover autophagy has an inhibitory effect on initial 
inflammasome activation, however it has a promoting effect on the secretion of 
inflammasome effectors IL-1β & IL-1899. 
A concerted unfolded protein response and/or autophagy activation might represent an 
innate mechanism to sense and appropriately respond to threatening changes of the mucosal 
microbial environment. As a consequence, (genetic) events causing imbalances in 
endoplasmic reticulum stress maintenance and/or normal autophagy are important drivers of 
human inflammatory diseases, like IBD. Preclinical studies have been performed with the 
conjugated bile-acid tauroursodeoxycholic acid and to a lesser extent 4-phenylbutyrate, which 
are both chemical chaperones and thus are able to resolve endoplasmic reticulum stress. 
These were efficacious in reducing acute and chronic dextran sulfate sodium-induced colitis, 
but also spontaneous colitis in IL-10 knockout mice87. Furthermore, Laukens et al. showed that 
clinical signs of dextran sulfate sodium-induced colitis are preceded by events that trigger 
epithelial apoptosis, such as caspase-3 upregulation and Bcl2 downregulation105. These events 
were prevented or reduced in tauroursodeoxycholic acid treated mice. As for autophagy, 
several of the already established IBD treatments (including anti-TNF therapy) already 
influence autophagic processes89. In 2008, the clear association of defective autophagy and 
IBD had led to the first successful clinical use of the chemical autophagic upregulator 
rapamycin (Sirolimus®) in a patient with failure to respond to standard treatments.106 More 
recently, Mutalib et al. showed in a small study that the same drug was effective to treat 
children with severe refractory IBD107. These still limited results support the initiation of larger 
clinical trials and the development of drugs that upregulate autophagy and/or reduce 
endoplasmic reticulum stress in the intestinal mucosa. 
Finally, the microbiota plays a pivotal role in the onset and perpetuation of IBD, as mentioned 
previously. Intestinal microbiota is essential for the development of inflammation in colitis 
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animal models as germ-free mice do not develop colitis108. Our group has contributed to the 
literature in this field by showing that the gut mucosa remains intact after diversion of the 
fecal stream in humans, whereas after exposure of the gut to luminal contents, recurrence of 
inflammation is observed109. The overall composition of the gut microbiota and the presence 
or absence of specific species is important for homeostasis and tolerance of the immune 
system. Metagenomics identified three human enterotypes based on the microbiota 
composition, each driven by different genera110. Patients with IBD have fewer anti-
inflammatory bacteria and more proinflammatory bacteria; this imbalance is also described 
as dysbiosis. A qualitative and quantitative reduction of the firmicutes and bacteroidetes phyla 
and concomitant increase of proteobacteria has repeatedly been demonstrated in IBD111, 112. 
A reduction of Faecalibacterium prausnitzii is the most replicated species-specific finding so 
far in Crohn’s disease and is confirmed both in fecal and mucosal samples. This species has 
anti-inflammatory and immunomodulatory effects in vivo and in vitro. In addition to F. 
prausnitzii, the adherent invasive Escherichia coli is increased in the ileal mucosa of patients 
with Crohn’s disease and may sustain inflammation113. In the meantime, such dysbiosis is also 
well-described in ulcerative colitis. We recently identified that Roseburia hominis and F. 
prausnitzii, both butyrate-producing bacteria of the Firmicutes phylum, are less abundant in 
patients with ulcerative colitis114. A recent study in pediatric Crohn’s disease could even 
discriminate the patient’s phenotype based on mucosal dysbiosis115. The authors generated a 
dysbiosis index that presents itself as a gradient (percentage of disease-associated organisms) 
across the patient population. As such, controlling the microbial composition may be an 
essential part of IBD management. Several approaches have been developed that alter the 
microbial composition of the gut toward more anti-inflammatory enterotypes (e.g., via dietary 
advice, pre/ probiotics, and fecal microbiota transplantation), which has gained large interest 
in the last few years, illustrated by the large number of active clinical trials (e.g., NCT02335281, 
NCT02033408, and NCT02390726). 
4.2. Toward personalized IBD management 
Not all pathways are believed to be equally important in all patients and contributing to 
disease in the same extent. A qualitative (which pathway?) and/or quantitative (how much 
defective?) estimate of the different measurable factors triggering disease in a given patient 
has, to our knowledge, never been attempted. Nevertheless, we feel the expertise and 
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technology is there to do it, but the challenge lies in the necessity of applying an integrative 
approach using various patient materials (DNA, inflammatory cells, mucosal biopsies, and 
stool) and techniques. However, we think it is the smartest way to really revolutionize 
management of disorders with a multifactorial etiology like IBD (Figure 6). 
 
Figure 6: Changing the paradigm of IBD treatment toward a personalized and mechanism-based approach. 
However, personalized medicine truly implies an individualized approach that starts at 
diagnosis and has the potential to aid in prognosis but should also apply to management. This 
last aspect has certainly not been the case in IBD, and although attempts have been made to 
identify biomarkers for differentiating Crohn’s disease from ulcerative colitis and 
differentiating subgroups of patients with a different outcome, the only successful application 
of personalized medicine in IBD at present is the therapeutic drug monitoring of azathioprine 
and anti-TNF agents116, 117.  
That being said, a personalized therapeutic approach is very well known and applied already 
in other disease areas. In oncology, gene expression profiling has been successfully used to 
identify transcriptional signatures that predict several aspects of disease behavior, including 
risk of metastasis and response to chemotherapy118, 119. These gene expression-based 
biomarkers have also been translated into clinical practice and have received FDA approval120. 
In contrast, in autoimmune and inflammatory disorders, such techniques have generally not 
detected signatures with equivalent prognostic utility. Typically, the tissues examined 
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(peripheral blood mononuclear cells, mucosal biopsies...) are heterogeneous, and, hence, any 
transcriptional variation detected could predominantly reflect differences in the cellular 
composition between samples. Researchers from the University of Cambridge identified a 
transcriptional signature in separated CD8+ T cells, which predicted prognosis in patients with 
Crohn’s disease and patients with ulcerative colitis121. Interestingly, the same signature was 
previously also found to predict disease prognosis in systemic lupus erythematosus and in 
patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. There was a higher 
incidence of relapsing disease in the subgroup of patients who had an elevated expression of 
genes involved in antigen-dependent T cell responses, including signaling initiated by both IL-
7 and TCR ligation. The fact that this signature could be found across several autoimmune and 
immune-mediated diseases suggests that, although being distinct autoimmune and 
inflammatory conditions, the course of these diseases may be influenced by common 
pathways. These subgroups, which can be identified by measuring expression of just three 
genes, raise the prospect of individualized therapy and suggest new potential therapeutic 
targets in autoimmunity. A large prospective randomized study is soon to start in the United 
Kingdom to validate these findings. Additionally, our group recently reported specific 
metagenomic signatures for Crohn’s disease and ulcerative colitis differentiating them from 
healthy individuals. We also identified a mucosal gene signature to predict response to IFX in 
IBD colitis (patent application #EP20090724342)122, 123.  
5. Conclusion 
The imminent introduction of new therapeutics marks promising times in IBD management. 
Recent approvals and novel therapies hopefully awaiting approval offer alternatives to the 
existing armamentarium. Some of these treatment options target early molecular events in 
disease pathogenesis and promise a long-lasting disease-suppressing effect. However, 
additional efforts are needed to improve patient categorization and select the best treatment 
strategy. Ten to 20% of patients cannot be classified to Crohn’s disease or ulcerative colitis, 
second, there is considerable inter- and intra-patient variability in the disease course, and 
good prediction models are lacking124. Also, from a therapeutic point of view, there is 
considerable room for improvement. One of the reasons for this may be that the registered 
therapeutic options (compared to rheumatologic diseases, for instance) are limited. However, 
more importantly, we feel that an essential explanation lies in the fact that the approved drugs 
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exert their effect by suppressing the end result of chronic inflammation in a nonselective way. 
A molecular approach of patients with IBD from diagnosis over prognosis to therapy could 
revolutionize the paradigm of disease management for IBD, but, potentially, also many other 
chronic inflammatory disorders characterized by a multifactorial pathophysiology. 
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CHAPTER 2: RESEARCH OBJECTIVES 
The major issue with IBD is the huge inter-patient variability and the large proportion of 
patients that do not respond to therapy or develop side-effects. Therefore, there is still an 
unmet need for novel therapies that target other inflammatory pathways. Over the last 
decade, genetic association studies have uncovered cellular mechanisms such as bacterial 
recognition, autophagy, ER stress, JAK/STAT-signaling, etc. that have been shown to play a 
role in IBD pathogenesis. These findings have spurred the development of novel therapeutic 
compounds of which some have recently been approved (vedolizumab and ustekinumab) and 
more are to come (Mongersen® and tofacitinib). These novel therapies are of help in 
expanding treatment options for patients, but also imply that clinicians need to choose the 
right therapy from an expanding armamentarium. In this time of blooming therapeutic 
diversity, we should evolve towards a personalized approach that is based on the relative 
contribution of disease-driving pathways in a given patient. We believe that this pathway-
based patient stratification approach will be useful for therapeutic decision making but also 
disease course/phenotype prediction.  
The general aim of this PhD thesis is to improve outcome for patients with IBD by investigating 
in a preclinical model how the class of JAK inhibitors work and by exploring how the underlying 
pathophysiologic pathways could be better characterized in patients with IBD.  
 The objective of the first part of this PhD thesis was to optimize the T cell transfer 
model of chronic colitis at our lab and to use this model to investigate the efficacy and 
mode of action of a new JAK1 inhibitor, filgotinib/GLPG0634  (CHAPTER 3). This project 
was part of a larger project in collaboration with Galapagos N.V. and Ghent University. 
We anticipate that the combination of preclinical and clinical data (ongoing large phase 
3 program) will provide sufficient evidence for the regulatory authorities for the 
eventual approval of filgotinib for the treatment of IBD.  
In the second part of this PhD we aimed to explore new ways to characterize underlying 
pathophysiologic pathways in IBD patients.  
 We first aimed to develop and characterize a novel method to culture biopsy-derived 
intestinal epithelial cell (IEC) monolayers to then characterize patient-specific 
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epithelial defects at a functional level. As a proof of concept, we attempted to use this 
model to translate the genetic risk in ER stress, autophagy and inflammasomes into 
functional readouts (CHAPTER 4). We expect that the genetic risk in a given pathway 
carried by patients will at least influence some of the functional readouts in these 
pathways. These results could then guide towards a more personalized therapeutic 
approach to be tested in a randomized controlled setting.  
 Our  final aim was to investigate the effect of disease activity and infliximab treatment 
on the expression of ER stress, autophagy and inflammasome genes in the colonic 
mucosa of IBD patients (CHAPTER 5-6). Given the well-evidenced involvement of these 
three pathways in IBD and TNF-α signaling, we expect their gene expression profiles 
will vary in different patient groups. Furthermore, by investigating multiple genes 
within a pathway we might be able to discover which key genes/proteins are 
dysregulated in IBD and potentially discover underlying mechanisms that lead to non-
response to infliximab. These findings could have value by providing novel therapeutic 
targets, as transcriptomic biomarkers for disease activity and disease course or for 
therapeutic decision making.
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CHAPTER 3: SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) WITH 
FILGOTINIB REVERSES PATHOGENIC PROCESSES IN PRECLINICAL MODELS 
FOR IBD 
This chapter describes the optimization of an experimental colitis model after which it was 
used to investigate the efficacy of filgotinib. This study was part of a larger multi-center project 
of which the manuscript is being prepared for submission in Gastroenterology:  Nys K, Merciris 
D, Laukens D, Vayssière B, Vanhove W, Ongenaert M,  Auberval M, De Vriendt V , Monjardet 
A, Borgonovi M, Lepescheux L, Dupont S, Clément-Lacroix P, De Vos S, De Vos M, Brys R, 
Vermeire S, Galien R. Selective inhibition of Janus kinase 1 with filgotinib reverses pathogenic 
processes in preclinical models for IBD 
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1. Introduction 
Inflammatory bowel diseases (IBD) are chronic inflammatory relapsing and remitting disorders 
of the gastrointestinal tract manifesting as Crohn’s disease (CD) or ulcerative colitis (UC). IBD 
are disabling conditions whose main symptoms are diarrhea, abdominal pain and rectal 
bleeding1. The fact that 20% of UC and over 60% of CD patients require surgical intervention 
within 10 years after diagnosis underscores the remaining unmet therapeutic need for IBD, 
despite the extended pharmacological armamentarium currently available2. 
The pathogenesis of IBD is considered multifactorial, with a combination of events ultimately 
leading to an abnormal immune response against microorganisms of the intestinal flora  in 
genetically susceptible individuals3. This immune response is the target of many drugs that 
have been assayed for the treatment of IBD4.  One of the prime advances of the past decades 
was the neutralization of tumor necrosis factor alpha (TNFα). However, even TNFα blockade 
ultimately establishes a stable remission in less than 50% of patients5.  
Due to their essential roles as signal transducers downstream of cytokine receptors, the Janus 
Kinase (JAK) family of tyrosine kinases have been proposed as valuable targets for treatment 
especially in UC, and phase 2 trials with tofacitinib have been completed successfully6. The 
JAKs are non-receptor tyrosine kinases constituting a family of 4 proteins, named JAK1, JAK2, 
JAK3 and TYK2 that interact as pairs with many receptors for cytokines and hormones7. The 
JAKs are able to activate signal-transducer-and-activator-of-transcription (STAT) proteins that 
once phosphorylated dimerize and translocate to the nucleus to activate the transcription of 
cognate genes8. The receptor / JAK combinations allow a diversity of signaling modules that is 
further increased by the existence of 6 STAT factors that function as dimers, whose 
composition directly depends on the JAK pairs involved. The diversity resulting from these 
combinatorial options allows a high specificity in ligand effects with a limited number of 
proteins involved.  
Several JAK inhibitors (JAKINIBs) are under development. Less selective compounds like 
tofacitinib (JAK3/JAK1/JAK2 inhibitor) or baricitinib (JAK1/JAK2 inhibitor) are marketed or in 
development for RA9, 10 and UC6.  
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Filgotinib (known as GLPG0634, GS-6034) is the first JAKINIB displaying a strong selectivity for 
JAK1 over the other JAK members11. Phase 2 proof-of-concept clinical trials were completed 
for RA, showing good efficacy and safety12-14. The role of JAK1 in the regulation of the 
polarization of TH1, TH2 and TH17 cells combined with the selectivity and safety 
characteristics of filgotinib prompted us to develop this molecule as a treatment for CD 
patients where it achieved recently a successful proof-of-concept study15.  
Filgotinib had already shown to effectively reduce colitis in the chronic DSS colitis model16 but 
pre-clinical data in a T cell-driven IBD model were lacking. The T cell transfer model of colitis 
is such a chronic T cell-driven IBD model that is characterized by colitis with epithelial damage, 
transmural immune cell infiltration, diarrhea and weight loss. These symptoms are induced by 
intraperitoneal injection of CD4CD45RBhigh T cells from WT donor mice into syngeneic 
immunodeficient acceptor mice. We therefore aimed to set up a chronic murine IBD model at 
our facilities in order to evaluate the efficacy of filgotinib and to confirm previous findings that 
were obtained in the chronic DSS model.  
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2. Materials and Methods 
2.1. Reagents 
GLPG0634 (filgotinib) was dissolved in 0.5% methylcellulose and treatment was given once a 
day by oral gavage at a dose of 30 mg/kg. During the optimization phase of this study we 
included two active comparator groups that were treated once a day with 30 mg/kg tofacitinib 
by oral gavage or 10 mg/kg infliximab by intraperitoneal (i.p.) injection.  
2.2. Mice 
Female 5-7 weeks old BALB/cOlaHsd donor mice and BALB/cJHanHsd-Prkdc SCID acceptor 
mice were bred under specific pathogen free (SPF) conditions (Huntington Life Sciences, East 
Millstone, NJ, USA) and were housed at a dedicated in-house SPF animal facility according to 
the Federation for Laboratory Animal Science Associations (FELASA) guidelines. The animal 
studies were ethically approved by the Ethical Committee of the University of Leuven, 
Belgium. 
2.3. Induction of chronic colitis and Experimental setup 
Naïve CD4+CD45RBhi T cells were isolated from spleens of normal Balb/c mice and adoptively 
transferred to immune-deficient SCID Balb/c mice as previously described17. In short, spleens 
from Balb/c donor mice were dissected aseptically dissociated and filtered (70 µm pore size). 
The resulting cell suspension was enriched using an EasySep Mouse naïve CD4+ T cell 
enrichment kit (Stem Cell, Vancouver, BC, Canada). Cell sorting (>99%) for CD4+CD25-
CD45RBhi(CD62L+) and CD4+CD25-CD45RBlo(CD62Llo) was done on a FACS Aria II (BD 
biosciences, San Diego, CA, USA). Finally 400,000 TH cells/mouse were transferred to the SCID 
acceptor mice by i.p. injection.  
2.4. Monitoring of disease 
Mice were weighed twice/week and at the end of each experiment they were euthanized with 
sodium pentobarbital (Nembutal, Ovation Pharmaceuticals Inc. Deerfield, US) followed by 
cervical dislocation. During necropsy, colitis severity was quantified with four complementary 
scoring systems. The disease activity index (DAI, Table 1) was determined based on body 
weight loss, stool consistency and presence of blood in the stool. This scoring method has 
previously been described by Breynaert et al., 201318.   
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Table 1: Criteria for calculating the disease activity index (DAI) 
 
 
The macroscopic damage score is based on the adhesion of the colon to the surrounding 
tissue, hyperemia and the length of moderately and severely inflamed colon (Table 2).  
Table 2: Criteria for macroscopic damage score calculation 
 
 
The colon weight/length ratio was also calculated and added as an objective indicator of colitis 
severity. Finally, histological scoring was performed on formalin-fixed, paraffin-embedded 
colon sections stained with hematoxylin and eosin. Colon lesion was scored as described by 
Perrier et al.19 (Table 3). All analyses were performed in a blinded manner.  
Table 3: Criteria for histological scoring 
  
0 Normal and correctly formed
2 Very soft but formed
4 Unformed and completely liquid 
0 No blood
1 Blood present
0 Normal or weight gain
1 0-5% weight loss
2 5-10% weight loss
3 10-15% weight loss
4 15-20% weight loss
5 >20% weight loss
Stool
Blood
Weight loss
0 No force is needed 
1 Significant amount force is needed
2 Scissors are needed
0 No blood
1 Blood present
x1 Moderatley inflamed
x2 Heavily inflamed
Macroscopic damage score
Adhesion
Hyperaemia
 Inflamed 
colon length 
0 None
1 Focal and mild
2 (multifocal or diffuse) and (mild or moderate)
3 (multifocal or diffuse) and severe
0 Within normal limits
1 Slightly increased infiltrate in LP
2 Dense infiltrate in LP
3 Cell aggregates in and beyond mucosa
0 None
1 Unequivocal focal erosion
2 Multifocal erosion
3 Ulceration
0 None
1 Focal
2 Multifocal
3 Generalized
Immune cell 
infiltration
Epithelial 
defects
Goblet cell 
loss
Mucosal 
architectural 
changes
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2.5. Statistical analysis 
Statistical analysis and calculations were performed using GraphPad Prism 5.3 (GraphPad, La 
Jolla, CA, USA). Data are represented as medians with IQR and the p-values were obtained 
using a one-way analysis of variance (ANOVA) test. 
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3. Results 
3.1. Pilot experiments 
We performed a pilot experiment to see whether we were able to induce colitis at our facility 
and whether the reference compounds infliximab and tofacitinib, had beneficial effects in this 
setting. Figure 1 illustrates how the weight of all four groups evolved the same way until week 
5.5, after which the weight-curve of tofacitinib group started to diverge from the negative 
control group, followed by the other treatment groups in week 6.5. At the end of the 
experiment, only the infliximab treated mice showed reduced weight loss compared to the 
positive control group. 
 
Figure 1: Pilot experiment: Weight gain/loss over time in CD4CD45RBlo injected negative control mice (n=10), 
CD4CD45RBhi injected untreated positive control mice (n=10), CD4CD45RBhi injected tofacitinib treated mice 
(n=10) and CD4CD45RBhi injected infliximab treated mice (n=9), (mean±SEM). Red arrows indicate the time of 
treatment and sacrifice. 
The effects of T cell transfer and pharmacological treatments on inflammatory scores are 
shown in figure 2.  
 
Figure 2: Pilot experiment: Quantification of colitis severity with the disease activity index (A), macroscopic 
damage score (B), colon weight/length ratio (C) and histological scoring (D) of the mice described in Figure 1, 
(median±IQR). *p<0.05; **p<0.01 
The results indicate that we were able to successfully induce colitis in BALB/C SCID mice at our 
facility. Furthermore, the beneficial effects of IFX treatment on body weight were confirmed 
by all four scoring systems as it significantly reduced the DAI, macroscopic damage scores, 
colon weight/length ratios and histological scores. Also, despite the fact that it did not 
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influence body weight loss, tofacitinib significantly reduced the macroscopic damage score 
and colon weight/length ratio. 
After this successful pilot experiment, we set up an identical second experiment that included 
GLPG0634 as a third treatment arm. During this experiment, the weight curves of all colitis 
groups already started to diverge from the negative control group at the beginning of week 5. 
IFX and GLPG0634 performed somewhat better than the positive control group from week 6 
to 8 but failed to show a clear beneficial effect on bodyweight at the end of the experiment. 
Furthermore, the median weight of the tofacitinib treated mice was even lower than that of 
the positive control group were doing even worse than the positive control group (Figure 3). 
 
Figure 3: Weight gain/loss over time in CD4CD45RBlo injected negative control mice (n=5), CD4CD45RBhi injected 
untreated positive control mice (n=10), CD4CD45RBhi injected tofacitinib treated mice (n=9), CD4CD45RBhi 
injected infliximab treated mice (n=9) and CD4CD45RBhi injected GLPG0634 treated mice (n=10), (mean±SEM). 
Red arrows indicate the time of treatment and sacrifice. 
Figure 4 illustrates how there were also no significant differences in inflammatory scores 
between the treatment groups and the positive control group. 
 
Figure 4: Experiment 1: Quantification of colitis severity with the disease activity index (A), macroscopic damage 
score (B), colon weight/length ratio (C) and histological scoring (D) of the mice described in Figure 3, 
(median±IQR). 
We hypothesized that the discrepancies between this experiment and the pilot experiment 
were due to the earlier disease onset and thus a later time point of therapeutic intervention 
in the course of experimental colitis. Therefore, some of the experimental conditions were 
adjusted in order to counteract these problems. First of all, an additional marker (CD62L) was 
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used during cell sorting in order to obtain a more specific T cell subset (CD4CD45RBhiCD62Lhi). 
We also chose to start treating the mice one week earlier and to include more mice in each 
treatment group. For ethical considerations, the reference compound groups (IFX and 
tofacitinib) were not included in this experiment.  
3.2. Filgotinib reduces body weight loss and inflammatory scores 
Figure 5 illustrates how CD4+CD25-CD45RBhiCD62Lhi-injected, SCID mice started developing 
colitis with loss in weight starting 4 weeks after T cell transfer, in contrast to the mice injected 
with CD4+CD25-CD45RBloCD62Llo T cells that followed a normal growth curve. Over the course 
of the next 3.5 weeks the diseased mice continued to lose weight until being sacrificed at the 
end of week 7, while the average weight of the negative control group stabilized in time. The 
evolution of body weight of mice treated with GLPG0634 was intermediate between the 
curves of the diseased, vehicle-treated mice and the non-diseased control group. The 
endpoint weight of the vehicle-treated diseased group was significantly lower as compared to 
the negative control group. The filgotinib-treated group showed a more favorable weight 
evolution compared to the untreated group, displaying a significant difference at the final 
endpoint.  
 
Figure 5: Weight gain/loss over time in CD4CD45RBloCD62Llo-injected negative control mice (n=10), 
CD4CD45RBhiCD62Lhi- injected untreated positive control mice (n=13), CD4CD45RBhiCD62Lhi- injected GLPG0634 
treated mice (n=12), (mean±SEM). Red arrows indicate the time of treatment and sacrifice. 
In the vehicle-treated colitic mice, typical histological colonic inflammatory changes were 
found including goblet cell loss, infiltration of leukocytes in mucosa and submucosa, epithelial 
erosion, altered crypt architecture and abscesses (Figure 6).  
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Figure 6: Representative microscopic images of the distal colon after H & E staining. 
Interestingly, as compared to the diseased group, the filgotinib-treated mice showed a strong 
and significant improvement in the macroscopic damage score (p<0.05) and histological 
inflammation score (p<0.01) (Figure 7B and 7D, resepctively). A comparable trend, although 
not significant, was found when evaluating disease activity index (Figure 7A). 
 
Figure 7: Quantification of colitis severity with the disease activity index (A), macroscopic damage score (B), 
colon weight/length ratio (C) and histological scoring (D) of the mice described in Figure 6, (median±IQR). 
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4. Discussion 
This study was optimized and designed to answer whether the selective inhibition of JAK1 is 
sufficient to reduce signs of T cell-mediated colitis. 
To enable to ascribe the effects of filgotinib to JAK1 inhibition, a pilot study was performed by 
Galapagos to ascertain that an adequate compound dose was selected for the in vivo studies. 
Analysis of the pharmacodynamic data in view of filgotinib potency in human whole blood 
assays (EC50= 629 nM for JAK1, deduced from a IL-6-driven STAT1 phosphorylation assay and 
IC50= 17,453 nM for JAK2, deduced from a GM-CSF-driven STAT5 phosphorylation assay) 
indicates that the plasma concentrations achieved in the mouse models can only support JAK1 
inhibition11.  
The chronic T cell transfer colitis model is relevant to the adaptive immune system as the 
homing of CD4+ cells to the gut ultimately leads to increased local levels of TH1 and TH17 cells 
in the absence of Treg cells20. This model thus allowed evaluation of the efficacy of filgotinib in 
T cell-mediated intestinal inflammation. Filgotinib conferred structural protection to the 
mucosal tissue in this challenging model impacting weight loss, goblet cell loss, leukocyte 
infiltration in the mucosa and submucosa, epithelial erosion, altered crypt architecture and 
abscesses formation. Identical protection of the colon was previously found in a study by 
Merciris et al. in the chronic DSS-induced colitis model16. The DSS model is based on the 
chemical injury induced by DSS on the intestinal epithelium, leading to a strong neutrophil 
response. Merciris et al. showed that the colons from the diseased mice had a loss of normal 
crypt architecture which was reflected in the disease activity index (DAI) and in the decrease 
in colon length. Filgotinib was able to delay crypt damage and improved the DAI while 
maintaining colon length. Structural protection was also reflected in the gene expression 
analysis results, showing a reduction of the colonic expression of several key cytokines (TNFα, 
IL-6, IL-12p40, IL-17A) induced by DSS treatment. The reduction in TNFα and IL-12p40 
expression is of particular interest, as biologicals blocking these cytokines are part of the main 
therapeutic strategies for IBD treatment5, 21. The expression of other key markers of 
inflammation in IBD was reduced by filgotinib treatment, notably Saa3 (an acute phase 
response protein associated with IBD disease severity)22 and S100a9 (a component of the 
disease marker in IBD patients, calprotectin)23.  
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Besides inhibiting cytokines with a pathogenic character in IBD, JAK1 inhibition also inherently 
has the potential to inhibit the signaling of cytokines such as IL-10 or IL-22 that might be 
protective. However, the clear structural protection of the gut achieved by filgotinib 
treatment in the two mouse models, indicates that the right balance in the affected cytokines 
is restored by filgotinib. Importantly, the histopathological changes were confirmed at the 
gene expression level, where a restoration of the expression of genes associated with 
intestinal barrier development, such as Pax6, Neurod1 or Ptk6 was observed. In addition, 
other genes that are involved in IEC homeostasis and protection of the mucosal tissue against 
pathogen invasion, such as Mcpt1, Mcpt4, Slpi, and Itln1, were also impacted by filgotinib 
treatment, highlighting the protective role of the molecule in the inflamed gut24. Of relevance 
in this context, the expression of IL-33, which emerges as protective cytokine in IBD25, was 
found to be restored upon filgotinib treatment. Overall, these observations are in line with 
the data observed in CD patients in the FITZROY study15 and confirm that as an endpoint, 
filgotinib favors mucosal healing of the gut. 
Histopathological data obtained after treatment with filgotinib in the two models support the 
fact that the compound is able to confer structural protection and impact inflammation 
originated by different pathogenic mechanisms.  Of interest, the ability of filgotinib to inhibit 
the infiltration of macrophages and T cells in an inflamed tissue was also observed in arthritic 
joints11. Together, the histopathological and gene expression data obtained in two models 
support the JAK1 inhibition concept in the treatment of colitis and Crohn’s disease. 
It is of particular interest to note that the JAK1-selective inhibitors filgotinib and upadacitinib 
provided interesting data in patients with moderate-to-severe CD while tofacitinib, which is 
less selective than filgotinib and upadacitinib, failed twice in proof of concept studies in CD 
patients26, 27. These observations suggest that a certain level of selectivity may be needed to 
impact significantly on Crohn’s disease in contrast to ulcerative colitis. Given that tofacitinib 
provided good results in UC6, 28, the ongoing phase 3 study with filgotinib in UC will provide 
key information regarding the role of JAK1 selectivity in this pathology. 
In summary, we present evidence that the JAK1-selective inhibitor filgotinib yields a strong 
anti-inflammatory activity in a T cell-driven mouse model of experimental colitis at efficacy 
exposures allowing only JAK1 inhibition. Importantly, the strong anti-inflammatory effects of 
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filgotinib resulted in clear structural protection. Filgotinib is currently undergoing phase 3 
clinical trial development for UC and CD. Combination of biomarker analysis from these 
studies with data presented here is expected to allow full understanding of filgotinib mode of 
action in IBD.  
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CHAPTER 4: BIOPSY-DERIVED INTESTINAL EPITHELIAL CELL CULTURES FOR 
PATHWAY BASED STRATIFICATION OF PATIENTS WITH INFLAMMATORY 
BOWEL DISEASE 
This entire chapter was submitted to JCC as an original research article and has been accepted 
for publication: Vanhove W, Nys K, Arijs I, Cleynen I, Noben M, De Schepper S, Van Assche G, 
Ferrante M, Vermeire S. Biopsy-derived intestinal epithelial cell cultures for pathway based 
stratification of patients with inflammatory bowel disease. 
1. Abstract 
Background: Endoplasmic reticulum stress was shown to be pivotal in the pathogenesis of 
inflammatory bowel disease. Despite progress in IBD drug development, not more than one 
third of patients achieve steroid-free remission and mucosal healing with current therapies. 
Furthermore, patient stratification tools for therapy selection are lacking. We aimed to 
identify and quantify epithelial ER stress in a patient-specific manner in an attempt towards 
personalized therapy.  
Methods: A biopsy-derived intestinal epithelial cell culture system was developed and 
characterized. ER stress was induced by thapsigargin and quantified with a BiP ELISA on cell 
lysates from 35 patients with known genotypes who were grouped based on the number of 
IBD-associated ER stress and autophagy risk alleles. 
Results: The epithelial character of the cells was confirmed by E-cadherin, ZO-1 and MUC2 
staining and CK-18, CK-20 and LGR5 gene expression. Patients with 3 risk alleles had higher 
median epithelial BiP-induction (vs. untreated) levels compared to patients with 1 or 2 risk 
alleles (p=0.026 and 0.043, respectively). When autophagy risk alleles were included and 
patients were stratified in genetic risk quartiles, patients in Q2, Q3 and Q4 had significantly 
higher ER stress (BiP) when compared to Q1 (p=0.034, 0.040 and 0.034, respectively). 
Conclusion: We developed and validated an ex vivo intestinal epithelial cell culture system 
and showed that patients with more ER stress and autophagy risk alleles have augmented 
epithelial ER stress responses. We thus presented a personalized approach whereby patient-
specific defects can be identified which in turn could help in selecting tailored therapies.  
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2. Introduction 
Inflammatory bowel diseases (IBD) comprise a spectrum of intestinal inflammatory conditions 
with Crohn’s disease (CD) and ulcerative colitis (UC) as the two main entities. They are 
characterized by chronic inflammation of the gastrointestinal tract and are believed to result 
from a dysregulated immune response towards the intestinal microbiota in genetically 
predisposed individuals1. Physicians and patients still face multiple challenges as no curative 
treatment yet exists. A significant advance in management of IBD was the introduction of 
biologic agents targeting tumor necrosis factor (TNF)2. Almost two decades following their 
approval, a second and third class of biologic agents respectively targeting gut-homing α4β7 
integrin-positive T-lymphocytes and interleukins (IL)-12/23, have been added to the 
therapeutic options. All approved biologic agents suppress a general adaptive immune 
response instead of the desired targeting of underlying pathogenic triggers3-5. Second, steroid-
free clinical remission and mucosal healing, two important treatment goals, are observed in 
no more than 30-35% of patients with large inter-patient variability in treatment response. 
The search for predictive biomarkers has been unsuccessful so far and as a consequence 
prediction of therapeutic success is poor6.  
Genetic association and gene/protein expression studies have uncovered novel underlying 
pathophysiologic pathways that are currently under (pre)clinical evaluation as a therapeutic 
target. IL-12/23 and Smad7/TGF-B signaling, endoplasmic reticulum (ER) stress and autophagy 
are accepted key players in IBD pathogenesis and are targeted by specific small molecules or 
antibodies that are in different stages of therapeutic development7-18. It is anticipated that 
treatment success will vary depending on which pathways drive disease in a given patient. 
Therefore, it will become increasingly important to identify triggers of disease in order to 
select the most appropriate therapy 3, 6, 19.  
The intestinal epithelium is crucial for intestinal homeostasis and prevention of inflammation 
as this tightly connected single cell layer limits translocation of luminal microorganisms and 
other antigens to the lamina propria. Intestinal epithelial cells (IECs) form a physical barrier 
that is maintained by strong tight junction protein expression and a continuous epithelial cell 
proliferation in the stem cell compartment at the crypt base20-22. The role of the epithelial 
barrier in IBD is underscored by studies that associate barrier defects with disease progression 
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and relapse23-25. As described above, several epithelial cell integrity pathways such as ER stress 
and autophagy have been associated with IBD21, 22, 26-28. 
ER stress signaling/unfolded protein response and autophagy are two well-characterized 
homeostatic pathways that closely collaborate and play a key role in the innate and adaptive 
immune system29-32. Autophagy serves as an intracellular clearance mechanism for 
components of endogenous and exogenous origin such as mitochondria, misfolded proteins, 
signaling complexes and (pathogenic) microorganisms30. The unfolded protein response is 
triggered by an increased abundance of un- or misfolded proteins in the ER, also called ER 
stress. Prolonged or uncontrolled ER stress will eventually lead to inflammation and/or cell 
death29. Both pathways have been genetically associated with IBD; e.g. the ER stress-related 
XBP1 and ORMDL3 genes and the autophagy-related ATG16L1, IRGM, LRRK2 and ULK1 
genes26-28. Nevertheless, little is known how these genetic variants functionally translate in 
patients with IBD. We hypothesize that inter-patient differences in the risk allele burden in 
these pathways will lead to distinctive functional readouts in IBD patient-derived epithelial 
cells. 
Therefore, the aim of this study was to translate an individual’s genetic risk in ER stress and 
autophagy into quantifiable, functional ER stress-readouts starting from patient-derived 
epithelial cells. To do so, we developed an ex vivo 2-dimensional epithelial cell culture system 
starting from human endoscopically-derived biopsies to quantify perturbed pathways in 
patients with IBD. As a proof of concept, we studied epithelial ER stress levels stratified by the 
number of ER stress and autophagy risk alleles.   
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3. Materials and methods 
3.1. Patients and ethical statement 
Patients with IBD followed at the IBD unit of the University Hospitals Leuven, who were 
genotyped as part of the international Immunochip project, were selected based on their 
mutations in ER stress or autophagy genes (Table 1, Supplementary figure 1)26, 33. We selected 
patients with 0, 1, 2 or 3 ER stress risk alleles and patients who had ≤3, 4, 5 or ≥6 autophagy 
risk alleles which was based on the risk allele distribution in the immunochipped IBD patient 
population at the University Hospitals Leuven (Supplementary figure 1). Only SNPs with a call 
rate > 90% and a minor allele frequency > 0.01 were included. Mucosal biopsies (8/patient) 
were obtained from the macroscopically non-inflamed colon of 35 patients undergoing 
endoscopy as part of their IBD management. Patient characteristics are provided in table 2. 
Table 1: IBD-associated ER stress and autophagy genes with their specific SNP-IDs, chromosome n°, risk alleles 
and SNP locations. 
 
ATG16L1: Autophagy Related 16 Like 1; IRGM: Immunity Related GTPase M; ULK1: Unc-51 Like Autophagy 
Activating Kinase 1; LRRK2: Leucine Rich Repeat Kinase 2; MTMR3: Myotubularin Related Protein 3; ORMDL3: 
ORMDL Sphingolipid Biosynthesis Regulator 3; XBP1: X-Box Binding Protein 1. 
Ethical approval was given by the Ethics Board of the University Hospitals Leuven 
(B322201213950/S53684) and all patients provided written informed consent. 
 
 
Pathway Gene
Studied 
SNP
Chromos
ome
Risk 
allele
Location
ATG16L1 rs2241880 2 G
non-
synonymous 
coding
rs10065172 T
exonic, 
synonymous 
coding
rs4958847 A
ULK1 rs12303764 T
LRRK2 rs11175593 T
MTMR3 rs2412973 22 A
downstream 
of gene
ORMDL3 rs2872507 17 A
upstream of 
gene
XBP1 rs35873774 22 C intronic
intronic
ER stress
Autophagy
IRGM 5
12
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Table 1: Patient characteristics 
# Patients 35 
Female [%]  20 [57] 
Median [IQR] age (yrs) 53 [42-57] 
Median [IQR] age at diagnosis 
(yrs) 27 [21.5-36.5] 
Median [IQR] disease duration 
(yrs) 20 [10.5-28.5] 
UC/CD [%] 4/31 [11/89] 
Prior abdominal surgery [%] 21 [60] 
Smoking [%]   
Yes 12 [34] 
Former 5 [14] 
No 11 [31] 
Unknown 7 [20] 
Therapy [%]   
Antibiotics 2 [6] 
Corticosteroids 2 [6] 
Thiopurines/methotrexate 4 [11] 
Anti-tumor necrosis factor 14 [40] 
Vedolizumab 1 [3] 
(IQR: interquartile range; yrs: years) 
3.2. Isolation and culturing of IECs  
The crypt isolation protocol and cell culture medium were adapted from the colonic organoid 
culture procedure which was developed by Sato et al.in 201134. Biopsies were immediately 
placed in DMEM-F12 (Lonza, Basel, Switserland) containing glutamine (15 mM), hepes (15 
mM) and penicillin/streptomycin (100 U/ml, Lonza, Basel, Switserland) at 4 °C for transport 
(on ice) to the research lab and stored (at 4 °C) for up to two hours until epithelial isolation 
was performed. First, the biopsies were washed in DMEM-F12 after which they were allowed 
to settle and the supernatant was discarded. Next, they were thoroughly washed with 
complete chelating solution (CCS, 0.996 g/l Na2HPO4*2H2O, 1.08 g/l KH2PO4, 5.6 g/l NaCl, 0.12 
g/l KCl, 15 g/l Saccharose, 10 g/l D-sorbitol, 80 mg/l DTT) by repeated pipetting. Finally, EDTA 
(10 mM, Thermo Scientific, Waltham, Massachusetts, USA) was added and the biopsy 
suspension was placed on a rocking platform at 4 °C for 45 minutes after which the EDTA 
containing solution was removed. The biopsy fragments were passed multiple times through 
a 10 ml pipette in CCS to mechanically disrupt the IECs from the remaining mucosal tissue 
leaving them in suspension as the remaining fragments settled down. The supernatant was 
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centrifuged after which the cell pellet was washed one more time in DMEM-F12 before 
resuspending the IECs in expansion medium (composition see Supplementary table 1) and 
plating the cells in collagen coated 12-well plates (7 wells/8 biopsies) in a humidified incubator 
at (37 °C, 5% CO2). The medium was replaced for the first time after 24 hours and every 48 
hours thereafter. 
3.3. Immunocytochemistry 
To further characterize these intestinal biopsy-derived cell cultures, several 
immunocytochemic stainings were performed. Isolated crypts were seeded on collagen 
coated CC2 Lab-Tek chamber well slides (Thermo Scientific, Waltham, Massachusetts, USA). 
At day 4, cells were washed with PBS and subsequently fixated in paraformaldehyde (PFA, 4%, 
20’, 37 °C)cells were washed again in PBS and permeabilized with methanol (10’, RT). After 
washing, the cells were incubated in glycine (0.1 M, 2x10’, RT) followed by washing and 
blocking (10 % FBS, 1% BSA, 1h, RT). The primary anti-E-cadherin antibody (ab1416, Abcam, 
Cambridge, UK) and the anti-platelet derived growth factor receptor-α (PDGFR-α) antibody 
(sc-338, Santa Cruz Biotechnology, Dallas, Texas, USA) were diluted in 1% BSA and cells were 
exposed for 1 hour. After washing in 1% BSA, the cells were incubated with the secondary goat 
anti-mouse antibody (Alexa Fluor 488, Thermo Scientific, Waltham, Massachusetts, USA) and 
goat anti-rabbit antibody (Alexa Fluor 594, Thermo Scientific, Waltham, Massachusetts, USA) 
for 1 hour followed by DAPI staining (1 µg/ml). After a final wash step in PBS-T, the cells were 
mounted with ProLong gold anti fade reagent (Life Technologies, Carlsbad, California, USA). 
Images were obtained using a BX41 microscope (Olympus, Tokio, Japan) and analyzed with 
the Scan R software (Olympus, Tokio, Japan). For the immunocytochemic staining of ZO-1, 
KI67 and MUC2 we used a slightly different protocol provided by the Gastrointestinal Motility 
and Sensitivity Research Group from KU Leuven. Washed cells (on Lab-Tek chamber slides) 
were fixated in PFA (4%, 30’, RT) and rehydrated in 100% (3x3’) and 70% (1x3’) ethanol 
followed by H2O (2x3’). Antigen retrieval was performed in sodium citrate buffer at 120 °C for 
10’ after which the cells were allowed to slowly cool to room temperature and were washed 
with PBS. Blocking was performed for 10’ with Protein Block Serum-Free (Agilent, Santa Clara, 
CA, USA) for 10’ after which they were incubated overnight at 4 °C with the primary 
antibodies: mouse-anti-ZO-1 (1/50, 339100, Thermo Scientific, Waltham, Massachusetts, 
USA), mouse anti-KI67 (1/150, MONX10283, Sanbio, Uden, The Netherlands), rabbit-anti-
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MUC2 (1/150, sc-15334, Santa Cruz Biotechnology, Dallas, Texas, USA) diluted in Antibody 
Diluent (Agilent, Santa Clara, CA, USA). After washing in PBS, the cells were incubated with the 
secondary goat anti-mouse antibody (Alexa Fluor 488, Thermo Scientific, Waltham, 
Massachusetts, USA), donkey anti-rabbit antibody (Alexa Fluor 594, Thermo Scientific, 
Waltham, Massachusetts, USA) and DAPI (all 1/1000) for 30’. After washing, the cells were 
mounted with citifluorTM (VWR, Radnor, PA, USA). Normal fluorescent images were obtained 
with the a BX41 microscope (Olympus, Tokio, Japan) whereas a LSM 880 microscope with 
Airyscan (Zeiss, Oberkochen, Germany) was used to obtain high resolution z-stack images. 
Analysis was performed with ZEN Blue software (Zeiss, Oberkochen, Germany) and Fiji 
(ImageJ, NIH, Bethesda, MD, USA).  
3.4. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis 
Expression levels of epithelial marker genes cytokeratin-18 and -20 (CK-18 and CK-20) were 
determined at 24, 72, 120 and 168 hours post isolation and compared with expression levels 
in the fetal human colon (FHC) cell line (positive control) and the IMR-90 lung fibroblast cell 
line (negative control). Furthermore, the expression of the intestinal epithelial stem cell 
marker LGR5 was measured at the same time points. Finally baseline expression of the 
GRP78/BIP gene was measured in 6-day-old untreated IECs from 19/35 patients who were 
included in this study.  
Cells were washed with PBS and mechanically removed in RNAlater using a cell scraper. After 
centrifugation the pellet was resuspended in RLT-buffer (Qiagen, Hilden, Germany) containing 
β-mercapto-ethanol and passed repeatedly through a 29G needle or Qiashredder tubes 
(Qiagen, Hilden, Germany). An equal volume of 70% ethanol was added and mRNA was 
extracted from this mixture with the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to 
manufacturer’s protocol. RNA quality was assessed with the NanoDrop 1000 
spectrophotometer (Thermo Scientific, Waltham, Massachusetts, USA) and samples were 
stored at -80 °C until cDNA synthesis with the Qscript cDNA supermix (Quantabio, Beverly, 
MA, USA) according to manufacturer’s protocol.  
The primers used for qRT-PCR analysis are given in supplementary table 2 and 10 µM stock 
solutions were used to make the reaction mixture (5 µl SybrGreen, 0.2 µM FW & RV primer, 
2.5 µl cDNA sample, 2.3 µl RNAse-free H2O). Samples were analyzed with the Lightcycler 480 
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(Roche, Basel, Switzerland) and the following amplification program was used: 5’ 95 °C, 45x 
(10” 95 °C, 15” 60 °C, 15” 72 °C), 5” 95°C, 1’ 60 °C, 4 °C. CK-18, CK-20,LGR5 and BIP/GRP78 
mRNA-levels were normalized to the housekeeping gene β-actin and quantified using the 
comparative (Δ or ΔΔ) Ct method.  
3.5. ER stress induction 
IEC cultures were treated for 14 hours (from the end of day 5 until the beginning of day 6) 
with the ER stress inducing compound thapsigargin (0.4 µM, Sigma-Aldrich, Saint Louis, 
Missouri, USA) in order to enhance potential inter-patient differences.Lysis and total protein 
measurement 
After 14 hours of thapsigargin-treatment, the IECs were placed on ice, the medium was 
aspirated and the cells were rinsed with ice cold PBS. Next, the IECs were scraped in PBS and 
spun down, the resulting cell pellet was resuspended in RIPA lysis buffer (Enzo Life Sciences, 
Farmingdale, New York, USA) and lysis was performed by incubating the suspension 45’ on ice 
followed by sonication. The cell lysate was spun down at maximal speed to pellet membrane 
fragments and the supernatant was used to determine the total protein content with the 
Pierce® BCA Protein Assay Kit (Thermo Scientific, Waltham, Massachusetts, USA), the 
remainder was stored at -80 °C until enough samples were acquired to perform an ELISA. 
3.6. Binding immunoglobulin protein (BiP)/Glucose-regulated protein 78 (GRP78) ELISA 
To quantify the ability of IECs to cope with ER stress, we measured BiP (also known as GRP78 
or HSPA5) levels before and after thapsigargin-treatment with a competitive BiP ELISA kit 
(Enzo Life Sciences, Farmingdale, New York, USA) according to manufacturer’s protocol. Plates 
were read with the Fluostar Omega microplate reader (BMG Labtech, Ortenberg, Germany) 
and quantified with a 5-PL logistic regression script in Microsoft Office Excell. ER stress 
induction rates were expressed as the BiP ratio between treated and untreated IECs 
([BiP]thapsigargin-treated/[BiP]untreated). 
3.7. Statistical analysis 
As data were not normally distributed, non-parametric tests were used, no multiple testing 
was performed. The BiP (ELISA) levels and ratios were compared between the different groups 
using a Mann-Whitney test with Graphpad Prism Software (La Jolla, California, USA). A p-value 
< 0.05 was considered significant.   
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4. Results 
4.1. IECs and epithelial characterization 
After isolation, the intestinal crypts retained their three-dimensional morphology while being 
suspended in the medium (Figure 1A). During overnight incubation, the crypts sunk and 
attached to the collagen-coated surface to form an epithelial monolayer. These two-
dimensional IEC-islands consisted of cuboidal cells, giving them a pavement-like appearance. 
Visually each IEC-island was formed around a growth center (Figure 1B, red arrow), suggesting 
these cells originated from proliferating intestinal stem cells originally located in the bottom 
of the crypts in vivo. Cells in this center divided and gradually pushed away earlier formed cells 
resembling the in vivo situation. These observations were confirmed by immunofluorescent 
stainings for the proliferation marker KI67 (Figure 2). Furthermore, as cells moved away from 
these areas of proliferation, a significant portion differentiated cells shows presence of MUC2-
positive cells with a goblet cell-like morphology (Figure 2, separate fluorescence channel 
images are provided in supplementary figure 2). 
 
Figure 1: Brightfield (BF) microscopic image of freshly isolated colonic crypts with intact crypt architecture (A); 
BF image of an IEC-island with growth center (blue arrow) in a collagen coated well 48 hours post isolation (B); 
BF image of a 12-day-old IEC culture with typical areas of cell death and detachment (orange arrows) (C). 
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Figure 2: Immunocytofluorescent staining for Ki67 (green) and Muc2 (red) in a 4-day-old IEC culture (20x 
magnification, blue: DAPI staining). 
Cells remained viable in culture for approximately 12 days, after which local cell detachment 
and cell death occurred (Figure 1C, red arrows). The combined isolation and culture success 
rate was 81% (39 out of 48 isolations). Failure was mostly due to low donor-dependent IEC 
isolation yields or inefficient cell attachment but was independent of presence of ER stress or 
autophagy risk alleles.  
In order to confirm the epithelial character, 4-day-old IEC cultures were stained for E-cadherin 
35, 36. Figure 3A and 3B illustrate how this epithelial transmembrane adherens junction protein 
was strongly expressed along the cell membranes of the cultured IECs. In order to rule out 
fibroblast contamination, we also performed a PDGFR-α staining which was negative in 4-days 
old IEC cultures. A positive control staining for this latter antibody on IMR-90 fibroblast cells 
is provided in supplementary figure 3.  
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Figure 3: Immunocytofluorescent staining for E-cadherin (green) and PDGFR-α (red) in a 4-day-old IEC culture 
The epithelial character of these ex vivo cell cultures was further assessed by measuring mRNA 
levels of CK-18 and CK-20 over time, as indicated in figure 4. In cultured IECs, CK-18 was stably 
expressed over time (up to 168h), whereas CK-18 mRNA could also be detected (in lower 
amounts) in FHCs but not in IMR-90 cells (Figure 4A). Figure 4B illustrates how CK-20 is initially 
expressed at high levels and a gradually decreases over time. Still, also at day 7 (168 hpi), 
expression levels were strongly present when compared to proliferating cultures of FHCs. 
Additionally, we also measured the expression of the intestinal epithelial stem cell marker 
LGR5 in IEC cultures at the same time points (24, 72, 120, 168 hpi) and showed that LGR5 
expression increased over time (Figure 5). 
 
Figure 4: Cytokeratin-18 (A) and Cytokeratin-20 (B) mRNA expression in IEC cultures at 24, 72, 120 and 168 
hours post isolation (hpi) and in the FHC and IMR-90 cell lines (ΔΔCt-method, fold change to expression levels in 
FHCs and all normalized to β-actin mRNA). 
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Figure 5: Lgr5 mRNA expression in IEC cultures at 24, 72, 120 and 168 hours post isolation (hpi). (ΔΔCt-method, 
fold change to expression levels at 24hpi and all normalized to β-actin mRNA). 
Finally, we assessed the polarity along the apical-basolateral axis, by staining the cells for 
zonula occludens-1 (ZO-1). We could show that ZO-1-postive signal (green) is distributed 
apically at a depth of 0-1500 nm, whereas this positive signal disappears completely when 
moving closer towards the basolateral side (Figure 6 and 7).  
 
Figure 6: z-stack images at three different depths (300, 1500 and 3000 nm from the apical border) of a 4-day-
old IEC culture stained for ZO-1 (green). (blue: DAPI staining) 
 
Figure 7: Cross sectional view of the reconstructed z-stack images from figure 6. 
4.2. Genetic risk in ER stress and autophagy genes and the epithelial ER stress response 
The IEC cultures were microscopically monitored daily between the time of isolation and lysis 
in order to exclude wells that had an aberrant morphology or showed signs of cell death. In 
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order to determine the cells’ intrinsic capability to cope with ER stress, we measured BiP-levels 
with and without a 14 h treatment with the ER stressor thapsigargin from day 5 until day 6.  
Patients were then grouped according to the number of ER stress risk alleles in XBP1 
(rs35873774) and ORMDL3 (rs2872507) (Table 1). Median [IQR] thapsigargin-mediated BiP-
induction was 2.67 [1.01-6.07], 1.87 [1.50-3.16], 1.70 [1.32-2.41] and 4.48 [3.76-4.64] in IECs 
from patients carrying 0, 1, 2 or 3 risk alleles respectively. Notice the absence of a group with 
patients carrying 4 ER stress risk alleles. Because of their low prevalence (0.14 %) in our patient 
genotype database (Supplementary figure 1A), we were unable to include these patients as 
this means that we had only 4 patients with 4 ER stress risk alleles in our entire genotyped 
patient cohort. These specific patients did not undergo an endoscopic investigated at our clinic 
during the time of inclusion. IECs from patients with three risk alleles had significantly more 
ER stress induction rates when compared to patients with one or with two risk alleles (Figure 
8A, p=0.0262 and 0.0430, respectively).  
We also grouped patients in risk quartiles, based on the number of risk alleles (RA) in 
autophagy genes ATG16L1 (rs2241880), IRGM (rs10065172 and rs4958847), MTMR3 
(rs2412973), LRRK2 (rs11175593) and ULK1 (rs12303764). The distribution of these risk alleles 
in the sampled population (Supplementary figure 1B) was used to define the number of risk 
alleles in each quartile: Q1 had ≤3 RA, Q2 had 4 RA, Q3 had 5 RA and Q4 had ≥6 RA. Median 
[IQR] thapsigargin-mediated BiP-induction was 1.58 [1.13-2.85], 1.78 [1.52-2.64], 3.57 [1.83-
4.64] and 2.74 [1.60-3.59] in IECs from patients belonging to Q1 to Q4 respectively (Figure 8B). 
No significant differences were observed between these groups (Figure 3B) although a trend 
towards higher ER stress induction rates in Q3 and Q4 compared to Q1 (p = 0.0507 and 0.1535, 
respectively) was seen.  
Finally, given that autophagy and ER stress show a clear interplay31, 32, 37, 38, ER stress and 
autophagy risk alleles were combined. This combination of risk alleles led to a change in the 
definition of the genetic risk quartiles (Q1: ≤4 RA, Q2: 5 RA, Q3: 6 RA, Q4: ≥7 RA; 
Supplementary figure 1C). Median thapsigargin-mediated BiP-induction [IQR] was 1.34 [1.08-
1.91], 2.16 [1.68-4.05], 3.60 [1.39-4.48] and 2.41 [1.61-3.27] in IECs from patients belonging 
to genetic risk groups Q1 to Q4, respectively (Figure 8C). Patients in Q2, Q3 and Q4 had 
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significantly higher ER stress induction rates when compared to Q1 (p = 0.0343, 0.0401 and 
0.0343, respectively). 
 
Figure 8: Boxplot diagrams showing the thapsigargin (Tg)-induced ER stress (BiP) levels of 6-day-old colonic IEC 
cultures from IBD patients carrying 0 to 3 ER stress-related risk alleles (n=4, 17, 11 and 3, respectively) in XBP1 
and/or ORMDL3 (A); From IBD patients carrying ≤3 (Q1, n=12), 4 (Q2, n=6), 5 (Q3, n=9) or ≥6 (Q4, n=8) 
autophagy-related risk alleles in ATG16L1, MTMR3, ULK1 and/or LRRK2 (B); from IBD patients carrying ≤4 (Q1, 
n=8), 5 (Q2, n=10), 6 (Q3, n=7) or ≥7 (Q4, n=10) ER stress and autophagy-related risk alleles in XBP1, ORMDL3, 
ATG16L1, MTMR3, ULK1 and/or LRRK2 (C). (*: Mann Whitney p-value < 0.05). 
At baseline, there were no significant differences in BiP mRNA or protein expression between 
the different patient subgroups (Figure 9 and 10, respectively). 
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Figure 9: Boxplot diagrams showing the baseline ER stress (BiP) mRNA levels (normalized to β-actin mRNA) of 6-
day-old colonic IEC cultures from IBD patients carrying 0 to 3 ER stress-related risk alleles (n=3, 9, 6 and 1, 
respectively in XBP1 and/or ORMDL3 (A); From IBD patients carrying ≤3 (Q1, n=4), 4 (Q2, n=4), 5 (Q3, n=5) or ≥6 
(Q4, n=6) autophagy-related risk alleles in ATG16L1, MTMR3, ULK1 and/or LRRK2 (B); from IBD patients 
carrying ≤4 (Q1, n=3), 5 (Q2, n=5), 6 (Q3, n=3) or ≥7 (Q4, n=8) ER stress and autophagy-related risk alleles in 
XBP1, ORMDL3, ATG16L1, MTMR3, ULK1 and/or LRRK2 (C). 
 
Figure 10: Boxplot diagrams showing the baseline ER stress (BiP) protein levels of 6-day-old colonic IEC cultures 
from IBD patients carrying 0 to 3 ER stress-related risk alleles (n=4, 17, 11 and 3 respectively) in XBP1 and/or 
ORMDL3 (A); From IBD patients carrying ≤3 (Q1, n=12), 4 (Q2, n=6), 5 (Q3, n=9) or ≥6 (Q4, n=8) autophagy-
related risk alleles in ATG16L1, MTMR3, ULK1 and/or LRRK2 (B); from IBD patients carrying ≤4 (Q1, n=8), 5 (Q2, 
n=10), 6 (Q3, n=7) or ≥7 (Q4, n=10) ER stress and autophagy-related risk alleles in XBP1, ORMDL3, ATG16L1, 
MTMR3, ULK1 and/or LRRK2 (C). 
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5. Discussion 
In this study we developed a novel ex vivo two-dimensional IEC culture model allowing 
characterization and quantification of pathogenic pathways in IBD in a patient-specific 
manner. We demonstrated that these biopsy-derived epithelial cell cultures remain viable for 
about 12 days and isolation success was more than 80%. The epithelial character was 
illustrated by a clear E-cadherin staining along the membranes of IECs, which resembles 
immunohistochemical E-cadherin stainings on human colonic tissue sections39, 40. We could 
not detect the fibroblast marker PDGFR-α which indicates that these cultures were free of 
contamination by mesenchymal cells. The areas where the crypts originally attached, 
remained a center of IEC proliferation as indicated by the abundance of KI67 positive cells. 
Daughter cells get pushed outward and either differentiate into intestinal epithelial cell types 
or retain their proliferative phenotype. 
We also analyzed gene expression levels of two epithelial cytokeratins over time. Cytokeratin 
18 is a type-1 keratin that is found in all simple epithelial tissues such as the intestinal epithelial 
lining and the proximal tubule of the kidney41, 42. We could detect stable CK-18 mRNA levels, 
illustrating our monolayer cultures have an epithelial character that is not lost over time. 
Cytokeratin 20, on the other hand, also belongs to the type-1 keratin family and is 
predominantly expressed in differentiated IEC subtypes41-43. In our IEC cultures, CK-20 mRNA 
levels were decreasing, suggesting loss of differentiation over time. This is further supported 
by the inverse correlation between the time-dependent CK-20 and LGR5 mRNA expression: 
LGR5 expression increases over time indicating a rise in the relative abundance of epithelial 
stem cells. 
Finally, since polarity is an important aspect of a functional epithelial monolayer, we stained 
the cells for zonula occludens-1 (ZO-1), a tight junction protein which should be located at the 
apical side of the epithelium. We could indeed show that ZO-1 is distributed apically when 
compared to the nuclei. 
Taken together, these data confirm that the isolated cells form polarized epithelial monolayers 
that contain both proliferating and differentiated cells. This model therefore shows the 
potential for measuring specific biologic responses in individual patients stratified on genetic 
susceptibility, disease location and/or therapies.  
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As a further proof of concept, we also showed for the first time that the genetic susceptibility 
in two important pathways associated with IBD, namely ER stress and autophagy, can be 
functionally translated and quantified in individual patients using biopsy-derived IECs. We 
chose to focus on these two pathways because of their functional interaction and importance 
for IEC homeostasis29-31. We measured intracellular BiP-levels as a quantitative readout for 
the amount of ER stress. BiP or GRP78/HSPA5 is a molecular chaperone protein that is strongly 
involved in ER stress signaling. It is upregulated when ER stress increases (eg. after 
thapsigargin treatment) and controls further activation of all three branches of the unfolded 
protein response (the ER stress signaling pathway)44, 45. 
Two ER stress-related risk loci have been identified so far (rs35873774 and rs2872507) and 
patients carrying more than two risk alleles in this pathway were rare in our patient 
population. Therefore, it was impossible to further group patients into genetic risk quartiles. 
Hence, the highest risk group (carrying 3 RA) contained only three patients. Nevertheless, this 
patient-group showed a significant increase in thapsigargin-mediated ER stress (BiP) induction 
when compared to patients carrying two or one risk allele(s). These data illustrate a functional, 
quantifiable consequence of two confirmed genetic risk variants in the ER stress pathway in 
patients with IBD. 
By clearing un- or misfolded intracellular proteins, autophagy by itself is an essential 
component of ER stress signaling31, 37. Accumulating evidence underscores the interaction of 
autophagy and ER stress signaling in the intestinal epithelium31, 32, 38, 46. For example, Adolph 
et al. showed in mice that epithelial specific genomic deletion of autophagy genes leads to 
increased ER stress signaling and vice versa. Both mechanisms thus seem to play 
compensatory roles in maintaining IEC homeostasis and preventing inflammation which is 
further demonstrated by the spontaneous ileitis that only occurs when both pathways are 
genetically perturbed46. Since it has been clearly demonstrated that dysfunctional autophagy 
also leads to increased ER stress in IECs32, 38, 46, 47, we tried to confirm these murine findings 
using our human IEC model but were unable to detect significant differences in ER stress 
induction rates between patients belonging to different autophagy genetic risk quartiles. 
However, when ER stress and autophagy risk alleles were combined, a significant association 
between genetic risk and ER stress induction rates was seen. This indicates that the genetic 
risk in both pathways should be taken into account when looking at the functional level. 
88 
 
Finally, we could show that none of these patient subgroups showed significant baseline 
differences in the expression of BiP both at the mRNA and protein level. Therefore, these 
results suggest that it mainly the ability to cope with ER stress-inducing insult (eg. 
Thapsigargin) is affected rather than the baseline ER stress levels in stress-free conditions. 
Our findings do not only show the functionality of this new ex vivo IEC culture system, they 
also demonstrate that disease-associated molecular pathways can be quantified in an 
individual patient. This may provide therapeutic opportunities such as the administration of 
ER stress reducing molecules in patients demonstrating increased ER stress levels in IECs. 
Despite the fact that ER stress is regarded a key player in the pathogenesis of IBD, it is currently 
not being considered as possible therapeutic strategy. Yet, the ER stress reducing conjugated 
bile acid tauroursodeoxycholic acid (TUDCA) may reduce epithelial apoptosis and 
inflammation and was shown to reduce severity of colitis in multiple IBD mouse models15-18. 
Furthermore, oral administration of TUDCA in the context of other diseases has not been 
associated with any adverse events so far 48-51. It would therefore be very interesting to study 
if TUDCA could reduce inflammation in patients with IBD characterized by increased ER stress 
levels, as demonstrated in our human culture model. Besides TUDCA, other ER stress reducing 
compounds such as 4-phenylbutyrate (PBA) and glutamine could also be considered as these 
compounds also have shown some effectiveness in murine IBD models 13-15.  
Likewise, the autophagic inducer rapamycin was effective in IBD case reports but failed to 
show efficacy in a randomized placebo controlled trial9-12. We wonder if functional 
characterization of the patients randomized in this study for defects in autophagy would shed 
a different light on the results. 
Since these cells are grown in two dimensions, the apical side is easily accessible for 
pharmaceutical compounds or micro-organisms which is a great advantage compared to the 
3-dimensional intestinal organoid model originally described by Sato et al34. Intestinal 
organoids are an excellent model to investigate multiple key aspects of intestinal epithelial 
physiology and pathologies such as epithelial stem cell proliferation studies. However, our ex 
vivo monolayer protocol may offer several practical advantages and an easier to use system 
for exposure studies.  
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This ex vivo IEC culture system may be used or modified for other applications than the 
investigation of IBD-associated genetic defects at the site of the intestinal epithelium. 
Epithelial defects in other diseases like celiac disease, post-infectious irritable bowel 
syndrome and intestinal cancer could be further elucidated and lead to more personalized 
therapeutic approaches. Another potential application of the ex vivo cell culture system is 
personalized drug toxicity screening assays. We are currently further modifying our protocol 
allowing the IECs to grow on transwell membranes in order to perform permeability assays. 
This setup could also be used for co-culturing IECs with other relevant intestinal cell types such 
as macrophages. 
In summary, we have developed and characterized a 2-dimensional IEC culture system that 
allows easy exploration of patient-specific epithelial defects and/or responses. We could 
detect defects in epithelial ER stress handling in genetically predisposed patients and hereby 
show that this approach can be used for the detection and quantification of underlying 
pathogenic mechanisms. Personalized tools such as this will become highly valuable in 
complex disorders and will allow treatment of a defective pathway instead of a disease 
phenotype. 
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6. Supplementary material 
 Supplementary table 1: Composition of the IEC expansion medium.  
Compound 
Final 
concentration 
Source 
Wnt3a 100 ng/ml In house, 
cell line Rspo1 100 ng/ml 
mNoggin 100 ng/ml 
Peprotech, 
USA 
Gastrin 10 nM 
Sigma-
Aldirch, 
USA 
Nicotinamide 10 mM 
N-
Acetylcysteine 
1X 
SB202190 10 µM 
EGF 50 ng/ml 
Invitrogen, 
USA 
B27 1X 
N2 1X 
A83-01 500 mM Tocris, UK 
(Wnt3a: Wnt Family Member 3A; Rspo1: R-Spondin 1; mNoggin: murine Noggin; EGF: Epidermal Growth Factor) 
Supplementary table 2: Primers for qRT-PCR analysis.  
Gene Forward primer Reverse primer 
CK-18 5'-TGAGACGTACAGTCCAGT-3' 5'-GCTCCATCTGTAGGGCGT-3' 
CK-20 5'-AGGAGACCAAGGCCCGTT-3' 5'-ATCAGTTGGGCCTCCAGA-3' 
Lgr5 5'-ACCTCCTACCTAGACCTCAGT-3' 5'-CGCAAGACGTAACTCCTCCAG-3' 
BiP/Grp78 5'-TGTTCAACCAATTATCAGCAAACTC-3' 5'-TTCTGCTGTATCCTCTTCACCAGT-3' 
β-actin 5'-CCCAGCACAATGAAGATC-3' 5'-CTGATCCACATCTGCTGG-3' 
(CK: Cytokeratin; Lgr5: Leucine-rich repeat-containing G-protein coupled receptor 5; BiP: Binding 
immunoglobulin protein; GRP78: 78 KDa Glucose-Regulated Protein) 
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Supplementary figure 1: ER stress (A), autophagy (B) and combined (C) risk allele (RA) distribution in the 
immunochipped UC/CD/IBD patient population at the University Hospitals Leuven. 
 
Supplementary figure 2: Separate channels of the immunocytofluorescent staining for Ki67 (green), Muc2 (red) 
in a 4-day-old IEC culture (Muc2: Mucin 2; DAPI: 4',6-diamidino-2-phenylindole).  
 
Supplementary figure 3: Immunocytofluorescent staining for PDGFR-α (red) in the IMR-90 fibroblast cell line. 
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CHAPTER 5: Strong Upregulation of AIM2 and IFI16 Inflammasomes in the 
Mucosa of Patients with Active Inflammatory Bowel Disease 
This entire chapter has been published as an original research article in Inflammatory Bowel 
Diseases: Vanhove W, Peeters P M, Staelens D, Schraenen A, Van der Goten J, Cleynen I, De 
Schepper S, Van Lommel L, Reynaert N, Schuit F, Van Assche G, Ferrante M, De Hertogh G, 
Wouters E, Rutgeerts P, Vermeire S, Nys K, Arijs I. Strong upregulation of AIM2 and IFI16 
inflammasomes in the mucosa of patients with active inflammatory bowel disease. 
Inflammatory Bowel Disease. 2015 Nov;21(11):2673-2682. 
1. Abstract 
Background: Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of 
the gut, partly driven by defects in the innate immune system. Considering the central role of 
inflammasome signaling in innate immunity, we studied inflammasome components in IBD 
mucosa.  
Methods: Expression of genes encoding inflammasome sensor subunits was investigated in 
colonic mucosal biopsies from two cohorts of IBD patients and controls.  
Results: A significant upregulation (>2-fold change in expression, false discovery rate <0.05) 
of the PYHIN inflammasomes AIM2 and IFI16, in active IBD versus controls was found. Also 
IFI16 was significantly increased in inactive IBD versus controls. Moreover, responders to anti-
TNF therapy showed decreased expression of these inflammasomes, although IFI16 remained 
significantly increased in responders showing endoscopic healing versus controls. AIM2 was 
mainly expressed in epithelial cells, whereas IFI16 was expressed in both lymphocytes and 
epithelial cells. Functional activation of predominant AIM2/IFI16-mediated inflammasomes in 
active IBD colon was shown by presence of the downstream effectors CASP1 and HMGB1, in 
inflamed mucosa. 
Conclusions: Our results highlight the importance of PYHIN inflammasome signaling in IBD, 
and also link anti-TNF responsiveness to inflammasome signaling. Together, this points to the 
potential value of the inflammasome pathway as new therapeutic target for IBD treatment.  
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2. Introduction 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic debilitating inflammatory bowel 
diseases (IBD) with increasing prevalence worldwide1. IBD mostly affects young people and 
often leads to a greatly decreased quality of life, with diarrhea and abdominal pain as major 
gastrointestinal symptoms. Anti-TNF therapy has become the mainstay of therapy in IBD 
patients refractory to corticosteroids and/or immunomodulators, and is the first efficacious 
biological therapy for IBD2.  
While the exact pathogenesis of IBD is unknown, there is accumulating evidence of a genetic 
predisposition associated with bacterial sensing, autophagy, and links between the local 
microbial community and the mucosal immune system3. A balanced and tightly regulated 
innate intestinal immune response is important for intestinal homeostasis4, preservation of 
an intact intestinal barrier function5, and the elimination of invading pathogens4. Maintenance 
of cellular integrity and control of inflammation are indeed primordial for the host‘s survival 
and fitness. In the gut, the pro-inflammatory cytokines IL-1β and IL-18, together with TNFα, 
IL-8, IL-6 and others, are potent alarm signals that are involved in beneficial repair mechanisms 
and bacterial elimination. However, under abnormal chronic inflammation, they become 
detrimental and fuel chronic inflammation as well as remodeling6-8. 
IL-1β and IL-18 are released from the cell upon activation of inflammasomes. These are multi-
domain protein complexes that assemble upon recognition of pathogen- or damage 
associated molecular patterns (PAMPs or DAMPs respectively) to comprise a platform for the 
primordial activation of inflammatory caspase-1 (CASP1)9, 10. Inflammasomes are 
characterized by their tripartite architecture: a sensor protein, an adaptor molecule 
(apoptosis-associated speck-like protein containing a caspase activation and recruitment 
domain (CARD) (ASC)), and an inactive enzyme precursor pro-caspase-1, that will be activated 
by proteolytic cleavage, and induce release of IL-1β, IL-18, alarmins (e.g. HMGB1) and growth 
factors6, 9, 10. Sensors can be classified as members of the NOD like receptor (NLR) protein 
family (NLRP1, NLRP2, NLRP3, NLRP6, NLRP7, NLRC4 and potentially NLRP12) or the pyrin and 
HIN domain-containing (PYHIN) protein family [myeloid cell nuclear differentiation antigen 
(MNDA), interferon-inducible protein X (IFIX, also known as PYHIN1), absent in melanoma 
(AIM2) and interferon inducible 16 (IFI16)]9, 10. 
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Genetic contributions to IBD have been intensively studied in the last two decades, leading to 
the discovery of 163 IBD-susceptibility loci11. The nucleotide-binding oligomerization domain-
containing protein 2 (NOD2) gene shows the strongest association with CD and pointed 
towards the importance of the innate immune system in triggering onset of disease. 
Interestingly, also mutations in the NLRP3 gene have been associated with CD while NLRP2 
and NLRP7 mutations are associated with both CD and UC12. The role of inflammasomes in IBD 
seems to be ambiguous and highly dependent on the cell type. For example, mutations leading 
to a hypoactive inflammasome signaling can, in epithelial cells, have aggravating effects on 
IBD development in animal models. The opposite is thought to be true for inflammasome 
activation in the intestinal lamina propria (LP) where immunological cells such as macrophages 
and dendritic cells reside (e.g. by microbes that breach the intestinal barrier)6.   
Considering the central role of inflammasome signaling in innate immunity and the strong 
association of defects in the innate immune system with IBD, we investigated the presence 
and the functional activation of inflammasomes in mucosal biopsies of IBD patients with active 
or inactive disease compared to control individuals. In addition, we investigated the effect of 
anti-TNF therapy by analyzing expression patterns of these inflammasome components 
before and after control of inflammation. 
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3. Materials and methods 
3.1. Patients and biopsy specimens 
Cohort 1 (see Supplementary table 1 for characteristics) contains colonic mucosal biopsies 
from 97 UC, 8 CD patients and 11 controls with normal mucosa. Biopsies were taken from the 
edge of the ulcers in the most inflamed part of the colon (sigmoid or rectum). Disease activity 
was endoscopically assessed. In UC, there were 74 patients with active disease (endoscopic 
Mayo subscore 2-3) and 23 with inactive disease (endoscopic Mayo subscore 0-1)13. In CD, all 
8 patients had active disease (presence of ulcers). All controls underwent endoscopy for 
screening of polyps and had an endoscopically normal mucosa. For cohort 2, we used the 
colonic mucosal biopsies obtained from patients that were previously described by Arijs et 
al.14. This cohort included endoscopically-derived colonic mucosal biopsies from 43 refractory 
IBD patients with active colonic disease (24 UC, endoscopic Mayo subscore 2-3 and 19 CD, 
ulcers present) before and 4-6 weeks after their first anti-TNF [infliximab (Remicade; Centocor, 
Inc., Malvern, PA, USA)] infusion and from 12 controls with normal mucosa who underwent 
endoscopy for screening of polyps.  
For both cohorts, half of the biopsies were immediately snap-frozen in liquid nitrogen and 
stored at -80°C for RNA isolation. The residual biopsies were used for routine histopathological 
examination. 
3.2. Mucosal gene expression analysis 
The mRNA expression of genes encoding members of the inflammasome complex that are 
discussed in the recent review of Aguilera et al. (NLRP1, NLRP3, NLRP6, NLRP12, NLRC4, AIM2, 
IFI16, MNDA and PYHIN1)6 was investigated in endoscopic-derived colonic mucosal biopsies 
from the two cohorts, with the use of Affymetrix microarrays and quantitative RT-PCR (qRT-
PCR). 
3.3. RNA isolation 
For both cohorts, total RNA was isolated from the biopsies with the RNeasy Mini Kit (Qiagen, 
Venlo, Netherlands) according to the manufacturer’s instructions. Total RNA quantity and 
quality was assessed using the NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA) and the 2100 Bioanalyzer (Agilent, Waldbronn, Germany), 
respectively. The extracted RNA was used for microarray and qRT-PCR analysis. 
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3.4. Whole-genome gene expression analysis 
For cohort 1, total RNA (150 ng) was used to analyze gene expression via Affymetrix 
GeneChip® Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA), which are comprised 
of 33252 gene probe sets covering 99% of all well-annotated human genes. All steps were 
performed according to manufacturer’s manual 4475209 Rev.B (Applied Biosystems, CA, 
USA). Protocol details are described in the online supplementary material. 
The microarray data from cohort 1 were deposited according to minimum information about 
a microarray experiment (MIAME) guidelines to the Gene Expression Omnibus database. The 
cohort 1 array data was analyzed in R (http://www.r-project.org/). The raw data (.cel files) 
were pre-processed with robust multichip analysis to obtain a log2 expression value for each 
gene probe set using the implementation in the aroma.affymetrix R package15. For 
comparative analysis, linear models for microarray data (LIMMA)16 was performed for all the 
gene probe sets present on the microarray to identify gene probe sets that are differentially 
expressed between the studied groups in cohort 1, based on moderated t-statistics with 
Benjamini-Hochberg false discovery rate (FDR) correction (adjusted p-value)17.  
To analyze gene expression in cohort 2 biopsies, total RNA was used to hybridise to Affymetrix 
Human Genome U133 Plus 2.0 arrays, which are comprised of 54675 probe sets representing 
most genes of the human genome according to manufacturer’s manual as described in14. The 
cohort 2 microarray data have been submitted in MIAME format to the Gene Expression 
Omnibus (series accession number GSE16879). The cohort 2 raw data (.cel files) were also 
analyzed with Bioconductor tools in R. The robust multichip average method was performed 
on the Affymetrix raw data to obtain a log2 expression value for each probe set18. For pair-
wise comparisons, LIMMA was performed for all probe sets present on the microarray to 
identify probe sets that are different between the studied groups in cohort 2, with Benjamini 
and Hochberg FDR correction.  
For both cohorts, probe sets with FDR < 0.05 were considered significant. 
3.5. qRT-PCR analysis 
For validating the microarray data, qRT-PCR was performed for AIM2 and IFI16 on the RNA 
samples from both cohorts. β-actin was used as the endogenous reference gene. The primer 
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and probe sequences are given in supplementary table 2. Protocol details are described in the 
online supplementary material. 
The relative target mRNA expression levels were calculated as a ratio relative to the β-actin 
reference mRNA19. Results were analyzed with SPSS software (SPSS, Chicago, IL, USA), using 
Mann-Whitney U-test for unpaired samples and Wilcoxon signed-rank test for paired samples. 
A p-value < 0.01 was considered significant. 
3.6. Immunohistochemistry 
To localize AIM2, IFI16, CASP1 and HMGB1 in the colonic mucosa, immunohistochemistry was 
performed on 5 μm-thick sections from formalin-fixed, paraffin-embedded endoscopic colonic 
biopsies from UC patients with active disease and control individuals (with n=3 in each group; 
patients were randomly selected from cohort 1). 
Protocol details are described in the online supplementary material. 
3.7. Western blot analysis 
To detect IFI16 and AIM2 protein in mucosal tissue homogenate from fresh-frozen UC patient 
and control biopsies, the techniques were used as described in Arijs et al. 201114. 
Densitometric analysis of AIM2 and IFI16 protein expression was performed by using the 
ImageJ software (National Institute of Health, Maryland, USA). The generated data were 
normalized to β-actin expression in order to obtain relative expression readouts. Anti-β-actin, 
anti-AIM2 and anti-IFI16 antibodies (mouse IgG) were obtained from Sigma-Aldrich, the 
secondary HRP-conjugated anti-mouse antibodies were purchased from Thermo Fisher 
Scientific. 
3.8. Ethical considerations 
The study was carried out at the University Hospital Gasthuisberg in Leuven, Belgium. 
Informed consent was obtained from all participants and the study was approved by the Ethics 
Board of the University Hospital Leuven (B322201213950/S53684).  
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4. Results  
4.1. Gene expression of different inflammasome subtypes in IBD colonic mucosa 
In cohort 1, the nine inflammasome genes (NLRP1, NLRP3, NLRP6, NLRP12, NLRC4, AIM2, 
IFI16, MNDA and PYHIN1) were represented by nine gene probe sets on the Affymetrix 
GeneChip® Human Gene 1.0 ST array (Figure 1A and Table 1). In cohort 2, 17 probe sets on 
the Affymetrix Human Genome U133 Plus 2.0 arrays represented the nine inflammasome 
genes (Figure 1B and Table 2). 
First, we investigated the differential gene expression of the inflammasome sensor subunits 
in (non-)inflamed colonic mucosa of patients with (in-)active IBD and controls (cohort 1; Figure 
1A; Table 1). The expression of all nine inflammasome genes, except NLRP6, was significantly 
upregulated in inflamed colon of active IBD patients when compared to non-inflamed colon 
of controls and inactive IBD patients. The increase of the colonic expression levels of the PYHIN 
inflammasomes AIM2, IFI16 and MNDA was more pronounced (>2-fold) than NLR 
inflammasome genes (<2-fold). Furthermore, IFI16 colonic gene expression was, although to 
a lesser extent, also increased in inactive IBD patients versus control colons. No significant 
difference in expression of the inflammasome genes was observed in inflamed colon between 
UC and CD.  
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Table 1: Fold changes of the gene probe sets (GeneChip® Human Gene 1.0 ST arrays) encoding the 
inflammasome genes from the comparative analyses performed in cohort 1 for UC, CD and IBD.  
 
*: FDR<0.05, **: FDR<0.001, NA: not applicable 
UC CD IBD UC CD IBD UC CD IBD
(n=74) (n=8) (n=82) (n=23) (n=0) (n=23)
(nA=74, 
nIA=23)
(nA=8, 
nIA=0)
(nA=82, 
nIA=23)
7921434 AIM2 2,61** 2,03* 2,55** 1,15 NA 1,15 2,27** NA 2,22**
7906400 IFI16 3,47** 2,64* 3,38** 1,69* NA 1,69* 2,05** NA 2,00**
7906377 MNDA 2.97** 2.96* 2.97** 1,00 NA 1,00 2.98** NA 2.98**
8051396 NLRC4 1,44* 1,45 1,44* 0,90 NA 0,90 1,59** NA 1,59**
8011884 NLRP1 1,57** 1,43* 1,56** 1,07 NA 1,07 1,46** NA 1,45**
7911178 NLRP3 1,88* 1,57* 1,85* 1,10 NA 1,10 1,72** NA 1,68**
7937305 NLRP6 1,02 1,00 1,02 0,93 NA 0,93 1,10* NA 1,10*
8039096 NLRP12 1,45* 1,41* 1,45* 1,04 NA 1,04 1,40** NA 1,40**
7906386 PYHIN1 1.67** 1.56* 1.66** 1,10 NA 1,10 1.52** NA 1.50**
versus versus versus
gene 
probe 
set ID
gene 
Symbol
active inactive active  (A)
control colons (n=11) control colons (n=11) inactive (IA)
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Table 2: Fold changes of the probe sets (Human Genome U133 Plus 2.0 arrays) encoding the inflammasome 
genes from the performed comparative analyses in cohort 2 for UC, CD and IBD. 
 
*: FDR<0.05, **: FDR<0.001, R: responders, NR: non-responders 
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Figure 1: Box plots representing the microarray colonic expression of the 9 inflammasome genes of the different 
groups in cohort 1 (A) and cohort 2 (B). 
The findings in cohort 1 were confirmed in cohort 2 (Figure 1B and Table 2). A significant 
increase in expression levels of AIM2, IFI16, MNDA and NLRP1, and a borderline significant 
increase (FDRIBDvscontrols_207075_at= 0.08) of NLRP3 expression in inflamed IBD colon vs. control 
colon was observed. Moreover, the colonic expression levels of AIM2 (>5-fold), IFI16 (>5-fold) 
and MNDA (>10-fold) were increased to a much greater extent than the colonic expression 
levels of NLRP1 (~1,2-fold) and NLRP3 (1.6-fold) in active IBD vs. controls. A significant 
decrease of NLRP6 gene expression was seen in inflamed IBD colon vs. control colons.  
Next, we studied the effect of anti-inflammatory treatment with infliximab on the expression 
of the inflammasome genes in inflamed colonic mucosa of active IBD (cohort 2; Figure 1B; 
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Table 2). After infliximab therapy, a significant decrease in expression of AIM2, IFI16, MNDA 
and NLRC4 was observed in IBD responders showing complete colonic mucosal healing, when 
compared to their baseline samples. Although a decreased expression of IFI16 was seen after 
infliximab therapy in IBD responders versus baseline samples, the IFI16 expression levels 
remained significantly higher after infliximab therapy in IBD responders (= inactive IBD) versus 
control colons. In contrast with IBD responders, the colonic expression of AIM2, IFI16, MNDA 
and NLRP1 remained significantly increased after infliximab therapy in IBD non-responders 
versus controls.  
As the PYHIN inflammasomes showed the strongest and most significant upregulation in UC 
patients, for our further investigation we focused on the two most described PYHIN 
inflammasome sensor subtypes AIM2 and IFI16 in tissue from UC patients and controls. We 
confirmed the differential colonic gene expression of AIM2 and IFI16 observed by microarray 
analysis by qRT-PCR (Supplementary figure 1 and Supplementary table 2 and 3). 
4.2. Validation of AIM2 and IFI16 expression at the protein level 
We next tested if AIM2 and IFI16 protein expression was also increased in colonic mucosa of 
active UC compared to controls on protein level, in randomly selected patients and controls 
from cohort 1. We confirmed the gene expression results, and found an increased colonic 
expression for both proteins in active UC mucosa versus normal control mucosa, although the 
increase of AIM2 protein was more pronounced. In the mucosa of patients with inactive UC, 
detected protein levels were intermediate between the levels of normal controls and patients 
with active disease, which is in accordance with our gene expression data. The readouts of the 
semi-quantitative densitometric analysis are represented in Figure 2. As the relative 
proportion of extracellular matrix protein versus intracellular protein can highly vary between 
biopsies and may severely affect total protein amount in the whole biopsy lysates, it is 
essential to normalize versus an intracellular housekeeping protein (such as β actin) in order 
to densitometrically quantify an intracellular protein. Pictures of the actual Western blot can 
be found in the supplementary material (Supplementary figure 2 & 3). 
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Figure 2: Semiquantitative densitometry analysis (ImageJ software) of the pooled AIM2 and IFI16 signal from 
Western blot on colonic biopsy lysates from control individuals and patients with active or inactive UC. 
AIM2/IFI16 expression levels were normalized to b-actin expression, and the relative expression in control 
colons was set to 1 (mean + SEM). 
4.3. Immunohistochemistry 
To evaluate whether AIM2 and IFI16 are expressed in distinct cell types of the mucosa, we 
localized these inflammasome sensor subunits by immunostaining of tissue sections from 
colonic biopsies from active UC patients and normal controls (Figure 3). These proteins 
demonstrate distinct localizations within the tissue but also within the cells. In normal colonic 
mucosa of healthy controls, AIM2 expression was seen throughout the epithelial cytoplasm, 
and not at the brush border (Figure 3C). In UC patients, the epithelial expression pattern of 
AIM2 was preserved and additionally some LP cells (Figure 3D, green arrow) and intra-
epithelial lymphocytes (Figure 3D, red arrow) expressed AIM2. The other investigated sensor 
subunit, IFI16, showed a clear nuclear localization in LP cells in healthy controls as well as in 
active UC patients. However, in active UC colon, IFI16 showed stronger expression in all 
epithelial cells. This is in contrast to healthy controls where a gradient in expression could be 
seen, with clear IFI16 expression in the crypt base and a decrease in expression towards the 
apical side. 
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Figure 3: Immunohistochemistry for detection and localization of AIM2 (C and D) and IFI16 (E and F) in paraffin-
embedded formalin-fixed tissue sections from colonic biopsies from control individuals (left) and patients with 
active UC (right). Negative controls with no primary antibody are shown in (A and B). Scale bars represent 100 
µm, red arrow indicates an AIM2-positive LP cell, green arrow indicates an AIM2-positive intraepithelial 
lymphocyte. 
Analogous to AIM2 and IFI16, we also analyzed the specific localization of two downstream 
effectors CASP1 and HMGB1 (Figure 4). CASP1 showed positive staining in the cytoplasm of 
epithelial cells but also in LP cells that are in proximity of the colonic epithelium of healthy 
controls. In UC patients, CASP1 was less abundant in the LP, but showed a high expression in 
the cytoplasm of epithelial cells from the crypt bases to the apical side. HMGB1 had a clear 
nuclear localization in a subset of LP cells, whereas in epithelial cells, this inflammasome 
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effector could be detected in both the nucleus and cytoplasm. This is in contrast with UC 
patients where HMGB1 was less abundant in the cytoplasm of epithelial cells, while nuclear 
expression remained the same. In the LP however, nuclear HMGB1 expression was generally 
increased.  
 
Figure 4: Immunohistochemistry for detection and localization of Caspase-1 (A and B) and HMGB-1 (C and D) in 
paraffin-embedded formalin-fixed tissue sections from colonic biopsies from control individuals (left) and 
patients with active UC (right). Scale bars represent 100 µm. 
Our immunohistochemical data could confirm our gene expression results and indicate a 
marked presence of PYHIN (i.e. AIM2 and IFI16) inflammasome components in the epithelial 
compartment of the colonic mucosa in IBD patients with active disease. 
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5. Discussion 
Current treatment options for IBD are far from successful in all patients20. Therefore, the 
identification of new pathways that contribute to the pathogenesis of IBD is essential in order 
to reveal new potential targets. We analyzed gene expression patterns and protein levels of 
inflammasome sensors in intestinal biopsies and compared these results between control 
individuals, (in-)active IBD patients and infliximab responding and non-responding patients. 
We report the upregulation of most inflammasome sensor subtypes (NLRP1, NLRP3, NLRP12, 
NLRC4, AIM2, IFI16, MNDA and PYHIN1) in the colonic mucosa of active IBD patients, with the 
double stranded DNA (dsDNA) responding PYHIN inflammasome subtypes (MNDA, AIM2 and 
IFI16) showing the strongest increase. Our immunohistochemical data show, besides 
inflammatory cell presence, an epithelial presence of AIM2 and IFI16 and some of their 
effector molecules (CASP1 and HMGB1). We have confirmed that dsDNA, which is a 
PYHIN/AIM2-IFI16-specific inflammasome trigger, can induce IL-1β maturation in vitro in 
primary intestinal epithelial cells (data not shown), suggesting AIM2 and/or IFI16-mediated 
inflammasome activation in this cell type.  
The increased presence of dsDNA-responding inflammasomes could indicate an augmented 
mucosal dsDNA exposure for which several sources are possible, including mitochondrial DNA 
from damaged mitochondria or fragmented nuclear DNA from the decaying nucleus of the cell 
itself or from neighboring cells. Old/damaged mitochondria generate excessive reactive 
oxygen species (ROS) and may release their mitochondrial dsDNA in the cytosol21. While ROS 
could induce NLRP3 inflammasomes22, 23, mitochondrial dsDNA has been shown to be able to 
act as a trigger of IFI16 & AIM2-inflammasomes. Additionally, mitochondrial inflammasome 
activation can be linked to defective autophagy, an event already associated with IBD11, 24-28, 
and known to result in reduced clearance and increased accumulation of malfunctioning 
mitochondria and release of mtDNA21 but also other disease related events such as decreased 
antigen sampling and IL-10 secretion by dendritic cells29. During chronic intestinal 
inflammation, there often is a strong imbalance between epithelial cell proliferation in the 
crypts and cell death at inflammatory hotspots. This may lead to epithelial barrier defects, an 
event which further promotes intestinal inflammation via an increased antigen exposure to 
the LP30, 31. Increased epithelial cell death results in fragmenting nuclear DNA, hereby 
potentially triggering PYHIN inflammasome activation.  
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Shimada et al. showed that oxidized mtDNA, which is formed and released during apoptosis, 
results in increased IL-1β secretion through NLRP3 inflammasome activation in 
macrophages32. The authors state that this response is probably a consequence of both NLRP3 
activation as well as AIM2 activation by non-oxidized mtDNA32. Our findings indicate that this 
might also be the case for epithelial cells in the stressful environment of an active IBD mucosa.  
Moreover, active CASP1 is a known inducer of pyroptosis6, an inflammatory form of cell death 
believed to prevent spreading of intracellular pathogens such as Lysteria monocytogenes, 
which in the case of Lysteria infection requires both NLRP3 and AIM2-inflammasomes33. 
Inflammasome activation could thus by itself lead to the induction of cell death and 
inflammation as a feedback loop on intestinal inflammation.    
Exogenous dsDNA sources are likely as well, for example from micro-organisms, bacteria or 
viruses that are able to invade the cell and release or produce dsDNA. Given the current 
hypothesis that IBD results from an aberrant immune response against commensal gut flora, 
and the higher concentrations of mucosal bacteria in IBD patients compared to healthy 
individuals34, it is not surprising that pattern recognition receptors (PRRs), such as the IFI16 
and AIM2-inflammasomes, are upregulated/stimulated in these patients. Moreover, shifts in 
bacterial composition or dysbiosis, a phenomenon associated with IBD35, 36, might allow 
pathogens to invade the mucosa more easily (e.g. due to decreased nutrient competition with 
commensals or disturbed intestinal homeostasis)37, which will consequently aid intestinal 
inflammation trough PRR stimulation.  This suggests that commensal microbial DNA could 
contribute to chronic intestinal inflammation through stimulation of dsDNA responsive 
inflammasomes. Besides commensal bacteria, the gut mucosa is continuously exposed to a 
variety of pathogens38. Interestingly, several studies demonstrated inflammasome 
involvement in response to invading pathogens. For example, the NLRP3 inflammasome is 
essential for the clearance of infections with pathogenic bacteria such as Staphylococcus 
aureus, Vibrio cholerae, Escherichia coli, Neisseria gonorrhoeae, Chlamydia pneumoniae and 
Citrobacter rodentium39, while AIM2 has been shown to be activated by Lysteria 
monocytogenes and Francisella tularensis39. Some of these bacteria can be found in the gut, 
as they are the cause of intestinal bacterial infections.  
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Both AIM2 and IFI16 expression can be induced by type I and/or type II interferons (IFN)40, 
which are the first line of defense against viral pathogens41. Increased IFN-γ levels have been 
associated with CD42, and the influence of the intestinal virome on IBD has recently been 
intensely investigated43. Foxman & Iwasaki suggested that highly prevalent viruses could be a 
partial causative factor of chronic diseases such as IBD43. Also, virus-induced intestinal 
inflammation has been linked to defective autophagy in a mouse model of colitis44. Paneth 
cell abnormalities such as secretion defects and morphological changes can be seen in biopsies 
from mice with hypoactive ATG16L1, and patients carrying the CD-associated ATG16L1 
allele45. More recently, it has been shown that a viral infection is needed for the CD-associated 
Paneth cell phenotype in mice. Interestingly, antibiotics could prevent this phenotype 
indicating that a bacterial component is also needed in this model44. The authors thus suggest 
a multi-hit model for the development of IBD where microbial, viral and genetic components 
coincide44, 45. It will be important/interesting to further explore the role of AIM2 and IFI16 for 
example by using knockout mice in the described IBD models. To our knowledge, only AIM2 
knockout mice have been used to investigate the role of this protein in the response to 
bacterial and viral infections. Fernandes-Alnemri et al. showed that AIM2 knockout mice are 
more susceptible to infection by F. tularensis, while Rathinam and collaborators showed an 
altered IL-18 secretion in these mice after cytomegalovirus infection46, 47. 
Our findings could have important implications with regard to more personalized therapies, 
which seems to become the future of IBD treatment48. For example, patients carrying 
mutations in one of the components in the microbial response (e.g. autophagy, IFN-signaling, 
PYHIN-inflammasomes and their effectors) might have difficulties in tolerating commensals 
and clearing intracellular pathogens, which could contribute to the induction and chronic 
maintenance of intestinal inflammation, and thus IBD pathogenesis. Furthermore, patients 
that carry additional mutations in bacterial clearing genes might have an even worse 
prognosis. Inflammasomes, mainly NLRP3 have already been investigated in animal models of 
IBD. Depending on the study, investigators identified aggravating or beneficial effects of 
NLRP3 knockout on intestinal inflammation49, 50. Later, Bauer et al. proposed that these 
contradicting findings might be the consequence of the presence of distinct micro-organisms 
in different animal facilities7. It could for example be the presence of a microbial/viral 
component that has an additive effect on the chemically-induced intestinal inflammation in 
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NLRP3 knockout mice in this experimental setup. Different microbial and/or viral composition 
of the gut might also explain why the NLRP3 association with IBD12 could not be replicated51. 
With regard to current IBD treatments, in this study we show that patients with colonic 
mucosal healing after infliximab treatment have a significant drop in the mucosal expression 
of the PYHIN inflammasome genes, while this is not the case for patients who do not respond 
to anti-TNF therapy. Therefore, although preliminary, it is tempting to speculate about 
potential clinical implications. For example, increased AIM2 and IFI16-expression in mucosal 
biopsies, and possibly also in blood immune cells, may hold potential as a biomarker for non-
responsiveness to therapy. Also, the fact that infliximab non-responsive patients show a 
sustained high expression of PYHIN inflammasomes could be an indication that in these 
patients a stronger viral component is present. Another interesting finding was the persistent 
up-regulation of IFI16 colonic gene expression in inactive IBD, and in IBD responders with 
mucosal healing. This may be one of the reasons why mucosal ulcers recur very early if 
patients do not receive maintenance therapy to control the intestinal inflammation.  
Our data do not allow us to determine whether IFI16 and AIM2 upregulation is either a cause 
or consequence of intestinal inflammation. It should be mentioned however that, 
independent from the sequence of events, the expression or activation of the inflammasome 
pathway holds potential as a biological marker or therapeutic target. 
In conclusion, our findings firstly suggest a new link between the pro-inflammatory PYHIN 
inflammasomes and IBD pathogenesis. Secondly, response to infliximab is associated with 
expression levels of PYHIN inflammasome components. Our study thus indicates that it is 
worthwhile to further investigate/validate (PYHIN-based) inflammasome signaling and its 
association with the microbial/viral gut environment as potential therapeutic target. 
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6. Supplementary material 
6.1. Protocol details  
6.1.1. Whole-genome gene expression analysis 
Briefly, in the first cycle, double stranded cDNA was prepared with random hexamers tagged 
with a T7 promoter sequence, followed by the generation of cRNA using the GeneChip WT 
Synthesis and Amplification kit (Ambion WT expression kit). cRNA concentration after cleanup 
was measured with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). In 
the second cycle, sense oriented single-stranded DNA containing dUTP was generated and the 
concentration is measured after clean-up using the NanoDrop. The cRNA is hydrolyzed and 
the single-stranded DNA is fragmented using uracil DNA glycosylase (UDG) and 
apurinic/apyrimidinic endonuclease 1 (APE1) (GeneChip WT terminal Labeling kit, Affymetrix). 
The quality of fragmentation (fragments should be between 40 and 70 nucleotides) is checked 
on the 2100 Bioanalyzer (Agilent). The fragmented DNA is labeled by terminal 
deoxynucleotidyl transferase (TDT) with the Affymetrix DNA Labeling reagent that is 
covalently linked to biotin (GeneChip WT terminal Labeling kit, Affymetrix). Labeled DNA was 
hybridized to the array during 17h at 45°C. The arrays were washed and stained in a fluidics 
station using the GeneChip hybridization, Wash end Stain kit (Affymetrix) and scanned using 
the Affymetrix 3000 GeneScanner. All image files were generated using AGCC. Quality 
assessment and outlier detection was performed before and after normalization using the 
Bioconductor package arrayQualityMetrics52. 
6.1.2. qRT-PCR analysis 
After cDNA synthesis from total RNA (0.5 μg) using the RevertAid H Minus First Strand cDNA 
synthesis kit (Fermentas, St. Leon-Rot, Germany), multiplex real-time PCR was performed in a 
total reaction volume of 25 µl on a Rotor-Gene 3000 instrument (Corbett Research, Mortlake, 
Australia) using the QuantiTect Multiplex PCR NoROX Kit (Qiagen, Venlo, NL). All samples were 
amplified in duplicate reactions. 
6.1.3. Immunohistochemistry 
After drying, deparaffinization and rehydration, epitope retrieval was performed at low pH for 
AIM2, and at high pH for IFI16 and CASP1 (Dako PT Link machine, Dako Belgium NV, Heverlee, 
Belgium). Sections were then washed 3 times for 5 min (Envision Flex wash buffer, Dako) and 
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Envision Flex Peroxidase-Blocking Reagent (Dako) was applied for 10 min at room 
temperature. After a second wash step, sections were incubated with an anti-human AIM2 
rabbit polyclonal antibody (Sigma-Aldrich, Bornem, Belgium; dilution 3.2 µg/ml), or with an 
anti-human IFI16 rabbit polyclonal antibody (Sigma-Aldrich, dilution 0.5 µg/ml), or with anti-
human CASP1 mouse monoclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany; 
dilution 2 µg/ml), or with anti-human HMGB1 rabbit polyclonal antibody (Abcam, Cambridge, 
UK; dilution 1 µg/ml) for 30 min at room temperature. Following a third wash step, bound 
primary antibody was visualized by incubating the slides for 30 min with Envision Flex/HRP 
(Dako) and application of the Envision DAB+ Chromogen (Dako) for 10 min at room 
temperature. After rinsing, the slides were counterstained with haematoxylin, dehydrated, 
cleared and mounted. Negative controls (no application of primary antibody) were run 
together with the test samples. 
Microscopical images were acquired with the Cell* software (Olympus Soft Imaging Solutions 
GmbH, Münster, Germany) using a Olympus SC30 camera (Olympus Corporation, Tokyo, 
Japan) mounted on a Olympus BX41 bright field microscope. Total magnification was 100x and 
the objective lens used is a UPlamSApo 10x/0.40na; ∞/0.17/FN26.5 from Olympus.  
117 
 
6.2. Supplementary tables 
Supplementary table 1: Characteristics of patients and controls in cohort 1.  
*: immunosupperessants = azathioprine/6-mercaptopurine and methotrexate, IQR: interquartile range, IFX: 
infliximab, NA: not applicable 
Characteristics 
UC CD 
Controls 
Active Inactive Active 
(n=74) (n=23) (n=8) (n=11) 
Male/Female (%) 43/31 (58.1/41.9) 
12/11 
(52.2/47.8) 
2/6 (25/75) 
5/6 
(45.5/54.5) 
Median (IQR)* age (years) 45.9 (33.19-54.97) 43.93 (29.6-57.2) 
38.9 (35.1-
45.3) 
69.6 (64-74.9) 
Median (IQR)* duration of disease (years) 5.46 (2.59-13.5) 8.65 (3.3-17.9) 2 (0,19-3.99) NA 
Extent of disease         
UC Left-sided colitis (%) 35 (47.3) 13 (56.5) NA NA 
Pancolitis (%) 39 (52.7) 10 (43.5) NA NA 
CD Ileocolon (%) NA NA 3 (37.5) NA 
Ileum (%) NA NA 0 (0) NA 
Colon (%) NA NA 5 (62.5) NA 
Concomitant medication at first IFX (%)         
5-Aminosalicylates 59 (79.7) 22 (95.7) 1 (12.5) NA 
Corticosteroids 31 (41.9) 2 (8.7) 2 (25) NA 
Azathioprine/6-Mercaptopurine 13 (17.6) 10 (43.5) 0 (0) NA 
Methotrexate 2 (2.7) 0 (0) 0 (0) NA 
Anti-TNF 0 (0) 11 (47.8) 0 (0) NA 
Active smoking (%) 9 (12.2) 3 (13) 3 (37.5) 0 (0) 
 
Supplementary table2: Primer and probe oligonucleotide sequences for qRT-PCR analyses of AIM2, IFI16 and β-
actin. 
Gene 
symbol 
  Sequence 
A
IM
2
 
forward 
primer 
5'-TCCTCATGTTAAGCCTGAACAG-3' 
reverse 
primer 
5'-CTTTCAGTACCATAACTGGCAAAC-3' 
Probe 5'-TCTGATAGATTCCTGCTGGGCCACCATCTG-3' 
IF
I1
6
 
forward 
primer 
5'-AGATAATACAGGGAAGATGGAAGT -3' 
reverse 
primer 
5'-GTCTTGATGACCTTGATGTGACT-3' 
Probe 5'-TGGTGCATGGACGACTGACCACAATCAACT-3' 
β
-a
ct
in
 
forward 
primer 
5'-CCCAGCACAATGAAGATCAAGATC-3' 
reverse 
primer 
5'-CTGATCCACATCTGCTGGAAG-3' 
Probe 5'-CCTCCTGAGCGCAAGTACTCCGTGTG-3' 
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Supplementary table 3: Statistical analyses (P-values) of the qRT-PCR data of AIM2 and IFI16 in colonic mucosa 
of controls and IBD patients. *significant P-value (P < 0.01), R: responders, NR: non-responders. 
  Comparison AIM2 IFI16 
    p-value p-value 
C
O
H
O
R
T 
1
 
active IBD vs control <0.001* <0.001* 
inactive IBD vs control colon 0,015 <0.001* 
inactive IBD vs active IBD <0.001* 0.009* 
C
O
H
O
R
T 
2
 
IBD before therapy vs control colons 0.001* <0.001* 
IBD R after therapy vs control colons 0,021 0.005* 
IBD NR after therapy vs control colons 0.001* <0.001* 
IBD R after therapy vs IBDc R before therapy 0,027 0,173 
IBD NR after therapy vs IBDc NR before 
therapy 
0,357 0,738 
 
6.3. Supplementary figures  
 
Supplementary figure 1: qRT-PCR analysis of A) AIM2 and B) IFI16 in colonic mucosa from IBD patients and 
controls. A line between 2 points represents the change in expression before and after infliximab therapy for 
one patient. Individual expression levels (♦) and median (▬) for each group are shown.  
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Supplementary figure 2: Western blot for detection and quantification of AIM2 in colonic whole biopsy lysates 
from healthy controls (HC;n=3) and patients with active (n=4) or inactive (n=4) UC. 
 
Supplementary figure 3: Western blot for detection and quantification of IFI16 in colonic whole biopsy lysates 
from healthy controls (HC;n=3) and patients with active (n=4) or inactive (n=4) UC.  
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CHAPTER 6: MUCOSAL EXPRESSION OF AUTOPHAGY AND ER STRESS 
GENES IN INFLAMMATORY BOWEL DISEASES 
1. Introduction and aim 
Endoplasmic reticulum stress and autophagy are two important processes that help to 
maintain intestinal homeostasis and have been identified as underlying pathophysiologic 
pathways in inflammatory bowel diseases (IBD). Besides being genetically associated to IBD, 
animal models and human histopathologic studies confirmed that (genetic) perturbations of 
these pathways lead to severe abnormalities in the intestinal mucosa and inflammation1-9. 
These pathways are now considered to be potential therapeutic targets in IBD10-19. A 
quantitative and qualitative assessment of these underlying pathophysiologic processes, 
might aid in therapeutic decision-making and prediction of disease course20-22. We investigate 
the link between ER stress and autophagy associated gene expression and disease activity in 
IBD or response to anti-TNF therapy. We used the same two cohorts that were used to study 
the inflammasome genes in Vanhove et al.23 (CHAPTER 5).  
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2. Material and methods 
This chapter is an addendum to CHAPTER 5, we refer to the material and methods section of 
that chapter for the methodological information on patients and biopsy specimens; RNA 
isolation; whole-genome gene expression analysis and ethical considerations. The selection 
and filtering of ER stress and autophagy genes, which is unique to this chapter, are described 
here. 
2.1. Selection of ER stress and autophagy associated genes 
We analyzed the mRNA expression of genes encoding proteins that are attributed to ER stress 
or autophagy according to the curated Reactome database (www.reactome.org) in 
endoscopic-derived colonic mucosal biopsies from patients in the two cohorts, with the use 
of Affymetrix whole genome gene expression microarrays. 
We used the Reactome database to acquire a curated list of genes that are involved in ER 
stress or autophagy (86 and 69 genes, respectively, Supplementary table 1 and 2). After 
matching these genes to their respective probeset(s) on both microarray platforms, the same 
comparative analyses were performed as described in Vanhove et al.23 and these results were 
used to filter and retain the strongest (top-10) significantly (FDR<0.05) upregulated and 
downregulated genes and their annotated probesets from each comparison. Furthermore, we 
filtered out genes that did not show consistent results in both cohorts in order to retain genes 
that were dysregulated in more than one cohort population. Genes showing strong fold 
changes between two patient groups in two independent cohorts, will be further discussed in 
this chapter. 
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3. Results 
3.1. ER stress genes 
We narrowed down the Reactome-based list of 86 ER stress genes to 23 by applying the 
described filtering steps, details of this filtering process can be found in supplement (5.1 and 
supplementary table 1). The refined lists of 23 ER stress genes (26 and 52 probesets in cohort 
1 and 2, respectively) are listed in Tables 1 and 2. In cohort 1 (Table1), the genes with most 
pronounced statistically significant fold changes in patients with active colonic disease (vs. 
colonic tissue from healthy controls) were KDELR3, XBP1 and DNAJB9 (≥2-fold between active 
colonic disease and control colons) followed by SSR1, HSP90B1, PDIA5 and HYOU1 (≥1.7-fold) 
and DNAJB11, HSPA5, SYVN1, FKBP14, SEC61A1, CALR, PDIA6 and WFS1 (≥1.5-fold). The 
expression of all of these genes was decreased in patients with inactive disease and most of 
them normalized to the levels of healthy controls. However, KDELR3, XBP1, SSR1, PDIA5, 
SYVN1, SEC61A1 were still increased in patients with inactive disease when compared to 
control colons. 
  
130 
 
Table 1: Fold changes of the gene probe sets (GeneChip® Human Gene 1.0 ST arrays) encoding the ER stress 
genes from the comparative analyses performed in cohort 1 for UC, CD and IBD. 
 
*: FDR<0.05, **: FDR<0.001, NA: not applicable. Probesets belonging to genes that were in the top-10 
up/downregulated genes in a given comparison are indicated in bold. 
  
UC CD IBD UC CD IBD UC CD IBD
(n=74) (n=8) (n=82) (n=23) (n=0) (n=23)
(nA=74, 
nIA=23)
(nA=8, 
nIA=0)
(nA=82, 
nIA=23)
8004271 ACADVL 0,72** 0,85 0,73** 0,71* NA 0,71* 1,01 NA 1,02
8002041 ATP6V0D1 0,72** 0,83 0,73** 0,77** NA 0,77** 0,95 NA 0,96
8026106 CALR 1,51** 1,37** 1,50** 1,03 NA 1,03 1,47** NA 1,45**
7964579 CTDSP2 0,71** 0,82* 0,72** 0,81* NA 0,81* 0,88* NA 0,89*
8084634 DNAJB11 1,66** 1,39* 1,63** 1,09 NA 1,09 1,52** NA 1,49**
8135480 DNAJB9 2,06** 1,50* 1,99** 1,09 NA 1,09 1,88** NA 1,83**
7969651 DNAJC3 1,41** 1,16 1,38** 0,87 NA 0,87 1,62** NA 1,59**
8145624 EXTL3 1,39** 1,24* 1,37** 1,20* NA 1,20* 1,16** NA 1,14**
8138834 FKBP14 1,56** 1,49 1,56** 1,03 NA 1,03 1,52** NA 1,52**
7995895 HERPUD1 1,33* 1,06 1,30* 0,86 NA 0,86 1,55** NA 1,52**
7958130 HSP90B1 1,73** 1,57** 1,72** 1,07 NA 1,07 1,62** NA 1,61**
8164165 HSPA5 1,62** 1,34* 1,59** 1,09 NA 1,09 1,49** NA 1,46**
7952145 HYOU1 1,71** 1,45* 1,68** 1,09 NA 1,09 1,56** NA 1,53**
8073015 KDELR3 2,86** 2,06** 2,77** 1,78* NA 1,78* 1,61** NA 1,56**
8119648 KLHDC3 0,78** 0,77* 0,78** 1,03 NA 1,03 0,76** NA 0,76**
7900468 NFYC 0,75** 0,82* 0,75** 0,86* NA 0,86* 0,87** NA 0,88**
7915345 NFYC 1,02 1,02 1,02 1,04 NA 1,04 0,98 NA 0,98
8082133 PDIA5 1,74** 1,51* 1,72** 1,55** NA 1,55** 1,12* NA 1,11*
8040249 PDIA6 0,78** 0,76* 0,78** 1,02 NA 1,02 0,77** NA 0,77**
8050278 PDIA6 1,50** 1,29 1,48** 1 NA 1 1,51** NA 1,49**
8082408 SEC61A1 1,53** 1,32* 1,51** 1,16* NA 1,16* 1,33** NA 1,31**
7952557 SRPR 1,46** 1,24 1,44** 1,05 NA 1,05 1,40** NA 1,37**
8123767 SSR1 1,86** 1,66* 1,84** 1,25* NA 1,25* 1,49** NA 1,47**
7949383 SYVN1 1,61** 1,41** 1,59** 1,20* NA 1,20* 1,34** NA 1,32**
8093906 WFS1 1,50** 1,23 1,47** 1,20* NA 1,20* 1,25** NA 1,23**
8075182 XBP1 2,64** 2,22** 2,60** 1,48** NA 1,48** 1,79** NA 1,76**
gene 
probe set 
ID
gene Symbol
active inactive active  (A)
versus versus versus
control colons (n=11) control colons (n=11) inactive (IA)
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Most findings in cohort 1 were confirmed in cohort 2 (Table 2), KDELR3, XBP1, DNAJB9, 
HSP90B1 and CALR expression was significantly increased (≥2-fold) in patients with active 
colonic disease (before infliximab) when compared to control colon. Other highly upregulated 
genes from cohort 1 such as SSR1, PDIA5, PDIA6, WFS1, SRPR, HSPA5 and HYOU1 were >1.5-
fold upregulated in patients with active colonic disease when compared to control colons. 
Most genes also normalized after successful IFX therapy (R after infliximab) except for KDELR3 
and XBP1 which remained significantly upregulated. In non-responders to IFX, all the 
aforementioned genes remained significantly increased after anti-TNF therapy.  
Finally, we found that, before therapy, a specific subset of ER stress genes is significantly 
increased in patients who will not respond to IFX when compared to patients who will 
respond: DNAJB9, XBP1, HSP90B1, FKBP14, SRPR, WFS1 and HERPUD1. Similar predictive 
transcriptomic profiles have already been discovered in this cohort24, 25. The current findings 
suggest that this ER stress-specific signature might be of additive value to the previously-
identified signature. 
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Table 2: Fold changes of the probe sets (Human Genome U133 Plus 2.0 arrays) encoding the ER stress genes 
from the performed comparative analyses in cohort 2 for UC, CD and IBD. 
 
*: FDR<0.05, **: FDR<0.001, R: responders, NR: non-responders. Probesets belonging to genes that were in the 
top-10 up/downregulated genes in a given comparison are indicated in bold. 
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Table 2-continued: Fold changes of the probe sets (Human Genome U133 Plus 2.0 arrays) encoding the ER stress 
genes from the performed comparative analyses in cohort 2 for UC, CD and IBD.
  
*: FDR<0.05, **: FDR<0.001, R: responders, NR: non-responders. Probesets belonging to genes that were in the 
top-10 up/downregulated genes in a given comparison are indicated in bold. 
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3.2. Autophagy genes 
We also narrowed down the list of 69 autophagy genes to 14 by applying the described 
filtering steps, details of this filtering process can be found in supplement (5.2 and 
supplementary table 2). The refined lists of 14 autophagy genes (15 and 33 probesets in 
cohort 1 and 2, respectively) are listed in Table 3 and 4. 
Table 3: Fold changes of the gene probe sets (GeneChip® Human Gene 1.0 ST arrays) encoding the autophagy 
genes from the comparative analyses performed in cohort 1 for UC, CD and IBD. 
 
*: FDR<0.05, **: FDR<0.001, NA: not applicable. Probesets belonging to genes that were in the top-10 
up/downregulated genes in a given comparison are indicated in bold. 
  
UC CD IBD UC CD IBD UC CD IBD
(n=74) (n=8) (n=82) (n=23) (n=0) (n=23)
(nA=74, 
nIA=23)
(nA=8, 
nIA=0)
(nA=82, 
nIA=23)
7979328 ATG14 0,68** 0,71** 0,68** 0,71** NA 0,71** 0,95 NA 0,95
8169272 ATG4A 1,04 0,93 1,03 0,72* NA 0,72* 1,45** NA 1,45**
8025659 ATG4D 0,68** 0,83 0,70** 0,93 NA 0,93 0,73** NA 0,73**
8077858 ATG7 1,21* 1,16 1,20* 1,02 NA 1,02 1,19** NA 1,19**
7955606 C12orf44 1,18** 1,09 1,17** 1,19* NA 1,19* 0,99 NA 0,99
8039796 CHMP2A 0,74** 0,77* 0,74** 0,86* NA 0,86* 0,86** NA 0,86**
8053562 CHMP3 0,78** 0,82* 0,78** 0,97 NA 0,97 0,80** NA 0,80**
8061958 CHMP4B 0,73** 0,78* 0,73** 0,86* NA 0,86* 0,84** NA 0,84**
7954810 LRRK2 2,86** 2,70* 2,85** 1,08 NA 1,08 2,64** NA 2,64**
8062023 MAP1LC3A 0,71** 0,87 0,72** 1,02 NA 1,02 0,70** NA 0,70**
8072302 MTMR3 0,71** 0,75** 0,71** 0,83* NA 0,83* 0,86** NA 0,86**
8072279 MTMR3 0,81** 0,85* 0,82** 0,94 NA 0,94 0,87** NA 0,87**
7919305 PRKAB2 0,61** 0,66** 0,61** 0,74* NA 0,74* 0,82** NA 0,82**
8150757 RB1CC1 0,80** 0,79* 0,80** 0,74** NA 0,74** 1,08 NA 1,08
8128123 RRAGD 1,28 1,17 1,27 0,93 NA 0,93 1,38** NA 1,38**
gene 
probe set 
ID
gene 
Symbol
active inactive active  (A)
versus versus versus
control colons (n=11) control colons (n=11) inactive (IA)
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Table 4: Fold changes of the probe sets (Human Genome U133 Plus 2.0 arrays) encoding the ER stress genes 
from the performed comparative analyses in cohort 2 for UC, CD and IBD. 
 
*: FDR<0.05, **: FDR<0.001, R: responders, NR: non-responders. Probesets belonging to genes that were in the 
top-10 up/downregulated genes in a given comparison are indicated in bold. 
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In cohort 1 (Table 3) only LRRK2 was significantly upregulated (> 2-fold) in patients with active 
disease when compared to control individuals and this was confirmed in cohort 2 (Table 4). 
All other autophagy genes with pronounced fold changes such as PRKAB2, ATG14/KIAA0831, 
ATG4D, MTMR3, MAP1LC3A, CHMP4B and CHMP2A were downregulated in patients with 
active disease in both cohorts. From these 7 genes, PRKAB2, ATG14/KIAA0831, MTMR3, 
CHMP4B and CHMP2A remain downregulated in patients with inactive disease (cohort 1) but 
this was only confirmed for MAP1LC3A and CHMP4B in the second cohort (after successful 
anti-TNF therapy). 
Interestingly, LRRK2 was differentially expressed when comparing IFX-responders and non-
responders before the initiation of IFX therapy with a >2-fold downregulation in the latter 
group. This difference was only significant in CD patients or when grouping CD and UC patients 
together (FDR < 0.05 and < 0.001, respectively) 
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4. Discussion 
Given the well-evidenced involvement of ER stress and autophagy in IBD, we analyzed 
expression patterns of genes encoding for proteins strongly involved in these pathways. We 
believe that characterization of the functionality (e.g. mucosal gene expression profiling) of 
these pathways could become a way to classify patients for therapeutic decision-making. 
Therefore, we used the curated Reactome Database to generate lists of genes/proteins that 
have been described to play a role in to either ER stress or autophagy. Comparisons were 
made between control individuals, IBD patients with (in)active disease and IFX-responding and 
non-responding patients.  
In this study we show that several ER stress/UPR genes (KDELR3, XBP1, DNAJB9, SSR1, 
HSP90B1, PDIA5, HYOU1, DNAJB11, HSPA5, SYVN1, FKBP14, SEC61A1, CALR, PDIA6 and WFS1) 
are upregulated in the colonic mucosa of patients with active disease. These observed 
differences were comparable between UC and CD patients and the reduced significance in the 
comparisons with the CD group is most likely due to the lower sample size (8 CD vs. 74 UC 
patients). Some genes remained upregulated in patients with inactive disease, however this 
was only significant (vs. control colons) in both cohorts for KDELR3 and XBP1. Nevertheless, 
this indicates that some molecular players of the ER stress pathway remain active even when 
there are no overt signs of inflammation, but could possibly trigger disease relapse. Another 
interesting finding was that DNAJB9, XBP1, HSP90B1, FKBP14, SRPR, WFS1 and HERPUD1 were 
upregulated in patients who will not respond to IFX therapy when compared to patients 
responding to IFX.  
KDEL (Lys-Asp-Glu-Leu) Endoplasmic Reticulum Protein Retention Receptor 3 (KDELR3) is a 
seven transmembrane spanning receptor that is responsible for anterograde transport of 
soluble components (such as chaperones) between the ER and the Golgi apparatus26. X-
binding protein 1 (XBP1) has already been described in chapter 4 since its respective gene is 
one of the IBD-associated genes that was included in the analysis. In short, XBP1 mRNA is 
spliced by the ER stress sensor IRE1α (after BIP dissociation) to form spliced XBP1 (sXBP1) 
which is subsequently translated into a transcription factor for ER stress response genes in 
order to reduce ER stress27. Therefore, when confirming these microarray data with qRT-PCR, 
we should use primers that distinguish unspliced XBP1 mRNA from the spliced form as the 
ratio between both forms has already proven to be a good indicator of UPR activity28, 29. DnaJ 
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Heat Shock Protein Family (Hsp40) Member B9 & B11 (DNAJB9 & DNAJB11), Signal Sequence 
Receptor Subunit 1 (SSR1), Heat Shock Protein 90 Beta Family Member 1 (HSP90B1), Protein 
Disulfide Isomerase Family A Member 5 & 6 (PDIA5 & PDIA6), Hypoxia Up-Regulated 1 
(HYOU1), Heat Shock Protein Family A (Hsp70) Member 5/Glucose-Regulated Protein, 78kDa 
(HSPA5/BIP) and FK506 Binding Protein 14 (FKBP14) all have protein stabilizing and/or protein 
folding functions and their upregulation might therefore be a direct consequence of increased 
ER stress (signaling)30-35. Synoviolin 1 (SYVN1) and Homocysteine Inducible ER Protein With 
Ubiquitin Like Domain 1 (HERPUD1) play a role in ER-associated degradation (ERAD) for the 
degradation of misfolded ER-proteins which is also a direct consequence of elevated stress in 
the ER36-38. Sec61 Translocon Alpha 1 Subunit (SEC61A1) and SRP Receptor Alpha Subunit 
(SRPR) are involved in handling secretory and transmembrane proteins in the ER (and Ca2+-
homeostasis in the case of SEC61A1) 39, 40. Calreticulin (CALR) is u multifunctional protein as it 
is necessary for Ca2+-storage in the ER but also has chaperone-like functions41. Wolframin ER 
Transmembrane Glycoprotein (WFS1) also is a ER stress response gene that encodes for 
another multifunctional protein that is part of the ERAD system, regulates ER Ca2+-
homeostasis, and suppresses prolonged ATF6α activation42, 43. 
In general, we can conclude that the observed upregulation of ER stress machinery 
components and response genes in active IBD is in line with current literature. A latent 
elevation of KDELR3 and XBP1 in patients with inactive disease or after successful infliximab 
therapy might indicate slumbering ER stress in patients who show no clear signs of intestinal 
inflammation. Finally, the association between DNAJB9, XBP1, HSP90B1, FKBP14, SRPR, WFS1 
and HERPUD1 expression and non-response indicates that increased ER stress at baseline 
could signify a risk factor for unsuccessful treatment with anti-TNF agents. Our group already 
discovered such a predictive genome wide transcriptional signature in this cohort with strong 
selectivity and specificity. Since our results were derived from the same cohort, including 
these ER stress genes in the signature by Arijs et al. will therefore not increase its 
performance24, 25. However, we do believe that the expression levels of these genes could, on 
the other hand, support the use of ER stress-reducing agents such as TUDCA and 4-PBA as an 
add-on treatment in these patients14, 16-19, 44. 
Besides ER stress, we also investigated how autophagy genes were expressed in the same 
cohorts. The most profoundly upregulated gene in patients with active colonic disease was 
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Leucine Rich Repeat Kinase 2 (LRRK2). This partially confirms a previous study by Gardet et al. 
where the authors also found this association, however only in CD patients and not in the UC 
group45. LRRK2 is an IBD-associated gene and is therefore also included in the functional 
analysis described in chapter 4. It encodes for a multi-domain protein that acts as a positive 
regulator of autophagy through the AMP-activated protein kinase (AMPK) signaling pathway, 
which is a possible pathophysiologic mechanism in Parkinson’s disease. However, in the 
context of IBD it could also act independent from autophagy: LRRK2-deficiency leads to 
exacerbation of experimental murine colitis through loss of its inhibitory effect on Nuclear 
factor of activated T-cells (NFAT1) which is independent from LRRK2’s kinase activity 46-48. 
Regardless of the exact mechanism, this protein seems necessary for maintaining intestinal 
homeostasis during times of stress and our results indicate a strong activation of this anti-
inflammatory mechanism, which appears to be insufficient to prevent or reduce intestinal 
inflammation in IBD. 
In the same analysis we also found 7 significantly downregulated genes in patients with active 
IBD. Protein Kinase AMP-Activated Non-Catalytic Subunit Beta 2 (PRKAB2) is a positive 
regulator and a subunit of AMPK that can stimulate autophagy through the 
AMPK/mTOR/ULK1 pathway49. Autophagy Related 14 (ATG14/KIAA0831/BARKOR) is an 
essential autophagy-specific component and regulator of the phosphatidylinositol (PtdIns) 3-
kinase complex which targets the complex to the site of autophagosome formation but also is 
involved in autophagosome/endolysosome fusion and autophagy-dependent beclin-1 
phosphorylation50-56. Autophagy Related 4D Cysteine Peptidase (ATG4D) and other ATG4 
family members are essential for the (de)conjugation of GABA Type A Receptor Associated 
Protein Like 1 (GABARAPL1/ATG8) to phosphatidylethanolamine (PE) during autophagosome 
formation but is also shown to be incorporated into the mitochondrial matrix which can 
induce ROS-generation and cell death57, 58. Microtubule Associated Protein 1 Light Chain 3 
Alpha (MAP1LC3A/LC3) belongs to the ATG8-proteins and thus is essential for autophagosome 
maturation. After conjugation to PE, it is recruited to the autophagosome56. Myotubularin 
Related Protein 3 (MTMR3) is a phosphatase that can dephosphorylate PtdIns 3-phosphate 
(PtdIns3P) and this increased PtdIns3P can act as a negative regulator of autophagy, a process 
which has been shown to occur in response to PRR-mediated signals59, 60. This can eventually 
cause to a loss of dampening of NFκB and inflammasome signaling leading to inflammation. 
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Charged Multivesicular Body Protein 2A & 4B (CHMP4B & CHMP2A) are part of the Endosomal 
Sorting Complex Required for Transport (ESCRT) III complex that is involved in multivesicular 
body formation which is required for efficient autophagic degradation of protein aggregates61, 
62. In summary, all of these downregulated genes, except MTMR3, encode for proteins that 
will generally stimulate autophagy. Their downregulation is thus in line with current literature 
where it has been shown that reduced or defective autophagy can lead to intestinal 
inflammation and IBD. MTMR3 seems to be the odd man out but its downregulation during 
active disease could lead to an increased responsiveness to microbial patterns which fits the 
consensus that IBD is an exaggerated immune response towards intestinal microbes.  
The fact that MAP1LC3A and CHMP4B are still downregulated in patients with inactive IBD (eg. 
after successful IFX-treatment) indicates – similar to the findings observed in ER stress – that 
not all components of the autophagy machinery are restored to their normal levels. These 
could contribute to new flares, possibly via inflammasome- or ER stress- dependent 
mechanisms. Pharmacologic induction of autophagy might therefore be an interesting 
approach for maintaining an inactive disease state, especially in patients who have a 
transcriptional signature of reduced autophagy. 
Finally, we found that LRRK2 is significantly downregulated at baseline in patients that will not 
respond to IFX. Since LRRK2 is a positive regulator of autophagy and LRRK2 KO leads to 
increased colitis susceptibility in mice, its downregulation in this specific subgroup of patients 
indicates that reduced or defective autophagy in the intestinal mucosa might be a risk factor 
for unsuccessful anti-TNF therapy. Also here, these expression profiles could be used for 
therapeutic decision-making and autophagic-inducers such as sirolimus should be properly 
studied in IBD treatment10-13. 
It is important to mention that the current analysis remains explorative and confirmation with  
quantitative RT-PCR and preferably also at the protein level is necessary. For example, some 
upregulated genes, such as SEC61A1, encode for proteins that are part of multimeric 
complexes, therefore their upregulation doesn’t necessarily imply a functional effect. 
Furthermore, as some of these genes encode multifunctional proteins (eg. CALR and LRRK2) it 
remains unsure which function could be affected stressing the need for confirmation at a 
functional level. Second, in this type of studies the question remains whether the 
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up/downregultation of specific genes is a cause or rather a consequence of the disease. The 
answer probably goes both ways as some of these proteins are part of an inflammatory 
reaction but defects in these pathways have also been shown to cause (intestinal) 
inflammation itself. 
In conclusion, we could show that there is a link between the disease status in IBD and ER 
stress/autophagy. The microarray analysis of autophagy genes revealed one striking 
difference when compared to the ER stress related genes. Most autophagy genes were 
downregulated in patients with active disease whereas the ER stress genes were upregulated 
in this patient group, corresponding to current literature and insights into the mechanisms 
driving or triggering disease. Differences in ER stress and/or autophagy gene expression could 
help in understanding (lack of) response to anti-TNF agents and eventually be used for 
predicting the response to therapy and to select possible ER stress reducing or autophagy 
inducing (add-on) therapies. 
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5. Supplementary material 
5.1. Filtering of ER stress genes  
From the Reactome database we obtained a list of 94 ER stress genes of which 90 were 
represented on the Affymetrix GeneChip® Human Gene 1.0 ST array platform and 
corresponded to 95 probesets. On the Affymetrix Human Genome U133 Plus 2.0 array, 89 out 
of 94 ER stress genes were represented by 247 probesets. After selecting and retaining the 
strongest (top-10) upregulated and downregulated genes from every comparison, 43 genes 
(47 probesets) remained in cohort 1 and 45 genes (109 probesets) remained in cohort 2. The 
majority of these genes were shared between both analyses. For some genes, the results were 
inconsistent when comparing both cohorts and were therefore filtered out in order to retain 
genes that were disregulated in more than one cohort population. This led to a truncated list 
of 23 ER stress genes. 
5.2. Filtering of autophagy genes  
From the Reactome database we obtained a list of 69 autophagy genes which were all 
represented on the Affymetrix GeneChip® Human Gene 1.0 ST array platform and 
corresponded to 75 probesets. All 69 autophagy genes were also represented on the 
Affymetrix Human Genome U133 Plus 2.0 array and were represented by 161 probesets. After 
selecting and retaining the strongest (top-10) upregulated and downregulated genes from 
every comparison, 38 genes (42 probesets) remained in cohort 1 and 34 genes (97 probesets) 
remained in cohort 2. Again, after filtering out genes that were only present in a single cohort 
or showed inconsistent results between both cohorts, we obtained a truncated list of 14 
autophagy genes. 
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5.3. Supplementary tables 
Supplementary table 1: ER stress genes under investigation in this study. 
ACADVL CUL7 EIF2S1 FKBP14  KLHDC3 PLA2G4B SRPR YIF1A 
ADD1 CXXC1 ERN1 GFPT1 LMNA PPP2R5B SRPRB ZBTB17 
ARFGAP1 DCP2 EXOSC1 GOSR2 MBTPS1 PREB SSR1   
ASNA1 DCTN1 EXOSC2 GSK3A MBTPS2 SEC31A SULT1A3   
ASNS DDIT3 EXOSC3 HDGF MYDGF SEC61A1 SYVN1   
ATF3 DDX11 EXOSC4 HERPUD1 NFYA SEC61A2 TATDN2   
ATF4 DIS3 EXOSC5 HSP90B1 NFYB SEC61B TLN1   
ATF6 DNAJB11 EXOSC6 HSPA5 NFYC SEC61G TPP1   
ATF6B DNAJB9 EXOSC7 HYOU1 ORMDL3 SEC62 TSPYL2   
ATP6V0D1 DNAJC3 EXOSC8 IGFBP1 PARN SEC63 WFS1   
CALR EDEM1 EXOSC9 KDELR3 PDIA5 SERP1 WIPI1   
CTDSP2 EIF2AK3 EXTL3 KHSRP PDIA6 SHC1 XBP1   
Supplementary table 2: Autophagy genes under investigation in this study 
AMBRA1 CHMP4C PIK3R4 
ATG10 CHMP6 PRKAA1 
ATG12 CHMP7 PRKAA2 
ATG14 DYNLL1 PRKAB1 
ATG16L1 DYNLL2 PRKAB2 
ATG3 GABARAP PRKAG1 
ATG3 GABARAPL1 PRKAG2 
ATG4A GABARAPL2 PRKAG3 
ATG4B GABARAPL3 RB1CC1 
ATG4C LAMTOR1 RHEB 
ATG4D LAMTOR2 RPTOR 
ATG5 LAMTOR3 RRAGA 
ATG7 LAMTOR4 RRAGB 
ATG9A LAMTOR5 RRAGC 
ATG9B LRRK2 RRAGD 
BECN1 MAP1LC3A TSC1 
BRICD5 MAP1LC3B2 TSC2 
C12orf44 MAP1LC3C ULK1 
CHMP2A MLST8 UVRAG 
CHMP2B MTMR14 WDR45 
CHMP3 MTMR3 WDR45B 
CHMP4A MTOR WIPI1 
CHMP4B PIK3C3 WIPI2 
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CHAPTER 7: CONCLUDING DISCUSSION 
1. General discussion 
Despite great advances in the last decades, the treatment of IBD is still far from perfect as 
there is currently no cure yet. Furthermore, even with the treatments available, a large 
proportion of patients lose response over time or suffer from inacceptable or severe side 
effects. In order to help this group of patients, often requiring multiple surgical interventions, 
there is an unmet need to expand the existing therapeutic array. This is already happening as 
vedolizumab and, more recently, ustekinumab have been approved by the regulatory 
authorities and have been introduced in clinical practice. Tofacitinib is the first JAKINIB that 
has been filed for EMA approval for the treatment of ulcerative colitis and more compounds, 
such as filgotinib, are in late stage clinical development and will hopefully follow soon. By 
targeting different (more underlying) inflammatory pathways in therapy refractory patients, 
it is believed that the total number of patients in remission will increase.  However, an 
expanding number of therapies and therapeutic targets also implies that there is an urgent 
and increasing need for tools and algorithms that help in therapeutic decision making. 
In this PhD thesis the general aim was  to improve IBD treatment at two fronts by, first of all, 
contributing to the development and potential approval of a novel therapeutic compound 
(CHAPTER 3) and second, by exploring ways to discriminate patients based on the present 
underlying pathways such as ER stress, autophagy and inflammasome signaling (CHAPTER 4-
6). We developed a method to culture patient-derived IECs to characterize patient-specific 
defects in the epithelium at a functional level. We used this model to translate the genetic risk 
in ER stress and autophagy into functional ER stress readouts (CHAPTER 4). Furthermore, we 
investigated mucosal gene expression of inflammasome sensor genes (CHAPTER 5) and ER 
stress/autophagy genes (CHAPTER 6) in two well-characterized patient-control cohorts. 
The first aim of this project was to assess the efficacy of filgotinib or GLPG0634, an oral JAK-
1-specific small molecule inhibitor developed by Galapagos N.V. for the treatment of IBD and 
RA1, 2. This study was part of a, multi-center, scientific project. An extensive in vivo mouse 
study had already been performed at Galapagos where it was shown that filgotinib effectively 
reduced chronic DSS-induced murine colitis3. Nevertheless, the translational value of a single 
in vivo IBD model has always been a subject of discussion as none of the existing models 
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perfectly resembles human IBD. However, this issue can be overcome by using multiple 
different animal models4. The next step was therefore to confirm the findings from the chronic 
DSS model in an alternative murine IBD model with a different mode of action at a different 
research facility (CHAPTER 3). The (chronic) DSS model is characterized by an UC-like 
phenotype which is initiated by chemical destruction of the epithelial barrier followed by 
dissemination of luminal microbes and their antigens to the lamina propria. It is commonly 
used because it is a relatively cheap, easy to perform and a very reproducible experimental 
model5. Furthermore, it is characterized by a fast disease onset which limits working hours 
but, more importantly, it also limits the total time mice suffer from the consequences of 
intestinal inflammation. As an alternative, we chose the T cell transfer model to confirm the 
efficacy of filgotinib in IBD. In contrast to the DSS model, it is characterized by a more CD-like 
phenotype with transmural inflammation in both the small and large intestine. This model is 
established by injecting the CD4CD45RBhi T cells into the peritoneum of SCID mice. This 
specific T cell fraction does not contain regulatory T cells and this imbalance between 
regulatory and effector cells will lead to intestinal inflammation6. Despite a relatively good 
resemblance to human CD, it is a very challenging model characterized by variation in disease 
severity and time of disease onset. Other disadvantages in comparison to the DSS model are 
the long duration of the experiment, higher costs and the use of donor mice. Because of the 
well-known difficulties with this model, we first conducted a pilot experiment and optimized 
the experimental protocol at our lab. Indeed, we observed great variation in disease severity 
within a single experiment and differences in disease onset between experiments. In order to 
reduce the variable disease severity in the final experiment, we included an additional marker 
for T cell sorting (CD62L) which should lead to the isolation of gut-homing T cells. Furthermore, 
we increased the number of mice per group and started treating the mice at a time point 
where we did not observe signs of colitis in the previous experiments. In this final experiment 
we were able to show that filgotinib, at a daily dose of 30 mg/kg reduced colitis in CD4+CD25-
CD45RBhiCD62L+-reconstituted SCID mice when compared to their vehicle-treated littermates. 
There were significant differences in body weight, macroscopic and histological scores and 
(although non-significant) a trend for a lower DAI in the filgotinib treatment group. These data, 
together with the results obtained in the chronic DSS model3 and data from human intestinal 
biopsies, supported the use of filgotinib for the treatment of CD and UC. Filgotinib is currently 
in phase III for the treatment of both CD (DIVERSITY) and UC (SELECTION, phase IIb/III) and 
153 
 
these studies are supported by promising results obtained in the phase II FITZROY trial in 
patients with moderate-to-severe Crohn’s disease7. As presented at the latest European IBD 
conference (ECCO), it was shown that filgotinib demonstrated induction of clinical, histological 
and biological responses and that clinical remission is associated to reduced pSTAT3-levels7, 8. 
Besides DIVERSITY and SELECTION, two additional phase II trials were initiated in march 2017 
for the treatment of small bowel and fistulizing CD (NCT03046056 and NCT03077412, 
respectively). The most recent available clinical trial data and the fact that tofacitinib has been 
filed at the EMA, indicate that filgotinib has a good chance to become the second JAKINIB (and 
the first JAK-1 specific inhibitor) in the therapeutic armamentarium for IBD7-11. The class of 
small molecule compounds has two major benefits over all biologicals: first, its oral 
administration should be more comfortable thereby leading to better acceptance by patients. 
Secondly, antibody-based therapies are easily recognized by the patient’s immune system. 
Even fully humanized antibodies such as adalimumab, trigger various forms of hypersensitivity 
ranging from local injection site reactions to more generalized infusion reactions to even 
anaphylactic shock. These events are not expected to occur after administration of small 
molecule compounds such as filgotinib12. It is currently too early to say exactly how filgotinib 
and other JAKINIBs will fit in the classic treatment schedule. In RA, JAK inhibitors have been 
investigated as an add-on therapy in patients who do not respond to MTX2 and the FITZROY 
trial showed that the response rate in anti-TNF naïve patients was twice as high as compared 
to patients who had already received at least one anti-TNF agent7. The latter effect does not 
appear to be specific for JAKINIBs as this was also observed in some of the vedolizumab and 
ustekinumab trials11. However, filgotinib is not the only promising pharmaceutical compound 
in late stage clinical development and also alternative treatment strategies such as fecal 
microbiota transfer and dietary interventions are being investigated for their therapeutic 
potential in IBD. Hence, the number of available therapies and their modes of action will keep 
on increasing in the future eventually reaching sufficient diversity in therapeutic 
armamentarium to maximally treat the entire spectrum of IBD13, 14. An increased number of 
therapies will require tools that allow clinicians to make the best therapeutic choices with the 
highest clinical and economical benefit/risk-ratio for the patient and the healthcare system. A 
possible approach is to use a combination of genetic, tissue, fecal and serum biomarkers to 
assess which pathways are defective in a given patient and their contribution to disease. This 
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could lead towards better therapeutic guidance by targeting defective pathways rather than 
the inflammatory phenotype that in the end is the consequence of these defects14. 
Therefore, the second part of this PhD aimed at characterizing three IBD-associated pathways 
in IBD patients at a functional (protein) level and at transcriptional level. The second aim was 
to develop a novel ex vivo tool that allows the investigation of patient specific effects/defects 
at the site of the intestinal epithelium. Furthermore, using this model, we tried to translate 
the patient’s genetic risk in ER stress, autophagy and inflammasomes into quantifiable, 
functional readouts (CHAPTER 4). We have established a short-term patient biopsy-derived 
two-dimensional ex vivo intestinal epithelial cell culture system which was adapted from the 
three-dimensional intestinal organoid system by Sato et al.15, 16. We used a nearly identical 
crypt isolation protocol, but instead of growing the cells inside a matrigel environment, we 
seeded them on top of a collagen coated well surface. This adaptation allows formation and 
short-term expansion of cell patches that have a clear epithelial phenotype as indicated by 
high CK-18 and CK-20 mRNA expression over time and E-cadherin-positive immunostainings. 
Furthermore, a positive MUC2-signal in a subset of these cells and the presence of mucus on 
bright field microscopy point towards differentiation into functional, mucus-producing goblet 
cells. Finally, the distribution of ZO-1 at the side facing the medium showed that these cells 
had a normal apical-basolateral polarization. This novel cell culture system has several 
potential applications such as the investigation of epithelium specific defects in a wide variety 
of intestinal diseases, personalized drug toxicity screening and co-culturing on transwells with 
other patient-derived (immune) cell types such as macrophages or dendritic cells17. In this 
study we showed that an increased number of IBD-associated risk alleles in ER stress and 
autophagy is associated with a more pronounced Tg-induced ER stress response in the 
intestinal epithelium; a relationship which was the strongest when the genetic risk in both 
pathways was combined18. Of note, we believe that the observed variation in the response to 
Tg-stimulation is not due to imprinting from the inflammatory environment since all included 
biopsies were taken from (macroscopically) non-inflamed areas of the colon. Furthermore, 
our group recently showed that the inflammatory phenotype of colonic organoids is lost when 
these cells are taken out of their natural environment, even when this was an inflamed 
region19. On the other hand, Hibiya et al. demonstrated that a 60 week long exposure of 
colonic murine organoids to an inflammatory environment in vitro led to long-lasting (11 
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weeks) alterations in NfκB signaling20. Therefore, it cannot be entirely excluded that such 
imprinting was also present in some of the included biopsy specimens in our study (eg. when 
these were obtained from healed unaffected areas that have been inflamed in the past) and 
that this has an influence on the observed BiP-induction levels. Nevertheless, we feel that such 
epigenetic changes should be taken into account when determining the functionality of a 
(disease-associated) pathway in a given patient, which is exactly what these functional assays 
do. In other words, one of the strengths of functional assays is that the generated readouts 
are more downstream than (epi)genetic or transcriptomic readouts.  
Our results indicate that the genomic risk burden results in altered functionality of the UPR. 
Nevertheless, we believe that such functional patient-specific readouts by themselves could 
become an essential part of the novel treatment paradigm which will be discussed below. 
Quantitative ER stress readouts could become of interest when ER stress reducing compounds 
become available for the treatment of IBD21-23. Furthermore, ER stress appears to be involved 
in fibrosis as Heindryckx et al. showed that IRE1α inhibition leads to reduced fibrosis in animal 
models but also reverses the fibrotic phenotype of patient derived myofibroblasts24. 
Therefore, it would be interesting to investigate whether there is a link between ER stress 
defects and a fibrotic disease course in IBD. Although there are no pharmacological therapies 
to treat intestinal fibrosis, some are under investigation such as the locally acting ROCK-
inhibitor AMA0825 which prevented and reverted intestinal fibrosis in two mouse models and 
an ex vivo explant model25. Before implementing such epithelial assays as a tool for 
therapeutic decision making into clinical practice, these findings have to be validated in an 
independent cohort. This confirmatory study should be performed in a prospective manner 
where the epithelial ER stress response has to be determined before deciding to apply an 
additional ER stress reducing therapy. We do realize that this approach has several pitfalls. For 
example, IBD patients do not always undergo an endoscopy when they visit the hospital and 
planning an endoscopic investigation for merely therapeutic decision making will probably be 
considered as being too invasive. Therefore, it will be interesting to investigate whether the 
readouts obtained in IECs can also be obtained in more accessible patient samples such as 
blood, feces or even saliva. Moreover, it takes one week before the epithelial ER stress status 
of a patient is known implying that patients will have to make an additional consultation to 
have their therapy adjusted. Finally, it must be mentioned that we only succeeded to 
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efficiently grow IEC cultures from non-inflamed areas in the colon and therefore patients with 
pancolitis will not be suited for this approach. Nevertheless, we believe that applying this 
technique around the time of diagnosis will provide a more extensive mechanistic and 
molecular signature of the patient. Furthermore, it also takes a week or more to have the 
results from other markers such as thiopurine methyltransferase (TPMT) and vaccination 
status in the blood, which need to be performed anyway. If around this time the biopsies could 
be tested for main underlying pathways, then this could help in deciding which drug(s) to give. 
Most likely, combining therapies targeting different (deficient) pathways may result in higher 
and better outcomes than what is observed currently with biologicals (30-40% remission with 
mucosal healing at most). 
Besides the ER stress readouts that were described in CHAPTER 4, we also obtained functional 
readouts for the quantification of the autophagic flux by measuring the accumulation of the 
autophagic cargo marker P62 after chloroquine treatment. In contrast to the functional ER 
stress readouts, we did not observe any significant difference in P62 accumulation when 
comparing genetically distinct patients. A possible explanation could be that the investigated 
risk alleles do not functionally affect autophagy in a profound manner. However, this would 
be contradictory to the many functional studies investigating the ATG16L1T300A variant26-29. 
Other possible explanations could be that this genetic effect is simply not present in the 
colonic epithelial compartment or that P62 is not the best marker to investigate the effect of 
genetic risk variants on autophagy in this setting. Finally, we also aimed to investigate the 
effect of the genetic risk on inflammasome activation by measuring the amount of secreted 
IL-18 in the cell culture supernatant. Unfortunately, read-outs were often below the detection 
limit which led to inadequate power to detect significant differences. Additionally, we set out 
to evaluate these pathways at a transcriptional level in the intestinal mucosa of IBD patients 
and controls.   
Although being as invasive as the IEC cultures described in CHAPTER 4, transcriptomic data 
from endoscopic-derived mucosal biopsies can be obtained much faster than functional 
readouts in IECs as there is no need for epithelial isolation or cell culture. Furthermore, instead 
of focusing on one or a few markers in a certain pathway, these techniques allow simultaneous 
analysis of the expression of all involved genes. Our third and final aim was therefore to 
investigate the expression of inflammasome, ER stress and autophagy genes in two whole-
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genome gene expression microarray cohorts that had already been well characterized in 
multiple studies by our group30-33. In the first cohort, we compared the colonic mucosal gene 
expression in patients (CD, UC and grouped together under IBD) with active disease, patients 
with inactive disease and healthy controls. The second cohort focused on the response to IFX 
treatment in IBD patients and also allowed comparison to healthy control subjects. In 
CHAPTER 5 we used the data from these cohorts to analyze the expression of inflammasome 
sensor genes that were described in a recent review by Aguilera et al.34. We found a 
pronounced increase (>2-fold) in the mRNA expression levels of the DNA-sensing 
inflammasome sensors AIM2 and IFI16 in the inflamed colon of active IBD patients when 
compared to non-inflamed colon of controls and patients with inactive disease. Furthermore, 
IFI16 colonic gene expression was, although to a lesser extent, also increased in inactive IBD 
patients versus control colons. These findings were confirmed in cohort 2 where a significant 
increase (>5-fold) in expression levels of AIM2 and IFI16 in inflamed IBD colon vs. control colon 
was observed. In this cohort we could also show that successful anti-inflammatory treatment 
with infliximab caused a significant decrease in of AIM2 and IFI16 expression when compared 
to their baseline samples. Although IFI16 expression decreased after infliximab therapy in IBD 
responders versus baseline samples, it remained significantly higher after infliximab therapy 
in IBD responders versus control colons. In contrast with IBD responders, the colonic 
expression of AIM2 and IFI16 remained significantly increased when IFX therapy did not induce 
remission (non-responders). These data were validated by qRT-PCR, WB and IHC.  
It was already known from genetic association and knockout studies that NLRP3 
inflammasomes are involved in IBD. In general, this is by far the best studied inflammasome-
forming sensor protein. Our data, however, show that the dsDNA-responsive inflammasome 
sensors AIM2 and IFI16 might also play an important role. Around the same time as our study, 
another group confirmed, in a much smaller cohort, that IFI16 is indeed upregulated in 
inflamed colonic mucosal biopsies from IBD patients in comparison to healthy controls. This 
upregulation was, at least in part, located in the epithelial cells as shown by 
immunohistochemistry, confirming our results35. More recently, this group has shifted their 
focus from the actual IFI16 protein to anti-IFI16 antibodies in serum of patients and their value 
as a biomarker for response to infliximab therapy36. Also, AIM2 recently gained more attention 
and seems to have multiple inflammasome dependent and independent functions that, in the 
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intestine, converge to intestinal inflammation and cancer. It exerts these effects by influencing 
antimicrobial peptide production, IEC proliferation, tight junction expression, cell death, 
barrier function and microbiota composition37-43. Both AIM2 and IFI16 or their downstream 
mediators might thus have some therapeutic potential besides the compounds that target the 
NLRP3 inflammasome that are currently under investigation44-47. Nevertheless, AIM2- and 
IFI16-selective compounds are not being considered as therapeutic targets since their 
complex role in IBD needs to be clarified.  
Finally, in CHAPTER 6 we analyzed the expression of ER stress and autophagy genes in the 
same two cohorts. We used the curated Reactome database to obtain a list of genes that have 
been involved in one of these two pathways.  After applying several filtering steps (FDR < 0.05; 
top-10 up/downregulated; consistency between cohort 1 and 2), 23 ER stress genes and 14 
autophagy genes remained that showed a significant and consistent dysregulation that was 
associated to disease state. Fifteen ER stress genes were upregulated in the inflamed mucosa 
of IBD patients when compared to non-inflamed areas and healthy controls, with KDELR3, 
XBP1 DNAJB9, HSP90B1 and CALR being the strongest upregulated genes. Furthermore, 
KDELR3 and XBP1 were still increased in patients with inactive disease (eg. after successful IFX 
therapy). LRRK2 was the only upregulated autophagy gene in patients with active disease 
together with seven other downregulated genes of which MAP1LC3A and CHMP4B didn’t 
normalize when disease was under control. The fact that some genes in both pathways 
remained dysregulated during remission suggests potential underlying mechanisms that can 
lead to disease relapse. It is possible that (pharmacological) restoration of these pathways 
could prevent relapse in patients who show such dysregulated gene expression patterns. 
Finally, we found ER stress and autophagy-specific baseline gene expression signatures in 
patients who will not respond to IFX therapy. Such predictive transcriptomic signatures have 
already been discovered in this cohort by our group but their use has so far not made it into 
clinical practice which might be due to the invasive nature of such biomarkers when compared 
to serum (CRP) or fecal (calprotectin) biomarkers32, 33. Furthermore, we do not believe that 
including the baseline-dysregulated ER stress and/or autophagy genes in the predictive 
signature by Arijs et al. will increase its performance as we used the same cohort to obtain our 
results32, 33. Despite being invasive, we do feel that until there are no alternative methods to 
detect mucosal defects in specific pathways, the mucosal expression levels of genes in the ER 
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stress or autophagy pathways could support the use of (add-on) therapies such as TUDCA or 
sirolimus.  
We believe that the best predictive models will arise from multi-omics approaches that 
combine genomic, transcriptomic and/or proteomic information in order to give a clear 
indication whether a certain pathway (eg. autophagy) is perturbed in a given patient. There is 
already some evidence that a functional autophagy pathway is needed for an adequate 
response to anti-TNF as autophagy is upregulated in anti-TNF induced immunosuppressive 
macrophages and that functional autophagy is necessary for this specific conversion48, 49. 
General conclusion 
This PhD thesis added potential improvements to IBD therapy by providing additional 
evidence for the acceptance of filgotinib for the treatment of IBD by the authorities and by 
exploring ways to identify and characterize underlying disease-associated pathways in the 
intestinal mucosa. This pathways-based approach could guide clinicians in deciding when to 
give a certain therapy. 
2. Future perspectives 
I would like to propose some additional experiments that could and should be performed in 
the future. Since most of the IBD-associated genetic variants that were investigated in 
CHAPTER 4 are located outside of exons, one possible functional effect might therefore be 
altered transcriptional regulation. Therefore, it would be very interesting to perform eQTL 
analysis with these SNPs in mucosal biopsies, but even more so in sorted cells of the same 
type (eg. separated IECs, T cells, macrophages). Also, the statements made in CHAPTER 6 are 
largely based on microarray data and will need to be confirmed by other techniques and 
preferably also by WB and IHC to determine the (sub)cellular location of interesting proteins 
such as XBP1, KDELR3, and LRRK2. We are also convinced that the epithelial cell culture system 
that was developed and described in CHAPTER 4 has a lot of potential applications. Given the 
clear involvement of the intestinal microbiota in IBD, a possible future approach might be to 
co-culture biopsy-derived epithelial cells with specific bacterial strains to study patient-
specific microbe-host interactions. 
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Finally, it is important to reflect how this thesis focuses on the evolving landscape of IBD 
management: filgotinib and other JAKINIBs may become important compounds for treating 
IBD but also other inflammatory disorders such as RA. An increasing number of therapies and 
therapeutic targets for the treatment of complex, multifactorial diseases demands a radical 
change of the current treatment paradigm. Our group has the ambition to play a leading role 
in this effort as illustrated by the second part of this thesis manuscript which fits into a larger 
ERC-granted project where IBD UZLeuven wants to develop and validate the Crohn’s and 
Ulcerative Colitis Characterization and Intervention (CrUCCial) index. In the CrUCCial project 
we aim to quantify different potential pathophysiologic players such as ER stress, autophagy, 
barrier dysfunction and dysbiosis in a personalized manner. These readouts will be generated 
from extensive and diverse sampling starting at the time of diagnosis. Thanks to this 
integrative multi-omics approach, we will be able to identify the proportional contribution of 
the different mechanisms in a given patient. Therefore, in this PhD thesis, we developed a 
method to quantify patient specific epithelial defects in pathophysiologic pathways and have 
initially validated this concept by demonstrating a link between genetic mutations and 
functional defects in ER stress. This is a possible readout that can now be generated from 
patient biopsies and that will be implemented in the CrUCCial index.  
We believe that also transcriptomics could be a valuable tool in this light as they form the 
basis for downstream functional effects. In this PhD I chose to work with the existing 
microarray cohorts because I felt that there was still some unexplored areas in these datasets. 
However, we are aware that more sensitive techniques, such as RNA sequencing, are 
available. This is part of new ongoing projects in our lab. Nevertheless, our microarray findings 
still indicate on the functionality and activation of a certain pathway and which genes to look 
for when assessing the relative contribution of inflammasomes, ER stress and autophagy to 
IBD. 
The CrUCCial index will statistically combine a variety of different readouts in a semi-
quantitative way into a multi-component index that will be used to tailor therapies to the 
specific needs of the patient. This index will be tested for its ability to predict clinical outcomes 
such as time to first surgery, stricturing disease behaviour, penetrating disease course, etc. 
The obtained findings from these discovery cohorts and the use of the CrUCCial index to guide 
therapeutic decision making in the clinic will eventually be evaluated in prospective cohorts. 
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Our integrative multi-omics and multi-pathway approach should lead to profound alterations 
in the future treatment paradigm of IBD and other complex, multifactorial conditions by 
treating specific defective pathways rather than a general disease phenotype. 
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SUMMARIES 
1. English summary 
Inflammatory bowel diseases (IBD), with Crohn’s disease (CD) and ulcerative colitis (UC) as the 
two most prevalent phenotypes, span a disease spectrum of lifelong, idiopathic conditions 
characterized by chronic inflammation of the gut with diarrhea and abdominal pain. Although 
its exact pathophysiology remains elusive, IBD is believed to be caused by an aberrant mucosal 
immune responses towards intestinal microorganisms in genetically predisposed individuals. 
During the last years, new pathophysiologic pathways have been uncovered and since there 
still is an unmet therapeutic need in IBD, this knowledge is currently being applied by 
pharmaceutical companies to develop compounds that target these pathways. Therefore, in 
the first part of this project we aimed to contribute to the therapeutic development for IBD 
patients by performing a preclinical efficacy experiment in mice for a new experimental JAK1-
specific inhibitor (GLPG0634/filgotinib) that has been developed by Galapagos NV (CHAPTER 
3). Since the efficacy of filgotinib was already shown in a chemically induced murine colitis 
model (DSS), we performed these experiments in the T cell transfer model of colitis which is 
an adaptive/T cell-driven model. Daily oral administration of filgotinib resulted in a significant 
reduction in body weight loss and histological inflammation scores. Our data, together with 
the data obtained from the chronic DSS model, provide convincing preclinical evidence for the 
application of filgotinib in IBD and meanwhile a large phase 3 program is ongoing. 
Other new therapeutic strategies, are in the research pipeline or reaching registration. This 
means that, in the future, the range of therapies will drastically expand. Furthermore, a well-
known characteristic of IBD is the large inter-patient variability in disease course and severity, 
which has consequences for the type, the dose and frequency of treatment. We believe that 
the IBD treatment paradigm should change towards a more personalized approach that is 
based on targeting the underlying pathophysiologic pathways that drive the disease in a given 
patient. The second part of this PhD project investigated the contribution of three IBD-
associated pathways (ER stress, autophagy and inflammasomes) in specific patient-subgroups 
at different levels. First of all, we developed a novel cell culture system that allows short term 
expansion of patient/biopsy-derived intestinal epithelial monolayers (CHAPTER 4). We 
confirmed that these monolayers had an epithelial character and a normal apical-basolateral 
polarization. In this model we showed that the number of risk alleles in ER stress and/or 
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autophagy leads to an increased BIP induction after thapsigargin treatment indicating 
functional alterations in the epithelial ER stress response. These readouts might in the future 
be used as an indication for ER stress reducing therapies such as TUDCA. Furthermore, we 
believe that this patient-derived intestinal epithelial cell culture approach has more potential 
applications such as co-culturing with other cell types and/or investigating patient-specific 
responses to pharmaceuticals or even microbes. 
Finally, we investigated the inflammasome, ER stress and autophagy at a transcriptional level 
in the mucosa of patients and healthy controls who were included in two well-characterized 
whole genome gene expression microarray cohorts. We found a strong upregulation of two 
dsDNA-responsive inflammasome sensors AIM2 and IFI16 in patients with active disease when 
compared to patients with inactive disease or healthy controls (CHAPTER 5). We are one of 
the first groups to identify the potential involvement of both inflammasome sensors which 
are now subject of investigation as a disease activity marker (IFI16) and a key player in 
intestinal homeostasis (AIM2). We also found a strong upregulation of several ER stress genes 
and a downregulation of autophagy genes that was associated with increased disease activity 
(CHAPTER 6). When disease was controlled normalization was observed for most of these 
genes, yet some (KDELR3, XBP1, MAP1LC3A and CHMP4B) remained dysregulated, indicating 
that these pathways are not entirely restored to their normal levels upon remission. Finally, 
we found a gene expression signature in these pathways that could aid in predicting the 
response to anti-TNF treatment caused by an altered ER stress or autophagy status. Although 
preliminary, these data hint towards the application of ER stress reducing or autophagy 
stimulating therapy in patients who show, already at baseline, dysregulated gene expression 
patterns. 
In conclusion, the promising filgotinib data demonstrate that we live in a time of increasing 
therapeutic diversity for IBD. In this PhD thesis we furthermore set the first steps towards a 
personalized pathway-based approach for treating this multifactorial disease spectrum.  
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2. Nederlandstalige samenvatting 
Inflammatoire darmziekten (IBD), met de ziekte van Crohn en colitis ulcerosa als de twee 
meest voorkomende fenotypes, zijn levenslange, idiopathische aandoeningen die worden 
gekenmerkt door chronische ontsteking van de darm met diarree en buikpijn. Hoewel de 
exacte pathofysiologie onduidelijk blijft, vermoedt men dat IBD wordt veroorzaakt door een 
overdreven immuunrespons tegen de intestinale microbiota in genetisch voorbestemde 
individuen. Tijdens de laatste jaren zijn nieuwe pathofysiologische mechanismen ontdekt die 
een rol spelen in IBD. Deze kennis wordt ook gebruikt om nieuwe geneesmiddelen te 
ontwikkelen die ingrijpen op deze nieuwe pathofysiologische mechanismen. In het eerste deel 
van dit doctoraatsproject hebben we daarom getracht een bijdrage te leveren aan deze 
therapeutische ontwikkelingen door de werkzaamheid van een JAK1-specifieke inhibitor 
(GLPG0634/filgotinib) na te gaan in een colitis muismodel (HOOFDSTUK 3). Dit molecule werd 
ontwikkeld door Galapagos NV en de werkzaamheid werd eerder aangetoond in een chronisch 
DSS muismodel. Bevestiging in een tweede model was echter noodzakelijk. Wij hebben 
hiervoor gebruik gemaakt van het T cel transfer muismodel en konden aantonen dat dagelijkse 
orale toediening van filgotinib leidde tot een significante reductie van het verlies aan 
lichaamsgewicht en histologische ontstekingsscores. Onze data leveren, samen met de 
gegevens verkregen uit het chronische DSS-model, kwalitatief preklinisch bewijs voor het 
gebruik van filgotinib in IBD. Een groot klinisch fase 3 programma in IBD patiënten is 
momenteel aan de gang.  
Er zijn nog andere nieuwe therapieën die zich in vergevorderde onderzoeksfasen bevinden. 
Dit betekent dat het aantal mogelijke therapieën voor IBD verwacht wordt verder toe te 
nemen in de toekomst. Bovendien is het een welgekend fenomeen dat IBD patiënten een 
grote diversiteit vertonen in het ziekteverloop en de ernst van de ziekte en dit heeft gevolgen 
voor het type, de dosis en de frequentie van de behandeling. Wij geloven dat het IBD-
behandelingsparadigma moet evolueren naar een meer gepersonaliseerde aanpak die 
gebaseerd is op het identificeren en behandelen van de onderliggende pathofysiologische 
mechanismen die de ziekte veroorzaken. In het tweede deel van dit doctoraatsproject hebben 
we daarom de bijdrage van drie IBD-geassocieerde mechanismen (ER stress, autofagie en het 
inflammasoom) onderzocht in specifieke patiënt-subgroepen en op verschillende niveaus. 
Allereerst hebben we een nieuw celcultuur systeem ontwikkeld dat ons toeliet om 
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darmepitheelcellen in kweek te brengen die werden geïsoleerd uit endoscopische 
darmmucosa biopten (HOOFDSTUK 4). We konden aantonen dat deze cellen een epitheliaal 
fenotype hadden met een normale polarisatie. Vervolgens hebben we dit model gebruikt om 
aan te tonen dat het aantal risico-allelen in ER stress en/of autofagie leidt tot een verhoogde 
BIP inductie na de behandeling met thapsigargine. Een verhoogd genetisch risico leidt dus tot 
wijzigingen in de epitheliale ER stress respons en deze aanpak zou in de toekomst gebruikt 
kunnen worden als indicatie voor het opstarten van ER stress-reducerende therapieën zoals 
TUDCA. Bovendien kunnen deze patiënt-afgeleide epitheliale culturen andere potentiële 
toepassingen hebben, zoals co-culturen met andere celtypes en/of het onderzoeken van 
patiënt-specifieke reacties op farmaceutische verbindingen of zelfs bacteriën. 
Tenslotte hebben we het inflammasoom, ER stress en autofagie op transcriptieniveau 
onderzocht in de colonmucosa van patiënten en gezonde controles in twee grondig 
gekarakteriseerde genexpressie microarray cohorten. We vonden een sterke toename van 
twee dsDNA-responsieve inflammasoomsensoren AIM2 en IFI16 bij patiënten met actieve 
ziekte in vergelijking met patiënten met inactieve ziekte of gezonde controles (HOOFDSTUK 
5). Hierdoor zijn we één van de eerste groepen die AIM2 en IFI16 naar voren schuiven als 
potentiële actoren in IBD. AIM2 wordt nu bestudeerd omwille van zijn veelzijdige rol in 
darmhomeostase terwijl IFI16 onderzocht wordt als een mogelijke ziektemerker in IBD. In 
dezelfde cohorten konden we tevens een sterke toename van meerdere ER stress genen en 
een afname van autofagie genen waarnemen in patiënten met actieve ziekte (HOOFDSTUK 
6). De meeste van deze genen normaliseerden weer wanneer de ziekte onder controle was 
met uitzondering van KDELR3, XBP1, MAP1LC3A en CHMP4B, wat aangeeft dat beide 
mechanismen, ondanks een normaal endoscopisch beeld, niet volledig herstellen. Tot slot 
vonden we een afwijkend genexpressiepatroon in enkele genen die mogelijks kunnen 
bijdragen aan het voorspellen van de respons op anti-TNF-behandeling. Hoewel deze data 
preliminair zijn, geven ze toch een indicatie voor het gebruik van ER stress vermindering of 
autofagie stimulatie therapieën bij patiënten met een afwijkend genexpressiepatroon.   
Samenvattend denken we dat we in deze doctoraatsthesis de eerste stappen hebben gezet in 
het sturen van een gepersonaliseerde behandeling van dit multifactoriële ziektespectrum.  
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3. Popular summary 
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC) 
are lifelong diseases of unknown cause characterized by inflammation of the intestine with 
diarrhea and belly pain. Although it remains unknown how these diseases arise, IBD are 
believed to be caused by an exaggerated immune responses towards intestinal microbes in 
people who have a genetic predisposition. During the last years, new disease mechanisms 
have been discovered while there is still a large proportion of patients that cannot be helped 
with the current therapies. Pharmaceutical companies are therefore developing drugs that act 
on these newly discovered disease mechanisms. In the first part of this PhD project we aimed 
to contribute to the therapeutic development for IBD patients by testing the efficacy of 
GLPG0634/filgotinib, which specifically blocks the inflammatory signaling molecule JAK1, in a 
mouse model of colitis (CHAPTER 3). In this model we showed that daily oral administration 
of filgotinib reduced intestinal inflammation as indicated by a strong reduction in body weight 
loss and this anti-inflammatory effect was also seen at a microscopic level. Our data, provide 
convincing evidence for the therapeutic application of filgotinib in IBD, meanwhile a large trial 
in IBD patients is ongoing. 
Other new drugs are under investigation and are close to becoming available for IBD patients. 
This means that, in the future, the number of therapies will further increase. Furthermore, a 
well-known characteristic of IBD is the large diversity between patients in disease course and 
severity, which has consequences for the type, the dose and frequency of treatment. We 
believe that the current way of IBD treatment should change towards a more personalized 
approach that is based on targeting the underlying disease mechanisms that cause the disease 
in a given patient. The second part of this PhD project investigated the contribution of three 
such disease mechanisms that play a role in IBD, namely “ER stress”, “autophagy” and 
“inflammasomes”. First, we developed a method to grow gut cells (in the lab) that were taken 
from patients during endoscopy (CHAPTER 4). We confirmed that these so called cell cultures 
were indeed epithelial cells and that these cells had the same orientation as they have when 
they are still in the gut. With this method, we showed that patients who have an increased 
amount of ER stress- and/or autophagy-related genetic risk factors show problems in the ER 
stress mechanism. This approach can thus be used to identify patients that would benefit from 
therapies that reduce ER stress such as TUDCA. Furthermore, we believe that this patient-
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derived gut epithelial cell culture method has more potential applications such as growing 
them together with other cell types and/or investigating the interaction between these cells 
and drugs or even microbes. 
Finally, we investigated the inflammasome, ER stress and autophagy mechanisms at the level 
of gene expression in the intestine of patients and healthy controls. We found a strong 
increase of the inflammasome genes AIM2 and IFI16 in patients with active disease when 
compared to patients with inactive disease or healthy controls (CHAPTER 5). We also found a 
strong increase of several ER stress genes and a decrease of autophagy genes in patients with 
active disease (CHAPTER 6). Most of these genes returned to their normal levels in patients 
with inactive disease, yet some (KDELR3, XBP1, MAP1LC3A and CHMP4B) remained 
dysregulated even when disease was controlled indicating that both pathways are not entirely 
restored.  
In conclusion, the promising filgotinib data are a clear example of an increasing number of 
therapies for IBD in the future. In this PhD thesis we furthermore set the first steps towards a 
personalized treatment based on the underlying disease mechanisms.  
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4. Popular summary (Dutch) 
Inflammatoire darmziekten (IBD), waaronder de ziekte van Crohn en colitis ulcerosa zijn 
levenslange aandoeningen van ongekende oorzaak die worden gekenmerkt door chronische 
ontsteking van de darm met diarree en buikpijn. Hoewel het exacte ontstaansmechanisme 
van deze ziekten onduidelijk blijft, vermoedt men dat IBD wordt veroorzaakt door een 
overdreven immuunrespons tegenover de normale darmbacteriën in personen met een 
genetische aanleg. Tijdens de laatste jaren heeft men nieuwe ziektemechanismen ontdekt die 
een rol spelen in IBD. Aangezien niet alle patiënten kunnen geholpen worden met de huidige 
therapieën, wordt deze kennis gebruikt door farmaceutische bedrijven om nieuwe 
geneesmiddelen te ontwikkelen die gericht zijn tegen deze recent ontdekte 
ziektemechanismen. In het eerste deel van dit doctoraatsproject hebben we daarom getracht 
een bijdrage te leveren aan de ontwikkeling van een nieuw medicijn voor IBD, filgotinib 
(HOOFDSTUK 3). We hebben de werkzaamheid van dit molecule nagegaan in een muismodel 
dat bepaalde eigenschappen van IBD nabootst en konden hierin aantonen dat de dagelijkse 
toediening van filgotinib leidde tot een verminderd gewichtsverlies en lagere microscopische 
ontstekingsscores. Onze data leveren bewijs voor het gebruik van filgotinib in IBD. Een grote 
klinische studie in IBD patiënten is momenteel aan de gang.  
Er zijn nog andere nieuwe therapieën die zich in de laatste onderzoeksfasen bevinden. Dit 
betekent dat het aantal mogelijke therapieën voor IBD verder zal toenemen in de toekomst. 
Bovendien is het een welgekend fenomeen dat IBD patiënten een grote diversiteit vertonen 
in het ziekteverloop en de ernst van de ziekte en dit heeft gevolgen voor het type, de dosis en 
de frequentie van de behandeling. Wij geloven dat de manier waarop we IBD behandelen 
moet evolueren naar een meer gepersonaliseerde aanpak die gebaseerd is op het 
identificeren en behandelen van de onderliggende ziektemechanismen die de ziekte 
veroorzaken. In het tweede deel van dit doctoraatsproject hebben we daarom de bijdrage van 
drie zulke ziektemechanismen (ER stress, autofagie en het inflammasoom) onderzocht in 
specifieke patiënt-subgroepen. Allereerst hebben we een nieuw celcultuur systeem 
ontwikkeld dat ons toeliet om darmepitheelcellen in kweek te brengen die werden geïsoleerd 
uit darmbiopten (HOOFDSTUK 4). We konden aantonen dat deze cellen inderdaad behoorden 
tot het juiste (epitheliale) celtype en dat ze normaal georiënteerd waren. Vervolgens hebben 
we deze zogeheten celculturen gebruikt om aan te tonen dat een toegenomen aantal 
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genetische risicofactoren in ER stress en/of autofagie leiden tot een gewijzigde ER stress 
respons in deze cellen.  Deze aanpak zou in de toekomst gebruikt kunnen worden als leiddraad 
voor ER stress-reducerende medicatie zoals TUDCA. Bovendien kunnen deze patiënt-afgeleide 
celculturen andere potentiële toepassingen hebben, zoals het opkweken samen met andere 
celtypes en/of het onderzoeken van patiënt-specifieke reacties op medicatie of zelfs 
bacteriën. 
Tenslotte hebben we de activiteit van inflammasoom, ER stress en autofagie genen 
onderzocht in het darmweefsel van patiënten en gezonde controles. We vonden een sterke 
toename van de inflammasoom genen AIM2 en IFI16 bij patiënten met actieve ziekte in 
vergelijking met patiënten met inactieve ziekte of gezonde controles (HOOFDSTUK 5). Verder 
konden we tevens een sterke toename van meerdere ER stress genen en een afname van 
autofagie genen waarnemen in patiënten met actieve ziekte (HOOFDSTUK 6). De meeste van 
deze genen keerden terug naar hun normale niveau wanneer de ziekte weer onder controle 
was met uitzondering van KDELR3, XBP1, MAP1LC3A en CHMP4B. Dit geeft aan dat beide 
mechanismen, ondanks een normaal endoscopisch beeld, niet volledig herstellen. 
Onze veelbelovende data met filgotinib in een colitismodel tonen reeds aan dat we leven in 
een tijd waarin het aantal therapieën voor IBD nog steeds toeneemt. Verder zetten we in deze 
doctoraatsthesis de eerste stappen in de richting van een gepersonaliseerde behandeling van 
dit multifactoriële ziektespectrum.
175 
 
SCIENTIFIC ACKNOWLEDGEMENTS 
CHAPTER 3: I would like to thank Jonathan Cremer and Willem-Jan Wollants for their help 
during the course of the in vivo experiment and at the time of sacrifice. Also many thanks to 
the people from Galapagos NV and Ghent University for allowing me to be a part of this project 
and for co-writing the preclinical filgotinib manuscript which was adapted to create this 
chapter. 
CHAPTER 4: First of all, many thanks to Sebastiaan De Schepper for his contribution to the 
development of the IEC culture system during his master thesis. I would also like thank Valérie 
Van Steenbergen, Michael Moons and An-sofie Desmet from the Lab of Enteric NeuroScience 
(LENS) of Prof. Pieter Vanden Berghe and Hanne Vanheel from the Gastrointestinal Motility 
and Sensitivity Research Group of Prof. Ricard Farré for their help with the immunostainings 
and microscopy. 
CHAPTER 5-6: Many thanks to Leentje Van Lommel from the gene expression unit of Prof. 
Frans Schuit for performing the RNA extractions and running the microarrays. Also a word of 
gratitude to Ingrid Arijs for performing the first rough analysis of the microarray data.  
General: I would like to thank Kris Nys, Ingris Arijs, Isabelle Cleynen, Magali de Bruyn and 
Severine Vermeire for critically reviewing all my manuscripts and conference abstracts.  
176 
 
PERSONAL CONTRIBUTION 
CHAPTER 1-2: All 
CHAPTER 3: Experimental design, disease monitoring, sacrifice, scoring, data analysis, 
manuscript revision 
CHAPTER 4: All 
CHAPTER 5: Confirmation of microarray data with PCR, WB an IHC, manuscript writing, figure 
creation  
CHAPTER 6-7: All 
 
  
177 
 
CONFLICTS OF INTEREST STATEMENT 
Wiebe Vanhove has no conflicts of interest 
Kris Nys is a MSL for Shire since 2016 
Ingrid Arijs is a project manager at the University of Hasselt since 2016 
Severine Vermeire reports following conflicts of interest: grant support from Abbvie, MSD and 
Takeda; lecture and consulting fees from Centocor, MSD, Abbvie, Pfizer, Takeda, 
Genentech/Roche, Janssen, Mundipharma, Hospira, Celgene and Second Genome. She is a 
senior clinical investigator for the FWO. 
Marc Ferrante reports following conflicts of interest: Grant support from Takeda; lecture and 
consulting fees from Abbvie, MSD, Takeda, Janssen, Boehringer-Ingelheim, Chiesi, Dr Falk 
Pharma, Ferring, Mitsubishi Tanabe, Tillots and Zeria. He is a senior clinical investigator for the 
FWO. 
Gert Van Assche reports following conflicts of interest: grant support from Abbvie and MSD; 
lecture and consulting fees from Abbvie, Ferring, MSD, Takeda and Janssen. He is a senior 
clinical investigator for the FWO. 
All other authors have no additional conflicts of interest regarding this PhD manuscript. 
The work in part I was supported by a grant from the “agentschap voor lnnovatie door 
Wetenschap en Technologie” (IWT, grant N° 120550). 
The work in part II was supported by grants from the Funds for Scientific Research-
Flanders/Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (FWO), Belgium (FWO grant 
numbers [G.0479.10, G.0681.14]). This work was also supported by an Advanced European 
Research Council (ERC) Grant [ERC-2015-AdG].
  
178 
“Sometimes science is a lot more art than science, a lot of people don’t get that.” 
Rick Sanchez 
ACKNOWLEDGEMENTS - DANKWOORD 
We now have arrived to the what is maybe the most important (an definitely the most read) 
part of my PhD where I would like to express my gratitude to all people that have been 
involved in my scientific career so far. 
Before going over to Dutch I would like to thank all the jury members for being here today and 
for taking the time to critically read and comment on my PhD manuscript.  
Professor Kaser, you probably don’t know this, but I’m a big fan of the work from your 
research group. I have read multiple publications with great pleasure and interest, they were 
always of very high quality and have made a substantial contribution to my knowledge on ER 
stress and autophagy in the context of IBD. It is therefore a great honor that you were willing 
to be part of my jury and for that, you have my eternal gratitude. I hope you will enjoy the rest 
of your short stay at Leuven and wish you a safe trip home tomorrow morning. 
Professor Laukens, I had the pleasure to get to know you at the beginning of my PhD as we 
were both involved in the filgotinib project. Also, besides the project with Galapagos, you 
showed great interest in my epithelial cell culture project. I was therefore always glad to have 
our brief but interesting face-to-face discussions at the scientific conferences. I think that we 
are both convinced that ER stress should become a therapeutic target in IBD and that our 
combined data could maybe pave the way for real clinical applications. Not so long ago, you 
got the position of Professor at Ghent University and I hereby wish you all the best in your 
future career and hope that this wasn’t our last collaboration.
Professor Boeckxstaens and Professor Agostinis, thank you for being part of my thesis 
advisory committee. During the last four years, you have both given me valuable feedback and 
made me look at my results in a more critical way. 
Dan gaan we nu verder in het Nederlands zodat iedereen mee kan lezen. Ik zal beginnen bij 
de mensen van de genexpressiegroep die mij voor het eerst van het echte wetenschappelijk 
onderzoek hebben laten proeven. Frans, bedankt dat ik mijn bachelorthesis mocht doen in 
jouw lab en dat ik daar tijdens de zomer nog wat langer mocht blijven als jobstudent. Katleen, 
Anica, Leentje, Lotte en Geoffroy, ik vond het zeer fijn om met jullie samen te werken, ik 
“Planning for failure is even dumber than regular planning.” 
Rick Sanchez  
voelde me meteen thuis in jullie groep en ben dat eigenlijk altijd blijven doen, ook al kwam ik 
de laatste tijd wat minder langs. Ik wens jullie allemaal nog veel succes in jullie carrières en 
hoop dat we elkaar nog mogen tegenkomen. 
Behalve de mensen die ik zonet vernoemd heb, leerde ik tijdens mijn tijd in het Schuit-lab nog 
een geweldig persoon kennen. Met een ongezien enthousiasme en de energie van wel een 
miljard duracelkonijntjes, is Ingrid gewoon iemand die je onmogelijk niet gezien (of gehoord) 
kan hebben. Je hebt me van bij het begin op sleeptouw genomen en als er iemand is die mij 
in de wetenschap gelanceerd heeft, dan ben jij het wel. Je zorgde ervoor dat ik ook tijdens 
mijn universitaire studies ’s zomers aan de slag kon blijven in het lab en dankzij jou was ik 
reeds coauteur op meerdere publicaties nog voor ik aan mijn doctoraat begon. Je 
introduceerde me zo aan de IBD groep en zorgde ervoor dat ik een doctoraatspositie had om 
tijdens mijn studies naar uit te kijken. Ik ben enorm blij dat je dan ook mijn co-promotor mocht 
zijn en je hebt dat geweldig gedaan. Je stuurde me bij of gaf me een stamp onder mijn gat 
wanneer dat nodig was. Jij geloofde in mij en bent dat altijd blijven doen. Ik hoop echt dat we 
elkaar nooit uit het oog zullen verliezen en dat we misschien nog eens kunnen samenwerken 
in de toekomst. Bedankt voor alles, je bent een supermadam en gaat ongetwijfeld nog een 
fantastisch leven tegemoet zowel op professioneel vlak als met uw twee prachtige dochters. 
Zoals gezegd, was het Ingrid die me bij de IBD-groep heeft gehaald en me dan ook voorstelde 
aan mijn promotor: Professor Vermeire. Beste Séverine, bij onze eerste ontmoeting werd mij 
meteen duidelijk dat je iemand was met enorm veel goede, creatieve ideeën en een duidelijke 
visie. Nadien leerde ik dat je dit dan ook nog eens wist te combineren met een bijna 
onmenselijke efficiëntie en fantastische people management skills. Ik heb me de afgelopen 
vier jaar meermaals afgevraagd of je een toverstaf, kristallen bol of teletijdmachine had, want 
ik begrijp nog steeds niet hoe jij al die dingen tegelijk aankan. Een andere eigenschap die ik 
enorm aan je apprecieer is dat ik nooit een echte drempel heb gevoeld om iets aan jou te 
vragen, ik ben altijd mezelf kunnen blijven en dat vind ik enorm belangrijk. Je stuurt onze 
groep als de beste en slaagt erin om ieders project in goede banen te leiden, ik prijs me dan 
ook erg gelukkig dat ik hier deel van uit mocht maken. 
Naast Séverine, staan er nog twee andere personen aan het hoofd van de IBD-groep die ik hier 
zeker niet mag vergeten. Marc, bedankt om elk jaar opnieuw uw schouders onder de 
“Let the world change you and you can change the world” 
Ernesto Che Guevara 
teambuilding te zetten, ik zal deze leuke laboweekendjes nooit vergeten. Je zorgde er tevens 
voor dat we tijdens DDW met de hele groep samen in een huisje konden verblijven en was 
ook steeds van de partij op de buitenlandse etentjes. Dankzij deze initiatieven is de IBD-groep 
een hechte familie waar iedereen zich thuis voelt, merci. Gert(jeuh!), je was dan niet 
rechtstreeks betrokken bij mijn project, toch ben ik blij dat ik je samen met jouw leuke 
anekdotes heb leren kennen en af en toe eens de Samson kon uithangen. Ook nog een dikke 
merci aan jullie alle drie voor de vele biopten die jullie voor mijn project hebben afgenomen!
Dan zou ik nu willen overgaan naar alle leuke collega’s binnen de IBD-groep en dat zijn er een 
heel aantal. Allereerst de mensen die reeds vertrokken zijn. Nils, je bent een topkerel die het 
zeker ver zal schoppen in San Diego, bedankt om ons steeds de weg te wijzen en op sleeptouw 
te nemen tijdens DDW. Thomas, je was een fijne collega, maar het is vooral buiten het werk 
dat ik je beter heb leren kennen. Jij was altijd degene die knopen doorhakte en de groep mee 
op sleeptouw kon nemen. Jouw organisatietalent bij het splitten/betalen van de rekening op 
restaurant wordt trouwens nog steeds gemist. Dominiek, bedankt om steeds voor de nodige 
dosis gezever en schurkenstreken te zorgen, hopelijk kunnen we hier af en toe op de oude 
markt nog een aantal vervolgen aan brijen. Karolien, ik vond het jammer om je te zien 
vertrekken, maar ben blij dat ik je nog af en toe tegenkom in de gang. Nikolai, nog zo iemand 
die ik liever bij ons had zien blijven, ik kon het altijd goed met je vinden en hoop dat we elkaar 
nog eens zien met een goeie pint erbij. Isabelle, je bent ondertussen zelf professor van je eigen 
groep(je), toch voelt het voor mij aan alsof je nog steeds bij onze groep hoort. Bedankt voor 
je hulp, feedback en het beantwoorden van al mijn geneticavragen. Sare, ik leerde je kennen 
tijdens je masterthesis waarin je dankbaar gebruik maakte van onze biopten. Ik ben heel blij 
dat je nadien ook zo nauw aan onze groep verbonden bent gebleven en wens je veel succes 
met de rest van je doctoraat. Alle begin is moeilijk, maar we gaan ongetwijfeld nog veel horen 
van ‘The Cleynen-lab’! Kostas (aka sports-guy), it was a pleasure to have you in our group and 
to have our daily football-talks. It is still a mystery to me how you manage to know all the 
results from every league, you really are a walking/talking encyclopedia when it comes to 
sports. I enjoyed having you at OHL to support my team or to see the Belgium woman team 
kick Greece’s ass. Thank you for the Olympiakos shirt and scarf, I hope that one day I will be 
able to join you for one of their home games! I wish you all the best in the US my friend. Also, 
best of luck to our two Spanish fellows Triana and Aranza. Anthony, het was leuk om u erbij 
“Het eten is de belangrijkste maaltijd van de dag.” 
Wiebe Vanhove 
te hebben op teambuilding, doe dat goed daar in Canada. Aan de twee mensen die bijna terug 
in Leuven zijn: Alessia en Willem-Jan, ik hoop dat jullie een leuke tijd hadden in Italië en kijk 
ernaar uit om jullie binnen enkele maanden terug bij onze groep te hebben. En dan onze meest 
recente vertrekker: Manuel, je was een leuke collega waar ik me goed me heb geamuseerd. 
Ik ben er helaas niet in geslaagd om je te leren drinken als een echte Belg, maar ik weet niet 
of dat écht aan mij lag… Op congres hebben we meerdere keren een veel te klein bed moeten 
delen, maar op 1 nachtje snurken na, had het veel erger gekund . Veel succes met je postdoc 
in Chicago, dat wordt vast en zeker een fantastische ervaring. 
Ten slotte, de persoon waar ik het zoveel aan heb gehad en die dan ook een grote indruk op 
mij naliet: Kris, ik zou eigenlijk niet weten waar ik moet beginnen. We werden samen op het 
Galapagos-project gezet en van bij onze eerste babbel wist ik meteen dat we helemaal op 
dezelfde golflengte zaten, ik ben dan ook heel content dat jij mijn co-promotor mocht zijn. Ik 
heb enorm veel van je geleerd, zowel op professioneel vlak als daarbuiten. Samen met Ingrid 
en Séverine heb je ervoor gezorgd dat mijn doctoraat tot een goed einde kwam. Ook nadat je 
onze groep verlaten had, ben je mijn vooruitgang steeds blijven opvolgen en maakte je tijd 
wanneer nodig. Buiten het werk zijn we een aantal keren kunnen gaan feesten, ik zal u dan 
ook blijven bestoken met uitnodigingen wanneer er weer iets leuks te doen is. Ik wens ook jou 
veel succes met uw carrière en uw gezinnetje, en hoop dat we vooral nog vaak samen aan de 
toog mogen hangen (maar ik ben er redelijk gerust in dat dit zo zal zijn)!
En dan nu de mensen die nog steeds deel uitmaken van onze groep. Allereerst de dames in de 
kliniek: Tine, Jolien, Ganel, Karolien, Liesbeth, Karen, Isolde, Leen, Maja, Ellen en Patricia, 
jullie zijn stuk voor stuk fantastische mensen waar ik de afgelopen jaren heel wat mee heb 
afgelachen. Bij jullie binnenspringen voor een korte babbel maakte mijn dag steeds goed, ik 
zal dit dan ook blijven doen zolang ik nog op gasthuisberg rondloop. Vera, en recent ook 
Liesbeth, jullie vormen de link tussen de kliniek en het labo, een lastige taak die jullie als geen 
ander beheersen. Bedankt om onze groep draaiende te houden, want zonder jullie zou er veel 
mislopen. Hetzelfde kan zeker ook gezegd worden van onze laboranten. Sophie, met jou kan 
ik steeds een leuk babbelke doen en op de laboweekends bleef je ook vaak plakken bij 
diegenen die het laatst gingen slapen. Veel succes met Selene’s garden en je andere muzikale 
projecten, het klonk heel goed tijdens het afgelopen IBD congres en ik zal zeker nog een 
“Ik ben blij dat gij in mijn team zit” 
Guido Pallemans 
optreden proberen mee te pikken in de toekomst. Nooshin, you are a wonderful person who 
is always willing to help. Thank you for being the friendly, caring person that you are and you 
for taking care of all the little extra things I asked you during the past years. Helene, met jouw 
aanstekelijke lach was je meteen een aanwinst voor ons team en je slaagt er ook telkens in 
om een glimlach op mijn gezicht te toveren. Hopelijk blijf je nog lang bij ons! Tamara, door 
omstandigheden heb ik je helaas nooit goed leren kennen. Ik hoop dat je er snel weer bovenop 
komt zodat je met een glimlach door het leven kan gaan. 
Hoog tijd om over te gaan naar mijn collega doctoraatstudenten en postdocs. Kathleen, 
dankzij onze gedeelde rookverslaving leerde ik je echt goed kennen tijdens onze pauzekes. 
Toen je naar Barcelona vertrok stond ik ineens alleen op het balkon en kreeg ik zelfs te horen 
dat je ginder gestopt was, dankzij jouw tips is het mij een half jaar later ook gelukt. We hebben 
samen heel wat afgelachen en er zullen zeker nog schatermomenten volgen, hopelijk slagen 
we er ooit eens in om elkaar tegen te komen op een festival. Magali, ook jij zat reeds bij onze 
groep toen ik erbij kwam en zorgde ervoor dat ik me meteen welkom voelde. Ik heb je zien 
groeien van doctoraatstudent tot postdoc en heb dat steeds met veel bewondering gedaan. 
Je hebt veel kennis van zaken en bent zeer kritisch, dat zorgde ervoor dat ik altijd extra 
gerustgesteld was wanneer jij iets had nagelezen. Ook buiten het werk hebben we samen vele 
leuke momenten beleefd die ik, ondanks het hoge alcoholgehalte, niet snel zal vergeten. Dat 
er nog vele parties, afterworkdrinks, choufkes en katers mogen volgen! João/j-wow, we zijn 
op dezelfde dag aan ons doctoraatsavontuur begonnen en ik ben dan ook heel blij dat we 
beiden dit jaar samen de eindmeet zullen halen. Je bent een super-collega die steeds bereid 
is om anderen te helpen met een glimlach. Ondertussen ben je in de kliniek begonnen en ik 
kan zeggen dat we je allemaal enorm missen. Ik wens je veel succes met jouw verdediging in 
december, maar ook met uw verdere carrière als arts en alle liefde en geluk met je prachtige 
vrouw en dochter. We zullen zeker samen nog eens een OHL-match of Groundation-concert 
meepikken! Maaike, jij kwam in onze groep als stille, verlegen masterstudent toen ik in mijn 
eerste jaar zat. Nadien ben je bij ons gebleven en leerde ik dat je veel meer in je mars had. Of 
het nu in het labo is of daarbuiten, je gaat er altijd voor en geeft nooit op. Ik ben dan ook heel 
blij dat we samen een masterthesis mochten begeleiden, het resultaat mocht er dan ook zeker 
zijn! Bram, je bent een enorm gedreven en gemotiveerde onderzoeker met een zeer brede 
wetenschappelijke kennis, ik zou soms bijna vergeten dat je maar een dokter bent. Ook als 
“Remember children, there are no stupid questions… 
…just stupid people” 
Herbert garrison 
mens heb ik veel bewondering voor jou, ik denk dan ook dat al jouw (toekomstige) patiënten 
zich enorm gelukkig (zullen) prijzen met zo’n zorgzaam persoon als arts. Als er één persoon is 
die alles heeft om het te maken als de volgende Leuvense IBD-professor, dan ben jij het wel.  
Brecht, je zit spijtig genoeg niet bij ons in het kantoor, maar ik ben blij dat je er steeds bij bent 
wanneer we na het werk nog iets gaan doen. Binnenkort zal ik hoogstwaarschijnlijk enkele 
muismodellen opstarten dus dan zullen we elkaar zeker wat meer zien op de werkvloer. Ik 
wens je nog veel succes met de ILCs en wens je nog oneindig veel steengoeie Radiohead 
concerten toe. (Tante) Sofie, je bent een fijne collega waar ik het heel goed mee kan vinden, 
ik ga dan ook blij zijn als je terug uit zwangerschapsverlof bent en er weer bij kan zijn. Clara 
(aka madam kak), ik ben content dat ik ook jouw eerste jaar bij ons nog heb mogen 
meemaken. Ik hou van je aanstekelijke, energieke, “zonder zeveren-mentaliteit” en ben ervan 
overtuigd dat je hiermee jouw FMT-project zeker tot een goed einde zal brengen. Ik hoop dat 
ik Caenepeel et al. in de toekomst nog veel ga mogen citeren! Kaline, jou ken ik nog niet zo 
lang, maar ik merkte op teambuilding meteen op dat je een heel sociaal en behulpzaam 
persoon bent. Ook op wetenschappelijk vlak ben je ongetwijfeld een aanwinst voor onze 
groep, ik ben dan ook heel blij dat ik tijdens de komende maanden nog veel met jou ga mogen 
samenwerken. Annick en Karen, jullie zijn onze twee nieuwste aanwinsten die ik daardoor 
helaas nog niet zo goed ken. De eerste maanden met jullie erbij waren alleszins heel 
aangenaam en ik ben dan ook blij dat ik er minstens nog enkele maanden bij mag doen. Ik 
wens ook jullie alle succes van de wereld met jullie doctoraat en alles wat erna nog zal volgen.
Tijdens de laatste maanden van mijn doctoraat had ik nog het plezier om een buitenlandse 
PhD in onze groep te verwelkomen en te begeleiden. Marcia, I know I didn’t always have 
enough time to help you or to work together in the lab. However, I’m so glad that I got to 
know you in person because we have many things in common. I really miss your crazy vibes in 
the lab (or at the bar/festival) but I will definitely pay you a visit in the beautiful city of Porto. 
Good luck with your PhD, scientific research is all about ups and downs, but I’m sure it will be 
fine in the end. Stay positive, stay crazy in the coconut, you are awesome!
“A hungry man, is an angry man” 
Robert Nesta (Bob) Marley 
Dan wens ik ook nog de mensen van het Gils-lab te bedanken. Ann, Thomas, Iris, Erwin en 
Sumin, bedankt voor de goeie sfeer op de congressen, afterwork dinners/drinks en zoveel 
meer. In mijn ogen horen jullie toch ook een beetje bij onze groep. Thomas, volgende keer 
wint OHL van dienen Beerschotse rattennest, mark my words! 
Aangezien de IBD-groep valt onder TARGID zijn er ook enkele mensen die ik hier moet 
bedanken voor de afgelopen vier jaren. Allereerst de PI’s die deze unieke werkplek in stand 
houden en niet vergeten dat teambuildings en kerstfeestjes een belangrijke bijdrage leveren 
aan de goeie werksfeer. Ricard en Pieter, maar ook Hanne, An-Sofie en Valerie, bedankt voor 
jullie hulp en feedback bij de revisie van mijn paper, mede dankzij jullie had ik mijn tweede 
publicatie vooraleer mijn thesis binnen moest. De PI’s zitten dan wel aan het stuur van de 
TARGID-motor, maar er zijn twee heel bijzondere mensen die er iedere dag opnieuw voor 
zorgen dat die motor niet meteen ontploft: Cindy en Phyllis. Dank u om telkens zo snel te 
reageren wanneer ik weer met een (administratief) probleem zat, maar ook voor de leuke 
babbeltjes af en toe, jullie zijn fantastisch. Ik heb zeer veel respect voor jullie en ben enorm 
dankbaar voor wat jullie allemaal doen voor onze groep. Verder nog enkele andere TARGID-
mensen die ik hier toch even wil vermelden, aan diegenen die ik hier vergeet: please don’t 
shoot me. July, good luck with your new job, I already miss our funny conversations in the 
hallway or during the after-work occasions. We will probably meet again in the beautiful city 
of Tienen and when that time comes we should just go for a drink (or six). Charlotte, je was 
een van de eerste mensen op TARGID waar ik een goeie band mee had en waar ik steeds een 
babbelke mee kon doen. Of je nu jouw doctoraat afmaakt of niet, ik wens je veel succes en 
plezier met je carrière! An-Sofie, we hebben tegelijkertijd de eindspurt naar onze verdediging 
ingezet waardoor we veel aan elkaar hebben gehad de laatste maanden. Ik ben er zeker van 
dat je dat fantastisch gaat doen volgende maand. Seppe, je hebt het epitheliale celcultuur 
project op de rails gezet tijdens jouw masterthesis en ik pluk daar vandaag de dag nog steeds 
de vruchten van. Buiten het werk hebben we een aantal matchen meegepikt aan den Dreef 
en misschien kom ik ooit eens mee naar Anderlecht (of toch niet, ik supporter niet voor 
jeanettenploegen, sorry ). Elisa, it was fun to have you in our group during the UEGW basic 
science workshop in Amsterdam and I’m happy that I got to know you a little better. I had a 
lot of fun at Rock Werchter even though we lost each other during the System of a down 
concert. The same goes for Alessandra and I’m pretty sure we’ll run into each other at a 
“Walking with a friend in the dark is better than walking alone in the light” 
Helen Keller 
(reggae) party or festival. (DJ-)Jess, I’m really sad that you had to leave us, but I’m glad we 
ended in style at the Metafoor. Good luck in Australia and next time you come back to 
Belgium, the Wolfkes are on me! To those that I didn’t mention here personally, please don’t 
feel offended, you are all great and you know that I love you . 
Ik heb nu reeds enkele pagina’s gevuld met lofzangen over al mijn fantastische (ex-)collega’s, 
maar de voorbereiding van dit doctoraat duurde eigenlijk nog veel langer (en het leven is meer 
dan werken alleen). Hoog tijd dus om over te gaan naar al mijn vrienden en familie die op één 
of andere manier een steentje hebben bijgedragen aan mijn studies en mijn (prille) 
wetenschappelijke carrière. Ik zou willen beginnen bij de kameraden die reeds het langst met 
mij opgescheept zitten. Silke, jij bent al zo lang mijn beste maatje dat ik wel met jou moet 
beginnen. Je bent er altijd voor mij geweest tijdens moeilijke momenten maar gelukkig 
worden die overheerst door de vele leuke dingen die we samen hebben meegemaakt. Ik hoop 
dat je voor altijd mijn maatje blijft en dat we nog vele feestjes kunnen bouwen samen. Ook 
nog bedankt om enkele keren mijn leven te redden toen ik door omstandigheden geen 
rijdende voertuigen meer zag aankomen, zonder jou(w reactievermogen) had ik hier letterlijk 
niet gestaan. Jonas, ik vind het uiteraard jammer dat je niet meer zo dichtbij woont, maar ben 
blij dat je content bent in Gent en dat je toch nog af en toe de weg naar Leuven vindt. Sander, 
nogmaals proficiat met uw aankoop, ik kijk al uit naar het eerste oogstfeest op uw boerderij. 
Julien, we zijn elkaar even uit het oog verloren, maar gelukkig is daar recent verandering in 
gekomen. Morgen geven we een kickass party in de sojo, like in the old days! Ewoud, blij dat 
ik steeds bij u kon komen chillen of met muziek bezig kon zijn, binnenkort zullen we zeker onze 
eerste “Dubsidizer meets General Fonz” opnemen! Stefan, ik hoop dat het plezant was in 
Oostenrijk, maar nu is het terug tijd om de Belgische feestjes en de tribunes van OHL onveilig 
te maken! Brecht, onze lasboyscout, ik ben super content dat wij als enigen zijn blijven 
supporteren voor OHL, ik hoop dat we onze vlag en sjaal nooit aan de haak zullen moeten 
hangen en dat we nog tientallen jaren lawijt mogen maken! Cajo, van feestkapitein tot echte 
family man, hopelijk word ik ook zo’n geweldige vader als jij. Joeri, ik zie u helaas veel te 
weinig, maar als ik u zie wordt het kot nog steeds met de grond gelijk gemaakt, zoals het hoort 
dus. Jef, ik ben blij dat je nu wél tevreden bent met je huidige job in Hoegaarden, spring zeker 
nog maar eens binnen na’t werk! Lars, door omstandigheden zie ik ook jou veel te weinig, 
maar ik ben super trots dat je ondertussen aan het hoofd staat in de keuken van de Faculty 
“One good thing about music, when it hits, you feel no pain” 
Robert Nesta (Bob) Marley 
Club en dat wij dadelijk bij jullie mogen komen eten. Aron, (mede) dankzij jou kon/kan ik elke 
vrijdagavond in de Sojo terecht voor een pint en het bijhorende gezever. Ik vind het echt de 
max dat jullie ervoor zorgen dat er steeds weer wat te doen is in Leuven. Michael, onze 
(twee)wekelijkse voetbalavondjes zorgend telkens voor de nodig ontspanning tijdens de 
werkweek, waarvoor dank. Laat ons deze traditie dan ook in ere houden zodat we binnen 2 
jaar OHL in de champions league kunnen zien sjotten. Bette, liefste ex-buurvrouw, we missen 
uw zottigheid nog steeds en hopen dat we binnenkort eens op bezoek mogen komen in uw 
nieuwe huisje. Kaat, we zijn samen aan onze laborantenopleiding begonnen en hebben dit 
verdergezet totdat we beiden ons masterdiploma in de biologie haalden. Ik ben heel blij dat 
jij nu ook aan een doctoraat bent kunnen beginnen. Hopelijk maakt Marc tussen de social 
media en de eeuwigdurende vete met Theo Francken ook wat tijd voor u. Maar je bent een 
harde werker en hebt reeds je eerste publicatie dus ik ben er zeker van dat ik binnen enkele 
jaren een uitnodiging voor jouw verdediging zal ontvangen. Verder wil ik ook nog de 
mannen/vrouwen van de Boom/Fazantenlaan-crew bedanken: Giel, Carmen, Brecht, Sanne, 
Koen, Iris, (Spons)Rob, Wanne, Jelle, Fre, Alwin, Lorenz merci om mij in jullie kliek op te 
nemen. Dankzij jullie ben ik altijd in het beste gezelschap op de meest loco parties en festivals! 
Last but definitely not least: Big up to the Dubsakee-crew!!! Ewoud, Sam, Mike, Jelle en 
Michael, jullie kunnen je niet voorstellen hoe blij ik ben dat ik sinds kort samen met jullie aan 
een muzikaal avontuur ben begonnen. Binnenkort zal onze soundsystem volledig klaar zijn 
zodat we de dansvloer van vele feestzalen en festivalterreinen kunnen doen beven als nooit 
tevoren. Bovendien zal ik dan ook volledig in de flow zitten zodat ik de leegtes kan opvullen 
met mijn gezever, we gaan ongetwijfeld nog mooie tijden tegemoet: One love, one message, 
one solution: join the Dubsakee revolution!  
Beste vrienden, onze vriendschappen gaan al even mee en ik ben er zeker van dit die nooit 
zullen eindigen. Het spijt me als ik jullie de laatste jaren wat meer in de steek heb moeten 
laten, maar ik weet dat jullie me dit nooit kwalijk hebben genomen. Echte vrienden zijn 
namelijk diegenen waarbij het lijkt alsof het gisteren was, terwijl je elkaar eigenlijk al twee jaar 
niet gezien hebt, een gevoel dat ik bij ieder van jullie heb. Woorden kunnen eigenlijk niet 
beschrijven hoe nauw jullie mij aan het hart liggen dus ik zal het hierbij laten.
“I don't know half of you half as well as I should like; and I like less than half of you half as well 
as you deserve.” 
Bilbo Baggins  
Ten slotte wil ik dit uitgebreid dankwoord afsluiten met de familieleden te bedanken die mij 
al heel mijn leven steunen en aanmoedigen. Tante Anne, aan jou heb ik altijd alles kunnen 
vragen en jouw creatieve geest zorgt er steeds voor dat elk feest net dat tikkeltje extra heeft. 
Dit was dan ook duidelijk te zien op ons trouwfeest, maar ook op de andere talrijke 
familiefeestjes. Je bent een super tante waar ik veel aan heb en altijd op zal kunnen rekenen.
 Seppe, mijn beste neef, we hebben samen al vele leuke tijden beleefd op de voetbal, op 
vakantie en op festivals. Ik hoop dan ook dat ik nog heel lang en heel vaak uw (zatte) 
“begeleider” mag zijn bij zulke aangelegenheden. Je bent ondertussen zelf aan je hogere 
studies begonnen en ben dan ook super fier dat je zonder problemen je eerste jaar bent 
doorgekomen. Ook in het rolstoelhockey gaat het steeds beter, ik zal je dan ook komen 
aanmoedigen waar en wanneer ik kan! Ieke, snotjonk, als kind trokken we al veel samen op 
en nadien in het middelbaar hebben we ook vele gekke avonturen meegemaakt. Ik ben dan 
ook heel blij dat we hier nu in Tienen een vervolg aan kunnen brijen en dat uw dochters veel 
slechte manieren aan mijne kleine kunnen aanleren. Sofie, het laatste familielid dat de Tienen-
clan heeft vervoegd, ik hoop dat ik jou en Myrthe dan ook terug wat vaker zal zien en dat jullie 
ooit terug een OHL-abonnement zullen nemen. Oma, ik zou eigenlijk een apart boekje kunnen 
vullen met wat jij allemaal voor mij gedaan hebt en voor mij betekent. Al van sinds mijn 
geboorte heb ik zoveel nuttige dingen van je geleerd en meegekregen: leren tellen, leren 
rekenen, Leuvens dialect, ijsjesdecoratie in brand steken, het vakkundig wegjagen van 
jehova’s getuigen en nog zoveel meer. Jij bent één van de personen die ervoor gezorgd heeft 
dat ik nu sta waar ik sta en dat ik ben wie ik nu ben en daar ben ik je eindeloos dankbaar voor. 
Lies, je bent dan wel een halve zus, toch ben je minstens even slim en prettig gestoord als uw 
broer. Ik vind het jammer dat we elkaar zo weinig zien en hoop dat daar snel verandering in 
zal komen als je voor de tweede keer tante wordt. Binnenkort zal jij ook afstuderen, je wordt 
vast en zeker een fantastische lerares. Weet dat ik je heel graag zie en dat je altijd welkom zal 
zijn bij ons. Maaike, je bent dan wel mijn hele zus, toch ben je minstens maar half zo lelijk als 
uw broer. Vroeger krabde je het liefst mijn armen en gezicht open en sloeg ik jou het liefst de 
kop in, gelukkig zijn die tijden veranderd en beseffen we beiden meer dan ooit dat we elkaar 
nodig hebben. Je bent een fantastische zus die het steeds opneemt voor haar familie. Mike, 
we kennen elkaar toch ook al even en ik ben blij voor u dat mijn zus het met u volhoudt. Vorig 
“Family is not an important thing. 
It’s everything.” 
Michael J fox  
jaar zorgden jullie ervoor dat ik de fierste peter ter wereld werd en ik beloof jullie dan ook dat 
ik altijd zal klaarstaan voor Lexie met raad en daad. Volgend jaar heeft ze er een 
speelkameraadje bij, al hoop ik dat die twee van in het begin overeen komen zonder al te veel 
ruzie. 
Tussen het bedanken van mijn zusjes en mijn ouders moet ik ook mijn schoon(stief)ouders 
bedanken (anders mag ik misschien niet meer binnen). Karine (en Benny), Wim (en Monica) 
bedankt om mij van in het begin zo welkom te laten voelen, zelfs al zag ik er zo raar en 
ongewassen uit. Ook jullie hebben mij van bij het begin gesteund, ik ben dan ook heel blij dat 
jullie mijn schoonouders zijn. Ook mijn schoonzus Chiara mag ik niet vergeten aangezien ik 
haar door de jaren heen mocht pesten en steken geven, maar ook omdat we samen al goed 
gelachen hebben. Mijne kleine gaat twee superleuke meters hebben en daar ben ik enorm 
dankbaar voor.  
 Pa, jammer genoeg zag ik jou vroeger slechts om de twee weken en was je dus minder 
rechtstreeks betrokken bij mijn opvoeding. Toch heb ik veel van je geleerd en kon/kan ik altijd 
op jou rekenen, je zorgde ervoor dat ik nooit iets tekortkwam. Je hebt me steeds 
aangemoedigd en onvoorwaardelijk gesteund, ik weet maar al te goed hoe trots je op mij 
was/bent en dat is voor mij van onschatbare waarde. Binnen een half jaar wordt je voor de 
tweede keer opa en ik hoop dat je jouw waarden en normen ook aan je kleinkind zal aanleren 
zoals je bij mij hebt gedaan. Mams, als er iemand is die mijn liefde voor wetenschap meteen 
zag en voedde dan was jij het wel. Jarenlang gingen we samen naar de bib en kwam ik telkens 
terug met enkele kilo’s aan encyclopedieën en wetenschapsboeken. Toen ik een chemiedoos 
vroeg aan de sint, kreeg ik die, ook al was ik nog enkele jaren te jong daarvoor (bij deze 
nogmaals sorry voor het in brand steken van de tafel en andere experiment-gerelateerde 
incidenten). Verder heb je mij en Maai altijd op de eerste plaats gezet, nu nog steeds 
trouwens. Wat wij ook aan jou vragen, niets is jou te veel. Ik ben dan ook super content dat 
mijne kleine zo’n fantastische oma gaat hebben! 
Ik ben nu bijna aan het einde van mijn dankwoord gekomen en ik zou graag eindigen met de 
belangrijkste vrouw in mijn leven. Yentel, lieve schat, jarenlang heb je tot vervelens toe mijn 
gezeur moeten aanhoren over hoe druk het was en hoeveel tijd ik tekortkwam. Toch was jij 
“If she's amazing, she won't be easy. If she's easy, she won't be amazing. If she's worth it, you 
won’t give up. If you give up, you're not worthy. ... Truth is, everybody is going to hurt you; you 
just gotta find the ones worth suffering for.” 
Robert Nesta (Bob) Marley  
de enige die me weer rustig kreeg wanneer ik weer eens aan het stressen en vloeken was. We 
zijn nu tien jaar samen en jij maakte in die tijd van deze ongewassen, langharige, werkschuwe 
vreemde vogel een (semi-)deftige, gedoctoreerde vreemde vogel. Ik ben er heilig van 
overtuigd dat ik zonder jou hier vandaag niet had gestaan. Binnen een half jaar zal ons kindje 
op de wereld komen, een dag waar ik enorm naar uitkijk. Het is allemaal heel spannend, maar 
ik weet dat jij een fantastische mama zal zijn. Bovendien kunnen wij als team de hele wereld 
aan en dat zal ook deze keer niet anders zijn. Ik hou enorm veel van je en zal dat ook altijd 
blijven doen. 
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